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ABSTRACT OF DISSERTATION 
 
 
 
 
 
POST DISCHARGE NAUSEA AND VOMITING IN AMBULATORY SURGICAL 
PATIENTS: INCIDENCE AND MANAGEMENT STRATEGIES 
 
Approximately 65% of all surgeries are conducted in the outpatient surgery setting 
involving more than 35 million patients. Thirty-five to fifty percent of these outpatients will 
experience post discharge nausea and vomiting (PDNV), nausea and vomiting that occurs after 
discharge from the health care facility after surgery.  A dearth of literature details the problems 
associated with nausea and vomiting experienced by patients after discharge home from 
outpatient surgery.  
The purposes of this dissertation were to (1) review the current knowledge in the area of 
post discharge nausea and vomiting; (2) present results of an integrative review of the research 
literature to determine best evidence for prevention of PDNV in adults or rescue of patients who 
suffer from post discharge nausea and vomiting (PDNV); (3) present a critical review and 
analysis of measurement of nausea and vomiting after discharge from outpatient surgery, and (4) 
present findings of a prospective research study.   
The purposes of the research study were to:  1) describe the incidence and severity of 
PDNV over a 7-day period in a sample of adult surgical patients undergoing outpatient surgeries 
under general anesthesia, 2) describe the pharmacologic and nonpharmacologic modalities of care 
used by patients with PDNV to manage it, 3) compare the incidence and severity of PDNV 
between those who do and do not use pharmacologic and nonpharmacologic modalities, and 4) 
determine outcomes associated with PDNV.  This study was part of a multi-site study that had as 
a primary objective development of a simplified risk model for predicting patients most likely to 
suffer PDNV.  In this research study we described the incidence and severity of PDNV in adult 
outpatients after ambulatory surgery, described the pharmacologic and nonpharmacologic 
modalities of care used by patients with PDNV to manage it, compared the incidence and severity 
of PDNV between those who do and do not use pharmacologic and nonpharmacologic modalities, 
and determined outcomes associated with PDNV. 
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CHAPTER ONE 
 
Nausea and vomiting after surgery was discussed in the literature as early as 1899 when 
Blumfeld linked vomiting after surgery to ether anesthesia. At that time the incidence of 
postoperative nausea and vomiting (PONV) was 75%.1  By 1956, Knapp and Beecher were 
evaluating antiemetic drugs available for patients and discussed the differences between nausea, 
vomiting and retching.2  During the 1990s, research began extensively with publication of an 
editorial calling PONV the “big, little problem”3 and with two significant articles, in which the 
authors discussed the etiology, treatment and prevention of PONV.4, 5 Research focused first on 
nausea and vomiting immediately after inpatient surgery.  Since that time, the number of 
ambulatory surgeries has increased exponentially, with the resulting adverse effects of nausea and 
vomiting impacting patients as they recover at home.  
The treatment and consequences of post discharge nausea and vomiting (PDNV) have not 
been as thoroughly assessed and evaluated as postoperative nausea and vomiting (PONV), nausea 
and vomiting experienced immediately after surgery and in the hospital.  Much time and effort 
has been expended in research and publication regarding PONV.  However, most of this research 
was conducted in the post anesthesia care unit (PACU), up to 24 hours in a hospitalized patient, 
or in postanesthesia phase II immediately before patient discharge home.6  
Approximately 65% of all surgeries are conducted in the outpatient surgery setting7 
involving more than 35 million patients.8 Thirty-five to fifty percent of these outpatients will 
experience post discharge nausea and vomiting (PDNV), nausea and vomiting that occurs after 
discharge from the health care facility after surgery.6, 9-12  That figure translates into millions of 
patients who suffer from PDNV yearly.13-15 Unfortunately, the incidence of PDNV is under-
reported.16  A dearth of literature details the problems associated with nausea and vomiting 
experienced by patients after discharge home from outpatient surgery.6, 17 Just this past year, one 
editorial, “We’re tired of waiting,” emphasized the effect of PDNV on daily function and pointed 
out that patients are tired of waiting for PDNV to end.18 In a second editorial last year the authors 
discussed PDNV as an overlooked aspect of ambulatory anesthesia and pointed out the necessity 
for further research in this arena.19 
In the first published study specifically conducted for the purpose of investigating PDNV 
in the outpatient, Carroll, et al.11 found an overall incidence of 35% for PDNV in 211 ambulatory 
surgery patients. In a systematic review of randomized, controlled studies, the authors reported an 
overall incidence of post discharge nausea as 32.6% and the overall incidence of post discharge 
vomiting as 14.7%.12 In another systematic review in which post discharge symptoms were 
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examined, the authors found that the incidence of post discharge nausea ranged from 0% to 55% 
and post discharge vomiting ranged from 0% to 16%.20  However, it has been difficult to compare 
the different incidences reported because the definitions of PDNV vary per researcher.  A recent 
multidisciplinary and evidence-based guideline published by the American Society of 
PeriAnesthesia Nurses is the first guideline to address PDNV.   Contained within this guideline 
are definitions of PONV and PDNV (See Figures 1-1 and 1-2) that have been formulated to aid in 
further research.9 
Only a small number of studies are available in which the investigator specifically 
examines strategies to reduce PDNV.6, 21  In one recent study, patients responded to PDNV with 
inappropriate responses such as stopping pain medication.22  In another study, 35% of patients 
who experienced PDNV lost time from work or normal activities.10  Postanesthesia care for the 
patient experiencing PDNV is not standardized, and there has been no research to determine the 
pharmacologic and nonpharmacologic modalities that have been used with PDNV and how that 
relates to PDNV.  Until a very recent multi-site study23, predictors for PDNV had not been 
determined, although it was assumed those predictors might be similar to predictors for PONV.9 
 
Risk Factors 
Risk factors specific to PDNV are only now being determined.  More is known about risk 
factors associated with PONV.24-26 The cause of PONV is multifactorial.16 Risk factors for PONV 
can be described as those related to the patient, the surgical procedure, the anesthesia, and the 
postoperative period.13, 25   Apfel, et al.24 developed a risk score to predict the risk that a patient 
would experience PONV.  The final score was derived from four predictors: female gender, 
history of motion sickness or PONV, nonsmoking, and the use of postoperative opioids.  If no 
risk factors were present, the incidence of PONV was 10%.  With 1, 2, 3, or 4 risk factors present, 
the incidences for an individual patient were 21%, 39%, 61%, and 79%, respectively. Koivuranta 
et al.27 developed a risk assessment tool that included five variables in the risk score calculation: 
female gender, nonsmoking status, history of PONV, history of motion sickness, and length of 
surgery (> 60 minutes).  The incidences based on the risk factors were 17%, 18%, 42%, 74%, and 
87% respectively. 
In general, increased age has been associated with a decreased incidence of PONV, 
although the predictive value was not supported in several studies.9, 25   Better health status as 
determined by the American Society of Anesthesiologists (ASA) physical status classification 
system is a possible risk factor for PONV.26, 28  The ASA classification system ranges from 1 (a 
patient who is normal and healthy) to 6 (a brain-dead patient who is having organs harvested)29  
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In other words, the healthier patient is more at risk for PONV than patients determined as less 
healthy.  This may have implications for PDNV because outpatient surgery is usually performed 
only on patients who have a better health status, typically a physical status of 1-3.30  Other factors 
that are associated with PONV include use of volatile anesthetics,31 use of nitrous oxide,28 
duration of anesthesia32, duration of surgery24, 32, and type of surgery.28 There is conflicting 
evidence on the impact of pain.25, 33  There is no definitive answer as to whether PONV is related 
to PDNV11, 34, although the answer may lie with differing physiologic mechanisms for PONV and 
PDNV.17  Until now, experts have recommended using the same risk factor assessment tool for 
PDNV as that used for PONV based on benefit versus risk. 9  Apfel et al. have recently 
determined predictors for a simplified assessment tool for early PDNV (48 hours after surgery).23 
The five statistically significant independent risk factors for PDNV for the first 48 hours are 
female gender, age less than 50 years, history of PONV, opioids administered in the PACU, and 
nausea in the PACU.23 
 
Consequences 
Identified consequences of PDNV in the outpatient surgery patient include impaired sleep 
time due to vomiting35, drowsiness as a side effect of the rescue antiemetic34, increased anxiety 
for parents of pediatric patients36, a delay in resumption of activities of daily living (ADL)11, 20, a 
negative effect on quality of life, 37 and a decision by the patient not to self-administer an 
analgesic for pain because they believe it is related to the nausea and vomiting.22, 38  
Other potential consequences of PDNV are numerous, but are speculative because they 
are based on information about PONV.  The patient may be unable to tolerate fluids or food and 
become dehydrated, possibly with an accompanying electrolyte disturbance such as alkalemia.  
The patient may aspirate contents after postoperative emesis resulting in pneumonia.  
Additionally, the patient may experience sweating, tachycardia, increased salivation, 
hypertension, hypotension or cardiac dysrhythmias.  Surgical consequences include disruption of 
suture lines, bleeding from the wound, increased intracranial and intraocular pressure, and 
esophageal tears.14, 39  Economic consequences include delayed discharge home, unplanned 
admission to the hospital, increased medication use, and nursing costs, as well as possible loss of 
work wages for the patient.14, 39, 40   
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Management and Treatment 
Prevention of PDNV begins with the anesthesia plan preoperatively with prophylaxis 
warranted only in high-risk patients.  Risk factors can determine high risk patients for PONV, and 
soon a simplified risk assessment tool will be available in the literature to further assess the 
potential for PDNV in outpatients.9, 23, 25  In one review of the literature only one systematic 
review and three studies specific to management and treatment of PDNV were discovered.6  Five 
algorithms published for care and treatment of PONV were discussed in this same review, but 
none of those algorithms guide management of nausea and vomiting for the surgical outpatient 
after discharge.6  Recent multidisciplinary and evidence-based guidelines published by the 
American Society of PeriAnesthesia Nurses are the first guidelines to address PDNV.9  The 
overall evidence concerning antiemetics as prophylaxis or other pharmacologic or 
nonpharmacologic treatment for PDNV is sparse.17  However, based on the limited evidence 
available, and until the risk assessment tool for PDNV is published, patients are assessed for 
PDNV using a PONV risk factor assessment tool.  If the patient is at risk for PDNV, prophylaxis 
is considered with dexamethasone, scopolamine patch, NK-1 receptor antagonist, or P6 
acstimulation.9  If the patient experiences PDNV, rescue treatment may include ondansetron 
dissolving tablets, promethezine suppositories or tablets, or a scopolamine patch.9 
 
Summary 
Modalities of care for patients who experience PDNV have been documented in no 
studies.  Risk factors have only recently been determined,23and only one study has reported self-
care activities for the patient experiencing PDNV.22   The three most common responses of self-
care for PDNV were stopping pain medications, altering physical activities and ingesting food or 
liquids.22   Many patients initiated no self-care activities at all, and none of the patients reported 
the use of complementary interventions.22  Little research is available that describes the incidence 
and severity of nausea and vomiting after discharge home.  Severity of nausea is rarely 
documented.  Management and treatment of PDNV has been seriously overlooked with patients 
suffering at home unable to return to work or perform other activities of daily living.  In one 
school project, the author discovered that patients who had experienced PDNV were very 
reluctant to return for future surgery.41   Therefore, initial exploration of the incidence and 
severity of PDNV, pharmacologic and nonpharmacologic modalities of care for these patients, 
and relationship to quality of life after surgery must occur in order to determine future relief for 
patients in the form of self-care. 
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The purposes of The dissertation were to (1) review the current knowledge in the area of 
post discharge nausea and vomiting; (2) present results of an integrative review of the research 
literature to determine best evidence for prevention of PDNV in adults or rescue of patients who 
suffer from post discharge nausea and vomiting (PDNV); (3) present a critical review and 
analysis of measurement of nausea and vomiting after discharge from outpatient surgery, and (4) 
present findings of a prospective research study.  The purposes of the study conducted as a part of 
this dissertation were to:  1) describe the incidence and severity of PDNV over a 7-day period in a 
sample of adult surgical patients undergoing outpatient surgeries under general anesthesia, 2) 
describe the pharmacologic and nonpharmacologic modalities of care used by patients with 
PDNV to manage it, 3) compare the incidence and severity of PDNV between those who do and 
do not use pharmacologic and nonpharmacologic modalities, 4) determine outcomes associated 
with PDNV, and 5) determine predictions for late (Days 3-7) PDNV.  This study was part of a 
multi-site study that had as a primary objective development of a simplified risk model for 
predicting patients most likely to suffer PDNV.23 
Overview of Chapters 
Chapters Two and three review the literature that is available concerning post discharge 
nausea and vomiting.  Chapter Two is a review of any study that been published through 2005 on 
the subject of PDNV.  The purpose of Chapter Two was to review the current knowledge in the 
area of discharge nausea and vomiting.6 The findings were that PDNV had not been as thoroughly 
assessed and evaluated as nausea and vomiting immediately post surgery.  Future implications 
were discussed as were research recommendations for the ambulatory surgery population.  
Chapter Three focused on interventional studies that specifically addressed the effect of an 
intervention designed to prevent PDNV or rescue the patient who develops PDNV.17 This chapter 
presents an integrative review of the literature that determined best evidence for prevention of 
PDNV in adults or for rescue of patients who suffer from PDNV.  The chapter synthesized 
evidence from interventional studies conducted with adult patients using pharmacologic or 
nonpharmacologic modalities of care.   
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 Chapter Four includes discussion of the measurement of nausea and vomiting.  
Inconsistent measurement of nausea, vomiting and retching has made it difficult to compare the 
incidence of PDNV among studies.  Further complicating the situation is that differing definitions 
of the terms PONV and PDNV have been used throughout the literature.  There is a lack of 
standardized instruments in studies of PONV and PDNV and a reliance on instruments developed 
by the individual investigator.  A critical review and analysis of measurement of nausea and 
vomiting after discharge from outpatient surgery is presented as are new directions for 
measurement. 
 Chapter Five is a study that describes the incidence and severity of PDNV over a 7-day 
period in a sample of adult surgical patients undergoing outpatient surgeries under general 
anesthesia, describes the pharmacologic and nonpharmacologic modalities of care used by 
patients with PDNV to manage it, compares the incidence and severity of PDNV between those 
who do and do not use pharmacologic and nonpharmacologic modalities, and determines 
outcomes associated with PDNV.   The study was comprised of data from 12 study sites across 
the United States for the first 48 hours post surgery and from 2 study sites for 7 days post surgery.   
Findings from the study presented in Chapter Five show that over a third of ambulatory 
surgery patients continue to suffer the effects of PDNV during the first week after surgery, some 
suffering symptoms up to 7 days.  Several factors were associated with an increased risk of 
PDNV including younger age, female gender, previous PONV or motion sickness, ASA status, 
and OR (operating room) time.  Patients were more likely to use minor self-care strategies to 
manage symptoms than to use antiemetics.  The presence of nausea and vomiting was 
significantly related to quality of life (QOL).  In this study, we recommend that future studies 
focus on patient education needs, use of risk assessment tools for PDNV and randomized 
controlled trials that determine appropriate long-term antiemetics and non-pharmacologic 
methods to control nausea and vomiting.  
 Chapter Six provides an overview of review and study findings, suggests 
recommendations on the development of comprehensive and effective interventions to promote 
prevention of PDNV and management of symptoms should they occur, and provides future 
research recommendations for patient education, risk assessment tools and further research into 
management strategies.  
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Future Impact of the Study 
 The data in this dissertation point out the extraordinary number of patients who undergo 
ambulatory surgery and then go home to struggle with nausea and vomiting.  There are some 
patients who continue to have problems up to 7 days later.  This dissertation builds a foundation 
for future studies to examine interventions that decrease the impact of nausea and vomiting.  
Further research can be conducted to look at newer long-acting antiemetics and the 
appropriateness of use for discharged ambulatory surgery patients.  Use of nonpharmacologic 
methods of care to manage PDNV is a wide-open field for research in this population.  Of special 
interest is research to determine an algorithm that patients could follow to alleviate symptoms.  
Also of special interest is the effect of anxiety on these patients and the effect of a patient 
education intervention.  Now that it has been confirmed that patients do suffer at home, typically 
without notifying the healthcare provider, the science can be built on further interventional 
studies. 
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Figure 1.1 PONV Timeline  
 
 
Used with permission.9 
 
 
 
 
Figure 1.2 PDNV Timeline 
 
 
Used with permission.9 
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CHAPTER TWO 
 
POST DISCHARGE NAUSEA AND VOMITING: A REVIEW OF CURRENT 
LITERATURE 
 
 
ABSTRACT 
 Postoperative nausea and vomiting continues to occur in approximately one third of 
patients who have surgery despite newer medications and emerging guidelines for care.  There is 
a paucity of literature that relates to patients who experience post discharge nausea and vomiting 
after outpatient surgery.   The purpose of this article is to review the current knowledge in the 
area of post discharge nausea and vomiting. The findings were that the problems with post 
discharge nausea and vomiting (PDNV) have not been as thoroughly assessed and evaluated as 
nausea and vomiting immediately post surgery. More research needs to be conducted in this 
population, as the rate of surgeries performed in this setting will only increase.   
 
Introduction 
Postoperative nausea and vomiting (PONV) is a known complication for patients after 
surgery and has been called the “big, ‘little problem.’ ”1  In spite of newer anesthetic agents, 
antiemetic medications, and considerable research into the subject, one third of all postoperative 
patients continue to experience PONV at some point after surgery.2-4  In a recent study of six 
interventions for prevention of PONV, the average incidence was 34%.5  The incidence of PONV 
in high-risk patients with four determined risk factors can be as high as 70-80%.6 
Today, approximately 65% of all surgeries are conducted in the outpatient surgery 
setting.7  The Federated Ambulatory Surgery Association states that approximately 6 million 
surgeries are performed yearly in 3,300 ambulatory surgery centers.8  The current healthcare 
environment requires that patients are quickly and efficiently moved through the system from 
admission to discharge.   
Only a small number of studies are available that specifically examine strategies to 
reduce PDNV.9  Much time and effort has been expended in research and publication regarding 
PONV.  However, most of this research was conducted in the post anesthesia care unit (PACU) or 
in postanesthesia phase II immediately before patient discharge home.  There is a paucity of 
literature that details the problems associated with nausea and vomiting experienced by patients 
after discharge home.   The problems with post discharge nausea and vomiting (PDNV) have not 
been as thoroughly assessed and evaluated as PONV immediate post surgery.  When conducting 
the literature review for this article, using “post discharge nausea and vomiting” as a keyword 
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elicited only 2 articles from CINAHL (1982-2004).  PubMed delivered 56 articles with the same 
keyword, but some articles that only had one or two lines applicable to the subject.   
 To perform the literature search for appropriate articles, the author used the keywords 
“ambulatory surgery” (933 results), “nausea and vomiting” (948 results), and “postoperative 
complications” (5749 results).  Combining those three keywords in one search resulted in 26 
articles.  The authors then searched the abstracts for suitable articles. The authors also searched 
the reference lists in those articles for additional articles.  The result was 24 articles that 
specifically mention nausea and vomiting after discharge home.  Of those 24 articles, several had 
only one –two sentences that were applicable.  One of the articles was a systematic review and 
analysis of postdischarge symptoms, including nausea and vomiting.  The purpose of this review 
is to synthesize a review of the literature that has been published on the subject of post discharge 
nausea and vomiting. 
 
Post Discharge Nausea and Vomiting 
Incidence 
 It is possible that PDNV has been underreported in the past because the symptoms were 
not identified.10  Upon discharge, patients are not as accessible to surveillance and care by 
healthcare workers, which may have contributed to underreporting of these symptoms.11  Carroll, 
et al.11found an overall incidence of more than 35% in 211 ambulatory surgery patients who had 
one of four selected surgeries:  laparoscopy, dilation and curettage, arthroscopy, or hernia repair.  
Interestingly, most of the patients who experienced PDNV in the study had not experienced 
PONV before discharge.  Wu, Berenholtz, Pronovost, and Fleisher found an incidence of post 
discharge nausea (PDN) that ranged from 0% to 55% and an incidence of post discharge emesis 
(PDV) that ranged from 0% - 16% in a systematic review that evaluated the incidence of reported 
postdischarge symptoms and included PDNV.12  In a systematic review of randomized, controlled 
studies published in the English literature, the authors examined whether routine prophylaxis with 
antiemetics affected the incidence of PDNV after ambulatory surgery.  The overall incidence of 
PDN was reported as 32.6% (35.7% placebo and 31.2% treatment) and the overall incidence of 
PDV was 14.7% (19.6% placebo and 12.1% treatment).13   
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Risk Factors 
 The cause of PONV is multifactorial.10  Risk factors can be described as related to the 
patient, the surgical procedure, the anesthesia, and the postoperative period.2  Apfel, et al. 
developed a risk score to predict the chances a patient would experience PONV.  The final score 
had four predictors: female gender, history of motion sickness or PONV, nonsmoking, and the 
use of postoperative opioids.  If no risk factors were present, the incidence of PONV was 10%.  
With 1, 2, 3, or 4 risk factors present, the incidences were 21%, 39%, 61%, and 79%, 
respectively.6  
There are no studies that specifically determine risk factors related to PDNV.  Carvalho 
et al.14 evaluated the influence of inhalational versus total intravenous anesthesia (TIVA) 
maintenance on functional recovery and symptom distress after gynecological surgery.  No 
significant differences were found between the two groups with respect to functional recovery, 
nausea, vomiting or pain. In one study of 211 outpatients who had one of four selected surgeries, 
PDNV was not related to PONV in the immediate postoperative period11while in another study 95 
healthy, female patients who had PONV immediately after laparoscopic surgery were reported to 
be four times more likely to experience PDNV.15   
Consequences 
 PONV is known to have physiologic consequences as well as an impact on patient 
satisfaction.3, 16-20 Identified consequences for the post discharge patient include impaired sleep 
time due to vomiting21, drowsiness as a side effect of the rescue antiemetic15, increased anxiety 
for parents of pediatric patients22, a delay in resumption of activities of daily living (ADL)11, 12, 
and a decision by the patient not to self-administer an analgesic for pain because they believe it is 
related to the nausea and vomiting.23, 24   
PDNV Published Information  
 Pfisterer, et al.25 studied the incidence and impact of PONV before and after discharge 
following outpatient surgery.  A total of 586 patients from nine countries were enrolled in the 
study.  Upon leaving the facility sixty-four patients experienced PONV, with 29 reporting 
moderate and 8 reporting severe symptoms.  Another 76 patients experienced PDNV while 
traveling home.  Some patients experienced PDNV five days after surgery.  There was also an 
impact on activities of daily living and time lost from work.  Of the 129 patients who experienced 
PDNV, 35% lost time from work or normal activities requiring 21 patients to take one or more 
days off work and 21 friends and relatives to take time off from work to assist the patient.  The 
11 
 
     
authors go on to state that PONV is “either not adequately recognized or treated in hospital and 
beyond, or that some of the anti-emetic agents may be inadequate”.25 
 Enever, et al.26 compared postdischarge morbidity after outpatient dental care under 
general anesthesia between pediatric patients with and without disabilities.  Symptoms were 
similar in both groups and included nausea and vomiting (20%), unexpected drowsiness (13%), 
and need for pain relief at home (42%).  One patient was readmitted for persistent nausea and 
vomiting.  Ernst and Thwaites27 evaluated post discharge pain, nausea and vomiting of outpatients 
undergoing elective surgeries over a 2-month period.  The types of surgeries were general 
surgery, orthopedic, dental, ENT, and gynecology.  They discovered that more patients suffered 
from nausea and vomiting after discharge (33% nausea; 10% vomiting) than before discharge 
(16% nausea; 6% vomiting).  The authors concluded that pain, nausea, and vomiting are 
persistent problems after discharge and that they increase in incidence after discharge. 
 Amanor-Boadu and Soyannwo28  followed pediatric patients from time of discharge to 
first outpatient visit.  They discovered that the most prevalent problem was pain (18.9%), but also 
discovered that vomiting (12.2%) was a significant finding. These authors did not address nausea 
in this population.  The authors conclude that “concerns for safety and comfort of the patients 
should extend beyond the recovery room to the ward and home”.28 
 Young, et al.29examined whether enhanced discharge education would make a difference 
once patients returned home after outpatient surgery.  While compiling symptoms that occurred 
after surgery, the authors discovered that many patients stated they were not feeling hungry, had 
no interest in food, or felt nauseous during the first two days at home.  The enhanced teaching 
package, a procedure-specific patient educational tool that was implemented, had no effect on 
patient recovery or the patient’s ability to self-manage.  The authors concluded that the patient’s 
own understanding of self-care affected the recovery more significantly than the enhanced 
teaching package.   
Waterman, et al.30 conducted qualitative research of postoperative pain, nausea, and 
vomiting after discharge.  They discovered that one third of patients found the pain and nausea 
worse than they had imagined.  They also discovered that some patients are reluctant to take their 
pain medications because they felt they were related to the nausea. One patient stated, “The first 
day post-op was awful….I had pain but I was reluctant to take painkillers because of nausea.”31  
The authors incorporate recommendations based on their interviews with the patients that include 
advising patients preoperatively on how to manage nausea and side effects of drugs and deferring 
discharge for those who have higher levels of pain or who are nauseous.   
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Kangas-Saarela, et al.32studied patients’ experiences with outpatient surgery.  This was a 
survey of the incidences of pain, nausea, and vomiting and patient satisfaction.  Overall, 11.3% of 
patients surveyed experienced nausea either during recovery, travel home, or after arriving home.  
The authors believe that the lower than usual incidence of nausea was due to the high number of 
orthopedic cases who received regional anesthesia during surgery.  See Table 2-1 for a summary 
of studies. 
Management and Treatment 
 Prevention of PONV and PDNV begins with the anesthesia plan preoperatively.  Because 
only one-third of surgical patients will experience PONV or PDNV, prophylaxis is warranted 
only in high-risk patients.33  The decision to give antiemetics should be based on risk factors with 
a focused plan of care developed to decrease the chances the patient will experience 
PONV/PDNV, e.g. use of local anesthetics to decrease opioid need or limiting use of 
neuromuscular agents to avoid reversal agents.  There is no one drug that can block all pathways 
mediating nausea and vomiting.  Different classes of drugs are available that affect one or more 
receptor sites, and alternative treatments for PONV are becoming more common although not yet 
tested specifically in the PDNV population.2, 3, 33-35  Most alternative treatments are completed in 
conjunction with pharmacologic methods of controlling nausea and vomiting. 
 One systematic review and three studies were found in which the efficacy of 
pharmacologic treatment was considered in patients with PDNV.  Gupta, et al.13 conducted a 
systematic review of randomized controlled trials to determine if the routine prophylactic use of 
antiemetics affected the incidence of PDNV after ambulatory surgery.  A total of 815 patient had 
PDN with an overall incidence of 26% PDN in the treatment group and 40.4% in the placebo 
group.  A significantly lower risk of PDN was discovered with ondansetron 4mg, dexamethasone 
4-10 mg and combination treatment with more than one drug compared to placebo.   The overall 
incidence of PDV was 14.6 % in the treatment group and 26.5% in the placebo group.  The 
relative risk was lower with ondansetron 4mg and combination treatment with two or more drugs 
than with placebo.   
Tang, et al.36compared ondansetron and droperidol as a prophylactic antiemetic agent for 
elective outpatient gynecologic procedures.  This study was included in the above systematic 
review.  Droperidol 1.25 mg and ondansetron 4 mg significantly reduced the incidence of PDNV 
when compared to placebo or droperidol 0.625 mg.  Parlow, et al.15 assessed the efficacy of 
prophylactic administration of promethazine for PDNV after ambulatory laparoscopy.    An 
intramuscular injection of either saline or promethazine 0.6 mg/kg was administered to patients 
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immediately prior to discharge home.  There was no difference between the placebo group and 
treatment group regarding the incidence of PDNV.  The incidence of “excessive drowsiness” was 
notably higher in those patients who had received promethazine (P = 0.008). 
Wright, et al.37 evaluated the effectiveness of promethazine suppositories in decreasing 
nausea and vomiting in adult outpatients following discharge home.  Patients who had a 
prolonged stay in PACU due to PONV, developed PONV after the IV was discontinued, or had a 
long car trip home were given two promethazine suppositories (25 mg each) upon discharge.   A 
high percentage of the patients who had PDNV used the suppositories.  All patients who used the 
suppositories stated that their PDNV improved after use, and no significant side effects were 
reported.  Promethazine suppositories were determined to be clinically, as well as, cost effective. 
Guidelines for Determining Prevention and Treatment 
 There were five algorithms published for the care and treatment of PONV.  Gan10 lists 
patient and surgical risk factors and advises avoidance of those risk factors.  The algorithm is 
specific for prophylactic antiemetic therapy and lists options for mild to moderate risk (1-2 
factors), moderate to high risk (3-4 factors) or very high risk (>4 factors).  The author believes 
that a multimodal approach to prevention of PONV should be adopted that includes identification 
of preoperative risk factors, reduction of avoidable risk factors, and use of combination 
antiemetics. The guideline is based on the 45 references, a mixture of clinical and research, 
included in the article. 
Watcha4identified guidelines for prophylaxis and therapy of PONV.  Patients were 
divided into four groups based on estimated risk: low risk (<10 %), mild to moderate risk (10-
30%), high risk (30-60%), and extremely high risk (>60%).  This guideline lists suggested 
prophylaxis, as well as, suggested rescue antiemetics.  The references for the guideline are two 
editorials published by White and Watcha.38, 39  One discusses the use of meta-analysis in 
improving an understanding of treatment of PONV, and the other includes recommendations on 
prophylaxis of high-risk patients based on several studies referenced in the editorial.  
Gan, et al.40, in a consensus guideline, listed an algorithm for management of PONV.  
The algorithm begins with evaluation of risk and divides patients into low, moderate or high-risk 
groups.  This algorithm does suggest consideration of nonpharmacologic therapies, consideration 
of regional anesthesia, and reduction of baseline risk factors, as well as, antiemetics alone or in 
combination for treatment. This group of experts considered an evidence rating scale that was 
based on study design and also considered strength of recommendation based on expert opinion. 
The panel consisted of ten physicians, 1 pharmacist, and 1 certified registered nurse anesthetist. 
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Notably missing from the panel were expert perianesthesia registered nurses.  There has been 
concern voiced in the literature about the make-up and selection of the expert panel and the fact 
that the panel was funded by a pharmaceutical company.41, 42   Others considered it important that 
for the first time, an international expert panel attempted to determine a guideline based on 
evidence-based strategies.20 
Tramer20 describes a possible decision tree for PONV prophylaxis.  Patients are identified 
as positive or negative for risk.  If patients are positive for risk factors, the decision tree suggests 
keeping baseline risk low and describes a prophylactic antiemetic cocktail. Tramer recognizes the 
difficulty in defining what “high-risk” actually means and assuring that the appropriate patients 
are identified.   Tramer further discusses the need for evidence concerning the efficacy of 
therapeutic antiemetic cocktails.  He believes that trials are needed to determine the best rescue 
treatment for patients who continue to vomit after surgery and that minimal effective doses are 
unknown.  Tramer’s premise is that more research is needed for dissemination of best practices 
and implementation of evidenced-based guidelines. 
Golembiewski and O’Brien34 illustrate the most extensive algorithm that covers the 
immediate perioperative period.  It begins with assessment of risk factors in the preoperative 
period. Patients are divided into mild to moderate risk (1-2 factors), moderate to high risk (3-4 
factors), or very high risk (>4 factors).  For all groups there is consideration of intraoperative and 
postoperative factors that can decrease the incidence of PONV or treat PONV should it occur, and 
then suggests rescue antiemetics.  The algorithm is based on nine references; two that discuss 
systematic reviews of the literature. 
None of the algorithms, guidelines, or decision trees attempts to guide management of 
nausea and vomiting in the post discharge phase of patient care.  Two of the algorithms address 
prophylactic antiemetic therapy only.  Even those algorithms that discuss postoperative care are 
specific to the immediate postanesthesia phase of care.  The only guidelines based on an evidence 
rating scale were those from Gan, et al.40 
Future Implications 
 Very little research has been conducted specifically regarding PDNV.  We do know that 
postdischarge symptoms, including PDNV, can affect patient recovery and resumption of normal 
activities. We do not know how those symptoms impact the recovery, how extensive the delay in 
recovery remains, or the costs attributable to these symptoms.12 
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Pfisterer, et al.25suggest the need to consider risk factors when using antiemetics for 
outpatients.  The authors also suggest that future studies should compare the use and effectiveness 
of older antiemetics with newer antiemetics.  They state that the newer anti-emetics seem to result 
in less impact on post discharge activity (due to less drowsiness or other side effects.)  Other 
authors10 suggest that study of the neurokinin 1 (NK-1) receptor antagonists may hold hope for 
the future in terms of preventing or limiting PDNV.  Further suggestions for research include 
creation of valid and reliable instruments to collect information on postdischarge symptoms.12   
 Carroll, et al.11 found that patients who experienced PDNV were more likely to report 
delay and inability to perform their normal daily activities.  The authors also discovered that 
patients usually did not call the health professional or purchase products to treat the problem.  
Fetzer, et al.24discovered that only 7 of 190 subjects who experienced PDNV contacted a health 
care provider for PDNV symptoms.  These authors discovered that patients’ most common 
response to PDNV was to stop the pain medication, even though pain can contribute to nausea 
and vomiting.   
One practice implication would be to provide education for patients including more 
detailed instructions for managing the PDNV episodes.11  The patient’s ability to self-manage 
should be considered because Young et al.29 discovered that the ability to self-manage was related 
to the patient’s understanding of self-care.  Fetzer, et al.24call for an antiemetic algorithm for 
patients to use upon discharge home.  This algorithm would take other algorithms one step further 
by adding the period of time that patients are recovering at home. This algorithm would also need 
to be written in lay-terms, easy to understand and follow.  Instructions for patients’ home care 
could also include suggestions for complementary therapy.  Further research is needed to validate 
the usefulness of complementary therapies at home for PDNV.  
The economic impact of postdischarge symptoms, including PDNV, is not known.12 
Research implications include studying the economic impact of PDNV on delays in resumption 
of normal activities and examining cost-effectiveness, cost-benefit, cost utility, as well as, direct 
and indirect costs.  These costs include not only the costs of unplanned hospital admission or 
increased rescue medication, but also delays in return to work, time that must be taken off, not 
only by the patient, but by the caregiver.12 
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Conclusion 
In conclusion, PDNV continues to be a problem for at least one third of patients after 
return home.  More research needs to be conducted in this arena as the rate of surgeries in the 
outpatient setting is only going to rise.  Suggestions for study include antiemetic efficacy in the 
post discharge setting, the effectiveness of a detailed education program for these patients, and  
economic impact.
Copyright © Jan Odom Forren 2009 
 
 
Table 2.1 Studies Addressing PDNV 
 
Reference Publication 
Year 
Study PDNV PDN PDV Findings 
Amanor-Boadu 
et al. 28 
1997 Complications after pediatric 
outpatient surgery 
  12.2% Need to continue to trend 
complications post-discharge to 
aid in prevention 
 
Carroll, et al. 11 1995 Patient experiences with 
nausea and vomiting after 
discharge from outpatient 
surgery 
35%   Significantly more likely to 
report impairment in daily 
activities if PDNV present.  Little 
correlation between predischarge 
NV and PDNV.  Few patients 
called HCP or purchased 
products to treat NV. 
 
Carvalho, et al.14 2002 Longterm functional 
recovery: Inhalation vs. 
TIVA 
 35% 
(during 
journey) 
10.3%  (during 
journey) 
Incidence of PONV similar 
between 2 groups (TIVA and 
inhalation) 
 
Enever, et al. 26 2000 Postoperative morbidity 
following outpatient dental 
care under general 
anesthesia in pediatric 
patients with and without 
disabilities 
 
20%   No differences between groups 
of patients with and without 
disabilities.  N/V most commonly 
reported symptom 
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Table 2.1 (Continued) Studies Addressing PDNV 
 
Reference  Publication 
Year 
Study PDNV PDN PDV Findings 
Ernst, et al.27 1997 Incidence and impact of 
pain, nausea and 
vomiting after 
outpatient surgery 
 33% 10% Pain, nausea, vomiting serious and 
persistent problems post discharge, 
increasing in incidence after 
discharge. 
 
Fetzer, et al.24 2005 Self-care activities for 
PDNV 
PDNV required for inclusion in study Few patients contacted their HCP. 
Significant number of pts believed 
PDNV due to analgesics and therefore 
did not self-administer analgesics. 
 
Grenier, et al.22 1998 Quality at home of 
pediatric patients after 
outpatient surgery 
 
  9% PDV and agitation was one of 3 main 
causes for anxiety by parents 
Gupta, et al.13 2003 Routine prophylactic 
use of antiemetics on 
incidence of PDNV 
after ambulatory 
surgery 
 
 32.6% 14.7% Prophylactic treatment with 
ondansetron 4mg or combination with 
2 drugs produced significant decrease 
in PDNV 
 
Kangas-Saarela, 
et al.32 
1999 Patients’ experiences of 
outpatient surgery 
 6%  Decreased incidence of PDN 
probably due to high number of 
patients in study who received 
regional anesthesia. 
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Table 2.1 (Continued) Studies Addressing PDNV 
 
Reference Publication 
Year 
Study PDNV PDN PDV Findings 
Kokinsky, et al.21 1999 Postoperative comfort 
after pediatric outpatient 
surgery 
20%   Incidence of PDNV significantly 
higher in those patients given 
intraoperative opioid (fentanyl) 
 
Parlow, et al.15 1999 PDNV after ambulatory 
laparoscopy is not 
reduced by promethazine 
prophylaxis 
 48% 17% Patients requiring an antiemetic in 
PACU are at higher risk for PDNV.  
Prophylactic promethazine IM 
before discharge did not reduce the 
incidence of PDNV. 
 
Pfisterer, et al. 25 2001 An international study of 
PONV in outpatient 
surgery 
21.4% (prophylactic antiemetic) 
19.2% (no prophylactic antiemetic) 
Some patients reported N/V up to 5 
days after surgery.  Inadequate 
control of PDNV remains a problem. 
 
Tang, et al.36 1996 Comparison of 
ondansetron and 
droperidol for antiemetic 
prophylaxis in outpatient 
gynecological procedures 
 
 68% (P) 
57% (D) 
41% (D2) 
32% (O) 
52% (P) 
27% (D) 
15% (D2) 
14% (O) 
Incidence of emesis and need for 
rescue significantly lower with both 
droperidol and ondansetron groups. 
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Table 2.1 (Continued) Studies Addressing PDNV 
 
Reference Publication 
Year 
Study PDNV PDN PDV Findings 
Waterman, et 
al.30 
1999 Postoperative pain, 
nausea, and vomiting—a 
qualitative perspective 
 
   One-third of the group (55) reported pain and 
nausea worse than imagined. 
Watt-Watson, et 
al. 23 
2004 Pain management 
following discharge after 
outpatient surgery 
 14%  Patients stopped taking analgesics despite 
considerable pain due to side effects of 
constipation or nausea. 
 
Wright, et al 37 1999 Efficacy of promethazine 
suppositories for home 
use after outpatient 
surgery 
55%   Promethazine suppositories well tolerated; used 
by 89% of patients with access.  All patients who 
used reported decrease in nausea. 
 
Wu, et al. 12 2002 Systematic review and 
analysis of postdischarge 
symptoms after outpatient 
surgery 
 0-55% 0-16% Post discharge symptoms may be significant 
factor in patient’s resumption of normal activities 
patient recovery. Need further studies to 
determine impact. 
 
Young, et al 29 2000 Does enhanced discharge 
instruction make a 
difference after outpatient 
surgery. 
 13-16% (Day 1) 
7-9% (Day 4) 
Majority of patients did not experience problems 
with recovery at home.  Patients needed carer 
assistance for average of 3 days. The enhanced 
teaching package 
made no difference 
 
 CHAPTER THREE 
 
EVIDENCE-BASED INTERVENTIONS FOR POST DISCHARGE NAUSEA AND 
VOMITING:  A REVIEW OF THE LITERATURE 
 
 
 
ABSTRACT 
 
Postoperative nausea and vomiting (PONV) and post discharge nausea and vomiting 
(PDNV) continue to be a problem for one third of all patients who require surgery and anesthesia.  
Very few studies have been reported that specifically target PDNV in the outpatient surgery 
population for interventions after discharge home.  Twenty studies were identified that 
specifically addressed the effect of an intervention for the purpose of preventing PDNV or 
rescuing the patient who develops PDNV.   This article presents an integrative review of the 
research literature to determine the best evidence for prevention of PDNV in adults or for the 
rescue of patients who suffer from PDNV. 
 
Introduction 
Postoperative nausea and vomiting (PONV) continues to be a problem in the 
postanesthesia setting for one third of all patients who require surgery and anesthesia. 1-5  The 
incidence can be as high as 70-80% among patients with predetermined risk factors.6  
Unfortunately, as many as 30% to 50% of outpatients will continue to struggle with post 
discharge nausea and vomiting (PDNV) after arrival home.3, 7, 8  With over 60 to 65% of all 
surgeries performed currently performed in the ambulatory surgery setting, thousands of patients 
experience PDNV.9  PONV and PDNV are not conditions that typically contribute to mortality; 
however, it has been called the “big, little problem”10 because of patient aversion to nausea and 
vomiting, the effect on quality of recovery, the potential for morbidity and hospitalization in high 
risk patients and loss of patient satisfaction.   
 Many investigators have focused on assessment of the patient risk for PONV.11, 12  In one 
study, a risk assessment using only 4 or 5 factors was determined as effective as other tools that 
predicted nausea and vomiting using up to 13 criteria.11  Other studies have focused on effects of 
anesthetic agents or other medications on the incidence and severity of PONV. 13-14  Prophylactic 
use of antiemetics has been considered, as well as the most effective timing of the administration 
of those antiemetics.7, 16, 17  Historically, most studies were limited to inpatient populations, 
although a few analyzed data for 24 hours after surgery. Some studies combine inpatient and 
outpatient data for the first 24 hours post operative. While PONV has been well described and 
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 interventions tested there is limited research on PDNV and interventions that could improve the 
care of outpatient surgery patients after discharge.   The purpose of this article is to present results 
of an integrative review of the research literature to determine best evidence for prevention of 
PDNV in adults or rescue of patients who suffer from PDNV. 
 
Defining PDNV 
A precise definition for PDNV has not been established.  Researchers have called for the 
post discharge period to be defined in a standardized manner.7   PDNV is clearly related to the 
discharge of a patient after ambulatory surgery.  But there have been questions as to whether 
PDNV encompasses the first 24 hours after discharge or whether a patient who was nauseated or 
had emesis during transport home had PONV or PDNV.  The members of the multidisciplinary 
PONV/PDNV Strategic Work Team, convened by the American Society of PeriAnesthesia 
Nurses, distinguished PDNV from PONV for the purpose of the consensus guideline and for 
future research.  PONV was defined as nausea and/or vomiting that occurs within the first 24-
hour period following surgery in relation to inpatients. 18  PDNV is “nausea and/or vomiting that 
occurs after discharge from the health care facility following surgery.”18   The terminology 
“delayed PDNV” is used for nausea and/or vomiting that occurs beyond the initial 24 hours after 
surgery.    
Researchers have posited that a patient history of PONV is predictive of PONV.  
However, findings have shown mixed results.  Carroll, et al.8 found that PDNV was not related to 
PONV in a descriptive study of 211 outpatients.  Conversely,  Parlow and others,19 conducted an 
interventional study and found that patients with PONV were found to be four times more likely 
to experience PDNV than those who had not suffered PONV. While there is no definitive answer 
yet, it is possible that the physiological mechanisms responsible for PONV are different from the 
physiological disturbances responsible for PDNV.  
 Guidelines developed to this point for the prevention and care of patients with PONV 
have focused on the preoperative and intraoperative period, while a few have targeted rescue 
treatment in the PACU.3  One consensus conference was held in 2003 to develop guidelines for 
PONV. These guidelines focused on prevention and rescue treatment in the immediate 
postoperative area, but there were no recommendations for established nausea and vomiting after 
discharge or new onset nausea and vomiting after discharge.20   Published algorithms and 
guidelines have focused on prophylaxis and therapy,21 risk factors, prophylactic antiemetic 
therapy and options for pharmacology.2 A decision tree for prophylaxis22 and an extensive 
algorithm that begins with assessment of risk factors and continues through the immediate 
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 postoperative period including suggestions for rescue have been presented.23   ASPAN’s newly 
developed evidence-based guideline on prevention and management of PONV/PDNV is the first 
to cover the entire period of the patient’s perioperative experience, including post discharge.18 
 
Methods 
Systematic Search 
To perform the literature search for applicable articles, the authors searched MEDLINE 
(Pubmed, from 1966) limited to research literature on adults.  The keywords used were 
“postdischarge nausea and vomiting” (26 results), “post discharge nausea and vomiting (62 
results) “postoperative nausea and vomiting” (1761 results), “complementary medicine” (85287 
results), and “outpatient surgery” (6116 results).  “Outpatient surgery” and “complementary 
medicine” were combined for a total of 58 articles, “ outpatient surgery” and “postoperative 
nausea and vomiting” for a total of 255 articles and “complementary medicine” and 
“postoperative nausea and vomiting” for a total of 73 articles.  The Cochrane Controlled Trials 
Register (2005, Issue 4) was also searched.  CINAHL (from 1960) was searched though no 
additional literature was identified.  Abstracts were searched for suitable articles, and reference 
lists were examined for additional sources.  The search resulted in 20 articles specific to 
interventions for the purpose of preventing or dispelling nausea and vomiting after discharge 
home.   
Inclusion and Exclusion Criteria 
  Articles that were not interventional studies or systematic reviews of intervention studies 
were excluded.  Any articles reporting findings on the pediatric population (age < 19 y) were 
excluded.  Studies reporting on PONV risk assessment, PONV prophylaxis or treatment of 
immediate PONV were excluded as well as any studies that had mixed populations of inpatients 
and outpatients.  The review was restricted to studies published in the English.  The included 
studies described interventions specific to PDNV in the adult population after outpatient surgery.  
(Table 3-1.) 
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 Analysis 
 Variables used by the authors in this analysis included sample description and size, 
research design, objective or purpose of the study, methodology, time of data retrieval after 
discharge, outcome measures, findings, and limitations.  The strength of the evidence was rated as 
suggested by ASPAN’s evidence-based practice (EBP) conceptual framework24 and Stetler, et 
al.25  The level of evidence ranges from Level 1, a meta-analysis to Level VI, expert opinion.  The 
quality of each study is rated from A to D with A representing a well-designed study and D 
representing a study with a major flaw or questions about scientific credibility.25  (Table 3-2.)   
 
Results 
The search identified two systematic reviews, 17 randomized controlled trials (RCTs), 
and one non-experimental study with a convenience sample.  All of the studies were published 
between 1990 and 2004.  All of the studies were published in medical journals; none in nursing 
journals.  The two systematic reviews were rated as IA according to strength of reviewed 
literature.25  The 17 RCTs were classified as IIA to IIC, with the one non-experimental study 
classified as IIIB.   
Four of the studies (20%) concerned anesthetic techniques, comparing some form of total 
intravenous anesthesia (TIVA) to inhalation anesthesia.  Ten studies (50%) compared various 
antiemetics and one study (5%) compared analgesics and the effect on PDNV.  Five studies 
included non-pharmacological variables.  One study (5%) compared therapeutic suggestions via 
tape to a comparison tape, three studies (15%) looked at acupuncture or acustimulation, and one 
study (5%) compared ginger to placebo.  See Table 3-1 for a full list of studies. 
 Interestingly, none of the 17 RCTs included information on the recruitment of patients.  
All authors assured that approval had been obtained from their facility IRBs and informed 
consent was obtained, but no recruitment guidelines were included in any of the studies.  None of 
the studies included reliability or validity data on the instruments used to obtain information.  In 
some studies, it was unclear as to how the information was obtained from the patient, or by 
whom.  Only four studies included information on the data collectors after discharge.  The 
training of research assistants or other data collectors was not addressed. 
 On the other hand, power analysis was included in 12 of the 17 RCTs.  The sample 
population was described in detail in all studies with a clear and concise purpose stated in all 
studies.  Exclusion and or inclusion information was detailed.    
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 Pharmacological Interventions 
Anesthetic Techniques 
Paech, Lee, and Evans14 conducted an RCT of 144 outpatients who were divided into 3 
groups: (1) inhalational anesthesia plus dolasetron, (2) total intravenous anesthesia (TIVA) plus 
dolasetron. and (3) TIVA alone.  Significantly more outpatients in the inhalational/dolasteron 
group had postdischarge nausea (PDN) with the lowest incidence of PDN in the TIVA plus 
dolasetron group. There was no significant difference among groups in regard to post discharge 
vomiting (PDV).14  Visser and others,26in an RCT oof 563 outpatients, found significantly less 
PONV in TIVA patients at 24 hours compared to patients who received inhalational anesthesia 
with isoflurane and nitrous oxide.  There was no significant difference at 14 days.   
Carvalho and associates27 separated 99 outpatients undergoing laparoscopic sterilization 
into two groups: one receiving TIVA with propofol and the other receiving inhalational 
anesthesia with isoflurane.  There were no significant differences with regard to PDNV between 
the groups.  Gupta and others15 conducted a systematic review to determine the effects of four 
different anesthetic techniques on postoperative recovery and complications, including PDNV.  
The incidence of PDNV was less frequent with intraoperative use of propofol compared to 
isoflurane, but not when compared to desflurane or sevoflurane.  The authors conclude their 
review by stating that the specific anesthetic appears to play a minor role in outcome after 
outpatient surgery.15 
Antiemetics 
 Gupta and others7 completed a systematic review to determine whether the routine 
prophylactic use of antiemetics affects the incidence of PDNV following outpatient surgery.  The 
review included only RCTs published in the English language.  They found an overall beneficial 
effect of using either combination treatment with two drugs or ondansetron alone for prevention 
of PDNV.  Dexamethasone prevented nausea, but not vomiting after discharge.  No differences 
between placebo and treatment groups were found when droperidol or meoclopramide were used 
as the antiemetic.  Numbers-needed-to-treat (the number of patients who would need to be treated 
for PDNV to prevent one adverse outcome) favored the use of combination therapy for 
prophylaxis of PDNV, especially in high-risk patients.7 
 Coloma and others17 investigated the antiemetic effect of dexamethasone (4 mg) as an 
adjunct to a 5-HT3 antagonist.  All patients who had undergone laparoscopic cholecystectomies 
received dolasetron 12.5 mg.  The control group received saline and the treatment group received 
dexamethasone 4 mg IV.  The dexamethasone group had significantly less nausea at home.  
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 Rothenberg and others28 compared the incidence of PDNV after dexamethasone versus droperidol 
following laparoscopic gynecologic outpatient surgery.  They found significantly less PDNV in 
patients who received dexamethasone even though there were no significant differences in early 
PONV before discharge.  The authors conclude that dexamethasone is as efficacious as droperidol 
and may have a longer duration of action. 
 Tang, Watcha, and White16 compared the efficacy, safety, and cost-effectiveness of 
ondansetron 4 mg with 2 differing doses of droperidol (0.625 mg and 1.25 mg) in the prevention 
of PONV and a placebo group.  They found that PDV was significantly decreased in groups 
receving droperidol of either amount and ondansetron versus placebo.  In regard to PDN, the only 
significant difference was between ondansetron and the placebo.  Their conclusion was that the 
lower dose of droperidol provided the same antiemetic relief as ondandsetron 4 mg and was more 
cost-effective.16 
 Gan, Franiak, and Reeves29 compared ondansetron orally disintegrating tablet (ODT)  
with placebo to determine if administration of ondansetron ODT (8 mg) would result in decreased 
PDNV.  All patients received ondansetron 4mg IV prior to induction. The treatment group 
received ondansetron ODT immediately before discharge and were given a second tablet to take 
12 hours later.  The investigators found that the patients in the treatment group had significantly 
less severe nausea and fewer vomiting episodes after discharge.  There was also a significant 
difference in patient satisfaction scores between groups.29  Thagaard and others30 compared 
ondansetron ODT 8 mg twice daily for three days to placebo.  There was no significant difference 
in groups, so the authors concluded that use of ondansetron ODT did not decrease PDNV in 
outpatients undergoing laparoscopic surgery. 
 Rajeeva and others31 compared an ondansetron/dexamethasone combination to 
ondansetron alone for prevention of PONV.  The medications were given intravenously 
immediately after intubation.  At 24 hours, there was significantly less PDNV in the combination 
group.  The authors concluded that PDNV was better controlled with the combination group than 
early PONV, where there was no significant difference between the two groups. 
 Bailey and others32 evaluated the effect of transdermal scopolamine on the incidence of 
PDNV.  After surgery, there was overall significantly less nausea, retching and vomiting in the 
scopolamine-treated group.  However, after discharge, only 10 of 138 patients experienced 
nausea, vomiting, or retching with no significance between groups. 
 Parlow and others19 assessed the efficacy of administering promethazine prophylactically 
prior to discharge home from the healthcare facility.  All patients received 0.5 mg droperidol 
during surgery and were then randomized to receive 0.6 mg/kg promethazine or a placebo 
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 intramuscularly prior to transfer from PACU.  There was no significant difference between 
treatment and placebo groups; however the incidence of drowsiness was higher in those receiving 
the promethazine on arrival home and bedtime.  Promethazine did not change the incidence of 
PDNV in this study.19  In a non-experimental study, Wright, Jilka, and Gentry33 assessed the 
usage of promethazine and evaluated the efficacy in ameliorating PDNV.  All outpatients during 
a year who had excessive PONV and were at risk for PDNV were sent home with two 
promethazine suppositories.  Fifty five percent of the patients in this groups experienced PDN, 
and of that group, 89% used the suppositories.  All of those patients reported improvement in 
symptoms with no reported side effects.  The authors concluded that promethazine suppositories 
were effective in treating PDNV and were well tolerated.33  
Pain Medication 
Claxton and others34 compared the analgesic efficacy and incidence of side effects of 
intravenous morphine and fentanyl for pain after ambulatory procedures.  Fifty-eight patients 
were randomized into either a morphine or fentanyl group for postoperative analgesia in the 
PACU.  There was no significant difference between groups in the PACU, but there was a 
significantly higher incidence of PDNV in the morphine group at 24 hours.34 
 
Non-Pharmacological Interventions  
Therapeutic Suggestions 
 Lebovits, Twersky, and McEwan35 compared two groups of outpatients, one group who 
listened to a therapeutic tape (TT) during surgery and the other group who listened to a 
comparison tape to determine if the TT resulted in improved recovery for the surgical outpatients.  
They found a significant difference between groups during the first 90 minutes, but no significant 
difference in PDNV at 2,4, or 24 hours.  The TT group did experience fewer overall side effects. 
Acupuncture/Acustimulation 
 Al-Sadi, Newman, and Julious36 assessed the efficacy of acupuncture as a prophylactic 
antiemetic.  Eighty-one outpatients were randomized to two groups: a treatment group that 
received acupuncture intraoperatively at the PC6 point, and a group that received placebo.  They 
found a significant difference between groups before and after discharge with the placebo group 
four times more likely to have PDNV than the acupuncture group. 
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  Coloma and others37 compared acustimulation to ondansetron for the treatment of 
established PONV in outpatient laparoscopic surgery patients.  All patients received prophylaxis 
with either droperidol 0.625 mg IV or metoclopramide 10 mg IV.  Ninety of 268 enrolled patients 
developed PONV and were randomized to one of three treatment groups: ondansetron 4 mg IV 
and sham acustimulation, acustimulation and 2 ml of IV saline, or a combination of ondansetron 
4 mg IV and acustimulation.  The combination group of ondansetron and acustimulation had a 
higher complete response rate (no emesis or complaints of nausea) than the acustimulation group 
within two hours.  Fewer patients in the combination group versus the acustimulation group 
experienced further emetic events.  There were no other significant differences among the three 
groups. The authors conclude that acustimulation may be a satisfactory alternative to ondansetron 
for established PONV, and that ondansetron seems to enhance the efficacy of acustimulation for 
treatment of established PONV.37 
 White and others38 compared the efficacy of acustimulation to ondansetron when used 
alone or in combination.  The 120 outpatients were divided into 3 treatment groups: ondansetron 
and sham acustimulation, acustimulation and saline, and a combination of ondansetron and 
acustimulation.  They found that acustimulation in combination with ondansetron significantly 
reduced PDN and PDV and the need for rescue antiemetics compared to ondansetron alone at 24 
hours post discharge.  There were no significant differences between the acustimulation and 
ondansetron groups.  At 72 hours the only significant difference was satisfaction with antiemetic 
treatment  The authors concluded that acustimulation with ReliefBand® appeared to be an 
effective alternative to ondansetron for prevention of PDNV in the plastic surgery patient. 
Ginger 
 Pongrojpaw and Chiamchanya39 conducted a study of 80 outpatients to determine the 
efficacy of ginger in prevention of PONV after discharge.  The treatment group received two 
capsules of ginger (0.5 mg ginger powder each) one hour before the procedure. The control group 
received placebo tablets.  They found significantly less nausea at two and four hours, but no 
significant difference at 24 hours.  There was no significant difference in PDV at any time during 
the study.  The authors concluded that ginger significantly reduced postoperative nausea 
compared to the placebo in outpatient laparoscopic gynecology procedures. However the group 
taking ginger experienced no significant difference in PDN or PDV than placebo.39 
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Discussion 
Pharmacological Interventions 
Three RCTs and one systematic review determined whether TIVA or inhalational 
anesthesia was more closely related to PDNV.  The results of one study determined that there was 
significantly more nausea with the isoflurane plus dolasetron group compared to other 
inhalational agents and TIVA.14  There was no significant difference among groups in regard to 
PDV.  One study found significantly less PONV in the TIVA group at 24 hours, but no difference 
in PDNV at 72 hours and 14 days.26  The third RCT found no significant difference between 
groups anesthetized either with TIVA or isoflurane at seven days post discharge.27  Results of a 
systematic review showed that the incidence of PDNV was less frequent with propofol than with 
isoflurane, but not compared to desflurane or sevoflurane.15  Based on Stetler et al.25 and 
ASPAN’s EBP conceptual framework,24 the studies ranked from IA to IIB.  See Tables 3-1 and 3-
2. 
The evidence supports the use of isoflurane as an influencing factor in early PONV, but 
not PDNV.  The evidence also points to TIVA as decreasing early PONV, but not an influence on 
PDNV.  This evidence is supported by Apfel and others40 who concluded that volatile anesthetics 
are the main cause of early PONV, but have no impact on delayed PONV (2-24 hours). 
 The overall evidence concerning antiemetics as prophylaxis or treatment for PDNV is 
sparse.  One systematic review that summarized whether routine prophylaxis with antiemetics 
had an effect on PDNV was found.  Nine studies compared antiemetics with other antiemetic 
treatments or placebo.  Strong evidence exists to support prophylaxis with antiemetics versus 
placebo, a beneficial effect of combination treatment as well as a beneficial effect of 
dexamethasone for prevention of PDN.7, 17, 31   There was mixed evidence as to the effect of 
ondansetron orally disintegrating tablets (ODT) to decrease PDNV, although there is evidence 
ondansetron does have a beneficial effect on PDNV.7, 16, 29-31, 37, 38  There is evidence that 
droperidol is not an effective prophylaxis for the post discharge population.7, 16, 28  The evidence 
in these studies varied from IA to IIC and is sufficient to recommend prophylaxis in the post 
discharge population. 
 There is some evidence that transdermal scopolamine reduces PDNV (IIB).32  This 
evidence is supported by a systematic review of efficacy and safety of transdermal scopolamine 
for prevention of PONV.41  Even though the review did not differentiate PDNV from PONV, the 
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 conclusion was that transdermal scopolamine significantly reduces the risk of postoperative 
vomiting although associated with some side effects such as visual disturbances or dry mouth.41  
 There is evidence (IIB) that promethazine given IM prior to discharge home does not 
decrease the incidence of PDNV, but does increase the incidence of drowsiness.19  There is some 
evidence (IIIB) from a non-experimental study that promethazine suppositories did improve the 
symptoms of PDNV.33 
 One study addressed the preferential use of an opioid on the incidence of PDNV.  There 
is some evidence (IIB) to indicate that even though morphine was associated with a better level of 
analgesia, it was also associated with an increased incidence of PDNV.343 
Non-Pharmacological Interventions 
 Based on the available evidence, it appears that therapeutic suggestions in outpatients do 
not decrease the incidence of PDNV (IIC).35  Although there was a significant difference over the 
first 90 minutes, the treatment group did not experience a difference in PDNV over later 
assessment periods.  This evidence is supported by a study conducted by Jelicic, Bonke, and 
Millar42 to determine the effect of different therapeutic suggestions on postoperative recovery 
well-being.  The results of that study demonstrated no significant differences on well-being the 
third and fifth day. 
 There is evidence (IIB) to support the use of acupuncture in the prevention of PDNV.  
Patients in the placebo group were four times as likely to experience PDNV as those in the 
treatment group.36   There is also evidence to support the use of acustimulation for the prevention 
of or treatment for PDNV.  Acustimulation in combination with ondansetron had a higher 
complete response rate than acustimulation alone (IIC).37  In another study, acustimulation in 
combination with ondansetron significantly reduced PDNV and the need for rescue antiemetics 
compared with ondansetron alone at 24 hours after surgery (IIB).38 
 Ginger is a botanical remedy used in China to alleviate nausea and vomiting that has also 
been suggested as beneficial to PONV.  The recommended dose is 1 g of powdered ginger given 
before surgery.43   There is no evidence supporting the use of ginger for PDNV (IIB).  This 
evidence is supported by a study conducted primarily on inpatients that showed no significant 
benefit of ginger for PONV.44 
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 Limitations 
The limited number of studies evaluated in each category limits the conclusions of the 
review.  On the other hand, only studies that specifically addressed the post discharge period of 
the perioperative period were included.  No previous reviews have addressed interventional 
studies to determine evidence for treatment of the postdischarge patient. 
Recommendations 
 There is a dearth of research that specifically targets and directly affects the patient after 
discharge home.  More studies should be conducted focusing on interventions for PDNV in the 
outpatient after discharge.  Research addressing those interventions that can best prevent or 
alleviate symptoms of PDNV need to be conducted.  Researchers need to determine if risk factors 
for PONV are the same for PDNV. 
 There was a total lack of nursing research in this review; all studies were conducted by 
physicians.  Nurse researchers could conduct studies on the effects of patient education or 
education of the responsible adult, preoperative anxiety, interactions of pain and pain medication, 
and non-pharmacologic methods of relief.  Nurse researchers could collaborate with physician 
researchers to determine the best antiemetics for use in the postdischarge setting or the most 
appropriate medication for pain relief in the postdischarge setting that will alleviate pain, but 
cause less symptoms of PDNV.   
Other research indications include the most effective risk identification tools in prediction 
of PDNV, reliable and valid tools to measure PDNV, most effective prophylactic interventions to 
prevent or relieve PDNV, identification of common self-care activities used by patients and 
effectiveness, most effective patient educational content, the impact of PDNV on patient 
satisfaction and quality of life, and the economic impact.18 
Finally, the terminology needs to be standardized in future research on this population.  
Until the terminology is standardized by all researchers, confusion will still exist. Use of the 
definitions as identified by ASPAN’s multidisciplinary strategic work team18 will begin to 
alleviate the confusion surrounding the operational definition of each term. 
 
Conclusion 
Thousands of patients continue to experience PDNV every year.  In spite of newer 
anesthetic medications and a focus in the past few years on PONV and PDNV, a significant 
percentage of patients still suffer. This review attempted to consolidate the findings from research 
that has been conducted specifically for the patient experiencing PDNV.  It is certain that 
prophylactic antiemetics and combination medications work significantly better than placebo to 
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curtail the symptoms post discharge.  It is unlikely that the type of anesthetic administered has 
any effect on PDNV.  It appears that acupuncture and acustimulation may work, but others, such 
as use of ginger and therapeutic suggestions may not work as effectively.  More research needs to 
be conducted to discover the interventions that allow patients to recover to their pre-surgery 
conditions at a quality and rate of recovery that is satisfactory to the patient and to the health care 
provider. 
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Table 3.1 Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & Tools Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Al-
Sadi, et 
al., 
199736 
81 
outpatients 
undergoing 
gynecologi-
cal 
laparoscopic 
surgery 
Double 
blind 
RCT 
To assess the 
efficacy of 
acupuncture 
as a  
prophylactic 
antiemetic 
2 treatment 
groups:  
acupuncture and 
control  
24 hr PDNV Significant difference 
between groups before 
and after discharge; 
placebo group 4 times 
more likely to have 
PDNV than acupuncture 
group 
 
Severity of 
PDNV was not 
measured 
 
IIB 
Bailey 
et al, 
199032 
199 
outpatient 
laparoscopy  
patients 
enrolled; 53 
excluded due 
to breach in 
study 
protocol 
RCT: 
Double 
blind, 
placebo 
control-
ed 
Study 
To evaluate 
the effect of 
transdermal 
scopolamine 
on the 
incidence of 
PON, 
retching, and 
vomiting  
Band-aid-like 
patch containing 
either 
scopolamine or 
placebo was 
placed behind 
the ear the night 
before surgery. 
48 hr PDNV and 
retching  
Overall significantly less 
nausea, retching, and 
vomiting in the 
scopolamine-treated 
group.  Only 10 patients 
experienced nausea, 
vomiting, retching at 
home with no 
significance between 
groups. Safe and 
effective antiemetic 
Only 10 patients 
had PDNV 
 
IIB 42 
 
 
                                                                                             
Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & 
Tools 
Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Carvalho, 
et al., 
200227 
99 
outpatients 
undergoing 
laparos-
copic 
sterilization 
RCT: semi-
open 
(attending 
anesthesia 
provider 
aware of 
allocated 
treatment, but 
neither  
patient, 
research 
nurse, nor 
recovery staff 
were aware) 
To evaluate the 
influence of 
anesthetic 
technique on 
functional 
recovery and 
symptom 
distress  
2 groups: 
received 
either total 
intravenous 
anesthesia 
with propofol 
or isoflurane 
inhalational 
anesthesia 
7 day Functional 
recovery 
and 
symptom 
distress 
including 
PDNV 
No significant 
differences 
between the 
groups 
Study was 
underpowered to 
detect differences 
in regard to 
nausea and 
vomiting 
 
IIB 
Claxton, 
et al., 
199734 
58 
outpatients 
undergoing 
surgery 
anticipated 
to be 
painful  
RCT: 
prospective,  
double blind 
To compare the 
use of IV 
morphine and 
fentanyl after 
ambulatory 
procedures 
with respect to 
analgesic 
efficacy and 
incidence of 
side effects 
2 groups: 
received 
either 
morphine or 
fentanyl IV 
for 
postoperative 
analgesia 
during PACU 
stay 
24 hr Side effects 
including 
PDNV 
Even though 
PONV not 
significantly 
different between 
groups in PACU, 
there was a 
significantly 
higher incidence 
of PDNV in the 
morphine group at 
24 hours. 
Small groups 
 
IIB 
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Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & Tools Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Coloma 
et al, 
200237 
Enrolled 
268 
outpatients 
receiving 
laparoscopic 
surgery; 83 
of 90 
patients with 
established 
PONV 
studied 
RCT: 
Double-
blind, 
placebo 
and sham- 
controlled 
study 
To evaluate 
acustimu-
lation 
compared 
with 
ondansetron 
for 
treatment of 
established 
postopera-
tive N/V of 
outpatient 
laparoscopic 
surgery 
patients 
All patients 
received 
prophylaxis with 
either droperidol 
0.625 mg IV or 
metoclopramide 10 
mg IV.  90 patients 
developed PONV 
and were 
randomized to 1 of 
3 treatment groups: 
ondansetron 4mg 
IV and sham 
ReliefBand®; 
ReliefBand® and 2 
ml IV saline; or 
combination of 
4mg IV 
ondansetron and 
ReliefBand®.  
Requested to keep 
ReliefBand® on 
arms for 72 hours 
except when 
bathing. 
 24 and 
72 hr 
PDNV as 
well as 
other 
effects, 
such as 
patient 
satisfaction 
and quality 
of recovery 
Combination group 
had significantly 
higher complete 
response rate than 
acustimulation group 
(73% vs 40%; P < 
.01) within 2 hours.  
Fewer patients in 
combination group vs 
acustimulation had 
further emetic events 
( P < .03).  No other 
significant 
differences between 3 
groups. Ondansetron 
in combination with 
acustimulation 
improved complete 
response rate to 
acustimulation 
therapy. 
Effect of 
acustimulation 
may have been 
increased if 
applied before 
surgery instead 
of after 
established 
PONV.  
Relatively 
small group 
sizes  
(N = 30).   
 
IIC 
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Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
Study Population Design Objective Method & Tools Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Coloma, 
et al., 
200217 
140 
outpatients 
undergoing 
laparoscopic 
cholecys-
tectomy 
RCT: 
placebo-
controlled, 
double-
blind 
To 
investigate 
the effect of 
administering 
4 mg IV 
dexametha-
sone as 
adjunct to a 
5-HT3 
antagonist 
2 groups: control 
group received 1 
ml IV saline, 
dexamethasone 
group received 4 
mg IV 
dexamethasone. 
All patients 
received 12.5 mg 
dolasetron 
24 hr Post 
discharge 
side effects 
Dexamethasone 
group had 
significantly less 
nausea at home.   
IIB 
Gan et 
al., 
200229 
60 
outpatient 
laparoscopic 
gyn patients 
RCT: 
Randomly 
assigned 
to groups. 
Research 
personnel 
collecting 
data were 
blinded 
To determine 
if adminis-
tration of 
ondansetron 
ODT would 
result in 
decreased 
PDNV 
All patients 
received 
ondandsetron 4 
mg IV at 
induction.  
Treatment group 
received 
ondansetron ODT 
immediately 
before discharge 
and given second 
tablet to take 12 
hours later; control 
group received 
placebo tablets.  
Nausea scored 
using 11-point 
linear numerical 
scale from 0 – 10. 
2 hr and 
24 hr 
PDNV: 
incidence, 
severity of 
nausea, side 
effects, 
satisfaction 
Ondansetron ODT 
patients had 
significantly less 
severe nausea and 
fewer vomiting 
episodes after 
discharge.   
PDV: ondansetron 
ODT 3%; Placebo 
23%.  P <.05 
Severity of nausea:  
ondansetron ODT 0 
(0-10), placebo 2  
(0-10). P < .05. 
Patient satisfaction: 
ondansetron ODT 
90%, Placebo 65%; P 
< .05. 
Small groups. 
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Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & 
Tools 
Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Gupta, 
et al., 
20037 
22 articles Systematic 
review of 
RCTs 
To assess whether 
routine 
prophylactic use of 
antiemetics 
influences 
incidence of PDNV 
MEDLINE 
via PubMed 
 PDN, 
PDV 
Incidence of PDN 
(32.6%) & PDV (14.7%) 
in placebo vs treatment 
groups significantly 
different (P < .05).   
Beneficial effect of 
combination treatment or 
ondansetron 4 mg for 
prevention of PDNV; 
beneficial effect of 
dexamethasone which 
prevented PDN, but not 
PDV; droperidol not 
effective as prophylactic 
for PDN 
IA 
Gupta, 
et al., 
200415 
58 articles Systematic 
review 
To assess whether 
use of propofol 
infusion, 
isoflurane, 
sevoflurane, or 
desflurane is 
associated with 
faster recovery and 
fewer side effects 
during ambulatory 
surgery in adults 
MEDLINE 
via PubMed, 
hand search 
through 
references 
 PDNV as 
subset of 
side 
effects 
The incidence of PDNV 
was less frequent with 
propofol compared to 
isoflurane but not 
compared to desflurane or 
sevoflurane.  Specific 
anesthetic appears to play 
minor role in outcome. 
IA 
46 
 
 
                                                                                             
Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & 
Tools 
Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Lebovits, 
et al., 
199935 
70 adults 
undergoing 
elective 
outpatient 
hernia repair 
under 
general 
anesthesia 
RCT:  
Double 
blind 
To determine if 
patients receiving 
intraoperative 
therapeutic 
suggestions 
would result in 
improved 
recovery in 
surgical 
outpatients 
2 groups: 
therapeutic 
tape group 
(TT) and 
comparison 
tape group. 
Played 
continuously 
during 
surgery. 
24 hr Pain, 
nausea, 
vomiting 
Significant difference 
between groups during 
first 90 minutes, but 
no significant 
difference in PDNV at 
2, 4, or 24 hours. TT 
group did experience 
fewer side effects. 
IIC 
Paech, 
et al., 
200214 
144 
outpatients 
receiving 
laparoscopic 
gynecology 
surgery 
RCT: 
Prospective 
double 
blind 
To compare the 
incidence of 
PONV using 
TIVA with or 
without 
dolasetron with 
balanced 
inhalational 
anesthesia using 
sevoflurane and 
dolasetron  
3 groups: 
Inhalational + 
dolasetron 
(I+D); TIVA 
+ dolasetron 
(T+D); TIVA 
alone (T) 
24 hr and 
4th day 
PDN, 
PDV  
Significantly more 
nausea in I+D, no 
significant difference 
of PDV between 
groups 
IIB 
47 
 
 
 
 
 
 
 
 
                                                                                             
Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & Tools Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Parlow et al, 
199919 
95 women 
who 
received 
ambulatory 
laparoscopic 
cholecys-
tectomy or 
gynecologic 
surgery 
RCT: 
Double 
blind, 
placebo 
controlled 
study 
To determine 
the incidence of 
PDNV after 
outpatient 
laparoscopic 
procedures and 
assess the 
efficacy of the 
prophylactic 
administration 
of promethazine 
prior to 
discharge from 
hospital 
All patients 
received 
prophylactic 0.5 
mg droperidol 
during surgery. 
Randomized to 
receive 0.6 
mg/kg -1 
promethazine or 
placebo IM 
before transfer 
from PACU. 
Incidence and 
severity of 
nausea, pain, 
drowsiness 
documented 
using patient 
diaries at 4 
intervals using 
4-point scales. 
24 hr PDNV PDN = 48% 
(moderate to 
severe = 30%) 
PDV = 17% 
Rescue anti-
emetic use 28% 
No statistical 
difference 
between groups 
regarding PDNV.  
Incidence of 
excessive 
drowsiness higher 
in those receiving 
promethazine or 
arrival home (P = 
.001) and bedtime 
 (P < .001) 
IIB 
Pongrojpaw, 
et al., 200339 
80 
outpatient 
gyneco-
logical 
laparoscopy 
patients  
RCT: 
Double 
blind  
To study the 
efficacy of 
ginger in 
prevention of 
PONV/PDNV 
2 treatment 
groups: 2 
capsules of 
ginger 1 hr 
before 
procedure and 
placebo 
2, 4, 24 
hr 
PONV/ 
PDNV 
Significantly less 
nausea at 2 and 4 
hours, but no 
significant 
difference at 24 
hrs; no significant 
difference in PDV.
IIC 
48 
 
                                                                                             
Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & Tools Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Rajeeva, et 
al., 199931 
51 female 
outpatients 
receiving 
diagnostic 
laparoscopic  
gynecologic
al surgery 
RCT:  
Double 
blind  
To compare the 
efficacy of 
ondansetron-
dexamethasone 
with ondansetron 
alone for 
prevention of 
PONV 
2 treatment 
groups: 
ondansetron-
dexamethasone 
or ondansetron 
alone. Drugs 
given IV 
immediately after 
intubation 
24 hr PONV/ 
PDNV 
Significantly 
less PDNV in 
combination 
group 
(ondansetron-
dexamethasone) 
Small group 
size 
 
IIC 
Rothenberg
, et al., 
199828 
95 
outpatient  
undergoing 
laparoscopic 
gynecology 
procedures 
RCT:  
Double 
blind  
To compare the 
incidence of 
PONV after 
dexamethasone 
versus droperidol 
following 
laparoscopic 
gynecologic 
outpatient surgery 
2 groups: 
dexamethasone 
0.17 mg/kg IV or 
droperidol 0.02 
mg/kg IV just 
before abdominal 
incision. 
24 hr PONV/ 
PDNV 
Significantly 
less PDNV in 
patients who 
received 
dexamethasone. 
No difference in 
early PONV 
before 
discharge. 
IIC 
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Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
Study Population Design Objective Method & Tools Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
Tang, et 
al., 
199616 
161 elective 
outpatients 
undergoing 
gynecologic 
procedures 
RCT:  
Prospective
, double-
blind, 
placebo-
controlled  
To compare the 
efficacy, safety, 
and cost-
effectiveness of 
ondansetron 4mg 
with 2 doses of 
droperidol (0.625 
mg and 1.25 mg) in 
prevention of 
PONV 
4 treatment 
groups: saline 
placebo, 
droperidol 0.625 
mg, droperidol 
1.25 mg, or 
ondansetron 
4mg given 
immediately 
before induction 
24 hr; 7 
days 
PDN, 
PDV 
 
PDV significantly 
less in groups 
receiving 
droperidol of 
either amount and 
ondansetron 
versus placebo.  
PDN only 
significantly 
different between 
ondansetron and 
placebo. 
IIA 
Thagaard
, et al., 
200330 
96 outpatients 
requiring 
elective 
laparoscopic 
surgery 
RCT:  
Double 
blind 
To compare 
ondansetron ODT 
with placebo during 
first 72 hours after 
ambulatory surgery 
focusing on PONV 
and other side 
effects 
2 groups: 
placebo and 
treatment, 
received 6 
tablets with one 
tablet taken 
twice a day until 
box was empty 
24 and 
72 hr 
PDNV 
 
No significant 
differences 
between groups on 
nausea, vomiting, 
or other side 
effects 
IIB 
Visser, et 
al., 
200126 
563 outpatients 
(and 1447 
inpatients) 
requiring 
elective surgery 
with general 
anesthesia) 
RCT: all 
personnel 
except 
anesthesia 
blinded to 
group 
To assess the 
incidence of PONV 
after TIVA with 
propofol versus 
inhalational 
anesthesia with 
isoflurane/nitrous 
oxide 
2 treatment 
groups: TIVA 
with propofol, 
inhalational 
anesthesia with 
isoflurane/ 
nitrous oxide 
24, 72 hr, 
14 d 
PONV, 
PDNV 
Significantly less 
PONV in TIVA 
group at 24 hr. No 
difference at 72 hr 
and 14 d. 
IIA 
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Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & 
Tools 
Duration Outcome 
Measures 
Findings Limitations/ 
Quality of 
Evidence 
White 
et al., 
200238 
120 
outpatients 
undergoing 
plastic 
surgery 
RCT: 
Double-
blind, 
placebo- 
and sham- 
controlled 
study 
To compare 
the efficacy of 
acustimulation 
to ondansetron 
when used 
alone or in 
combination 
All patients 
received low 
dose droperidol 
prophylaxis.  
Groups were: 
ondansetron 4 
mg IV and 
sham 
ReliefBand®; 
acustimulation 
and 2ml saline 
IV; 
combination 
with 4 mg 
ondansetron IV 
and active 
ReliefBand®.   
IV medications 
were given in 
the PACU. All 
groups request 
to wear 
ReliefBand® 
for 72 hours 
except when 
bathing. 
24 hr and 
72 hr 
PDNV, 
quality of 
recovery 
score, 
patient 
satisfaction, 
need for 
rescue 
antiemetics, 
ability to 
resume 
normal diet 
within 24 
hours 
Acustimuation using 
ReliefBand® in 
combination with 
ondansetron significantly 
reduced PDN and PDV, 
and need for rescue 
antiemetics compared with 
ondansetron alone at 24 hr 
after surgery.  No 
significant differences 
between the acustimulation 
and ondansetron groups. 
At 24 hr: 
combination group 20% 
with PDN and 0% with 
PDV; Acustimulation PDN 
35%; PDV 10%; 
ondansetron group PDN 
50%, PDV 20%.  PDN, 
PDV and need for rescue 
antiemetic medication were 
significantly reduced in the 
combination (vs 
ondansetron) group         (P 
< .05).  At 72 hr only 
significant difference was 
satisfaction with antiemetic 
(P < .05.) 
IIB 
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Table 3.1 (Continued) Interventional Studies in Adults for PDNV in the Discharge Setting 
 
Study Population Design Objective Method & 
Tools 
Duration Outcome 
Measures 
Findings Limitation 
/Quality of 
Evidence 
Wright 
et al., 
199933 
99 adult OP 
discharged OP 
surgery  with 
promethazine 
suppositories 
(80 GA, 18 
MAC, 1 
spinal)  
Non-
experimental 
study 
To assess the 
usage of 52 
romethazine 
and evaluate 
the efficacy 
in 
ameliorating 
nausea & 
vomiting in 
adult OP 
following 
discharge 
All patients 
who had 
excessive 
PONV& at 
risk for 
PDNV sent 
home with 
two 
promethazine 
suppositories 
24 hr PDNV 
Choice of 
responses to 
supp use: no 
improvement, 
great 
improvement, 
worsening of 
symptoms 
PDN = 55% 
(N = 54); 
PDV = 15% 
(N = 15); 
89% of PDN used 
suppositories       
(N =  48). All 
reported 
improvement. 
There were no 
reported side 
effects.  
Promethazine 
suppository was 
effective in 
treating PDNV. 
Well tolerated. 
Study design was 
non-experimental 
 
IIIB 
 
Abbreviations:  GA, general anesthesia; MAC, monitored anesthesia care; N/V, nausea/vomiting; ODT, orally disintegrating tablet; OP – 
outpatient; RCT, randomized controlled trial; TIVA, total intravenous anesthesia. 
ODT – orally disintegrating tablet 
 
 
 
                                                                                             
Table 3.2 Rating Study Design and Quality of Evidence 
 
Level I  Meta-analysis/Systematic review  
Level II Experimental 
Level III Quasi-experimental 
Level IV Non-experimental or qualitative 
Level V Case reports 
Level VI Expert opinion 
 
Quality Rating 
A   Well-designed study with up to one issue unaddressed 
B  Well-designed study with two issues unaddressed 
C  Design of study fair, with two – three issues unaddressed 
D  Design of study has major flaw 
 
Quality Indicators 
? Power analysis 
? Recruitment of patients detailed 
? Hypothesis/objective of study 
? Randomization issues 
? Blind assessment issues 
? Drop-outs/attrition rates addressed 
? Exclusion/inclusion information 
? Data collection methodology 
? Appropriate statistical analyses  
? Instruments addressed 
? Factor analysis/dimensions on instruments, if appropriate 
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CHAPTER FOUR 
 
MEASUREMENT OF NAUSEA AND VOMITING FOR PATIENTS WITH POST 
DISCHARGE NAUSEA AND VOMITING:  A CRITICAL REVIEW AND ANALYSIS 
 
ABSTRACT 
 
 Both postoperative nausea and vomiting (PONV) and post discharge nausea and vomiting 
(PDNV) continue to affect over 30% of patients after surgery.  There is a lack of standardized 
definitions and instruments that measure PONV and PDNV, and a reliance on instruments 
developed by the individual investigator.  This article presents a critical review and analysis of 
measurement of patient nausea and vomiting after discharge from outpatient surgery and 
discusses relevant needs and new directions in the area of measurement. 
 
Introduction 
Despite newer anesthetic agents and antiemetic drugs, post surgery patients continue to 
experience nausea and vomiting at a rate of over 30%.1-3  Postoperative nausea and vomiting 
(PONV), nausea and vomiting immediately after surgery, has been studied in more detail than 
nausea and vomiting after discharge home from an outpatient setting.4  In a recent study of six 
interventions designed to prevent PONV, the average incidence was 34%.5 Some patient or 
anesthesia-related factors, (i.e. female gender, nonsmoking status, postoperative opioids, history 
of PONV, elevate the risk of PONV for patients to 70-80%).6 
Today more than 34 million patients undergo ambulatory surgery annually in the United 
States and over one third will experience post discharge nausea and vomiting (PDNV).7 2, 4, 8-10   
The need for research into this growing population of patients has intensified.  With that research 
comes the necessity for reliable and valid instruments to study the phenomena surrounding the 
experience of PDNV.   The purpose of this paper is to present a critical review and analysis of 
measurement of nausea and vomiting after discharge from outpatient surgery. 
 
Defining PDNV 
 Post discharge nausea and vomiting (PDNV) is not well defined in studies that measure 
nausea and vomiting.  The terms PONV and PDNV are frequently used interchangeably with 
some investigators using PONV as nausea and vomiting immediately after surgery and others 
using the term to denote nausea and vomiting after discharge home.  In some instances, any 
nausea and vomiting experienced from the moment the patient leaves the ambulatory surgery 
center or hospital is defined as PDNV.  In other instances, PDNV is defined as any nausea and 
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vomiting that occurs more than 24 hours after the patient is discharged.  In some studies, PDNV 
has been measured over a 24 hour period and in other studies, where the phenomena is considered 
to be PDNV, PDNV has been measured for 5 – 7 days.   
 Knapp and Beecher in 1953 defined nausea as a subjective sensation; the desire to vomit 
without the expulsive muscular movements.11 The authors also noted that vomiting produced 
stomach contents as a result of the expulsive efforts of the patients and retching did not.11  
Definitions of nausea and vomiting as well as retching have remained similar to definitions 
offered by Rhodes12 who defined nausea as a subjective, unobservable experience of an 
unpleasant sensation experienced in the back of the throat that may or may not end in vomiting.  
She further defined vomiting as the forceful ejection of the contents of the stomach, duodenum, or 
jejunum through the mouth, and retching as an attempt to vomit, otherwise known as dry heaves.  
The terms vomit or emesis are used interchangeably to describe the forceful ejection of contents 
through the mouth in medical literature.  Retching and dry heaves are occasionally used 
interchangeably.   
Twenty years ago, Olver, et al.13 stated the “clear need for standardization of definitions” 
in antiemetic studies and went on to declare that one of the greatest needs was the adaptation of 
standards of measurement with nausea and vomiting.  Researchers have specifically called for a 
standardized definition of PDNV.10 The members of a multidisciplinary PONV/PDNV Strategic 
Work Team convened by the American Society of PeriAnesthesia Nurses differentiated PONV 
from PDNV for the purpose of the consensus guideline they were charged to develop and, further, 
to aid in future research.8  This group defined PONV as nausea and/or vomiting that occurs to 
patients after inpatient surgery.  Post discharge nausea and vomiting is defined as nausea and/or 
vomiting that occurs after discharge from the health care facility following outpatient surgery.  
PONV and PDNV are further delineated as early, late, or delayed PONV or delayed PDNV.  See 
Figure 1 and Figure 2.  The ASPAN guideline contained the first published definition of PDNV 
that addressed standardization for research.3, 8 
 
Measurement of PDNV 
Research using measurement of nausea and vomiting began in the patient population 
receiving chemotherapy.  The instruments used now in PONV or PDNV began as instruments to 
measure nausea and vomiting after treatment for cancer and then were refined for use with 
surgery patients and pregnant women.  Measurement of PONV and PDNV has been conducted 
for the most part through the use of investigator-developed instruments.  Most commonly, 
patients are asked to rate nausea on a subjective visual analog scale (VAS), numerical rating score 
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(NRS), or verbal rating scale (VRS).  Emesis has been measured in most studies by reporting the 
number of episodes.  Rhodes noted the lack of information on reliability and validity of 
instruments used to measure nausea and vomiting.  Her concern was that the results of studies 
may not be valid if the instrument used to measure nausea and vomiting is not an accurate 
measure.12 
 
Method 
To perform the literature search for appropriate articles that measured nausea and 
vomiting after discharge in the outpatient surgery patient, the author searched MEDLINE 
(PubMed from 1966-2009) using the keywords “postdischarge nausea and vomiting” (37 results), 
“post discharge nausea and vomiting” (95 results), “ambulatory surgery-index of nausea, 
vomiting, and retching,” (0 results), Morrow assessment of nausea and emesis (MANE; 15 
results) and “functional living index emesis” (45 results).  A search through CINAHL did not add 
further articles. The author then searched the abstracts for suitable articles. The author also 
examined reference lists in those articles for additional sources.  The result was 28 articles that 
specifically mention nausea and vomiting after discharge home.   
Only articles that were descriptive or interventional studies of PDNV were included.  
Any articles findings, in which were reported on the pediatric population (age <19 years) were 
excluded.  The review was restricted to studies published in English.   
 
Results 
In 28 studies of PDNV, only in four studies were instruments with established reliability 
and validity used (14.3%). (Table 4-1.) In nine studies (32.1%) only the incidence of nausea and 
vomiting was obtained by telephone. In the other nineteen studies (67.9%) a VRS, VAS, or NRS 
scale was used to obtain incidence and intensity of symptoms.  In twenty-one (76%) of the studies 
telephone calls were used to interview the patients, in seven (25%) a mail-in investigator-
developed diary or questionnaire was used that required return to the investigator.  In many of the 
studies, patients completed an investigator-developed questionnaire, but these were supplemented 
with telephone interviews to obtain the information from the diary.  In one study a telephone 
interview at 24 hours was used in conjunction with a mail-in questionnaire to return after five 
days.  In one study data were obtained with a phone call at 24 hours and then another telephone 
call 1 –2 weeks later to ask if PDNV was present from 24 to 48 hours after surgery. 
 In the majority of studies (22), data were obtained at 48 hours; thirteen of those had data 
obtained exclusively at 24 hours.  Of those 22 studies, in the remaining nine studies data were 
also obtained at other time points including 48 hours, 72 hours, 5 days, or 7 days.   In one study 
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data were obtained at 9 hours after surgery, in three studies data were obtained after 7 days only, 
and in one study at 5 days only. 
 
Description of Existing Self-Report Measures of Nausea and Vomiting 
Diaries and Scales 
 Ponce de Leon, et al. studied the performance of VRS, VAS, and NRS scales for rating 
visual stimuli.14  The VRS was a 5-point response scale using the terms “very little”, “little”, 
“intermediate”, “much” and “very much.”  The VAS was a 100 mm line with “none” and “the 
highest possible” as anchors.  The NRS was an 11-point scale (0 – 10) with 0 = white and 10 = 
black.  Participants were shown cards showing five intensities of gray.  The VRS (kw = 0.71) 
ranked as more consistent than either the VAS (kw = 0.58) or NRS (kw = 0.63).  Validity was 
analyzed by distribution, progression and correlation.  The authors stated that it is unknown if the 
greater consistency of the VRS results from its verbal descriptors or use of only five response 
categories, but go on to assert that some clinicians believe subjective phenomena are articulated 
more easily in words than numbers. 14 
 In an article on methodology and assessment in clinical anti-emetic research, Morrow15 
discussed the use of categorical scales using adjectives such as mild, moderate, or severe, and 
VAS with a 10 cm line marked as no nausea on one end and extreme nausea on the other end as 
useful for standardized reports of nausea.  Both types of scales have been reported as reliable and 
valid using correlations between scales and consistent results over time.15-19 Interestingly, 
reliability and validity of scales used in PDNV studies, whether VRS, VAS, or NRS, are not 
typically reported. 
In many of the studies for PDNV a patient diary and the number of nausea and emetic 
episodes as recorded by the patient or nurse before patient discharge was used.  The investigator 
created these diaries; there are no standardized diaries with reliability and validity mentioned in 
the literature for report of nausea and vomiting.20 Investigators also reported use of visual analog 
scales (VAS), numerical rating score (NRS), and verbal rating scales (VRS) to evaluate 
subjective and objective stimuli.   
 In most studies, to rate nausea, the VAS and NRS scales are 0 – 102, 21-30, but have been 
reported as 0 – 3.31, 32  Grimsehl, et al. and Tang, et al. used a VAS of 0 to 100 mm.33, 34  VRS 
scales have descriptors that vary among investigators, e.g., worst possible, severe, or as bad as it 
can be.9, 23, 35  Some investigators simply asked whether nausea occurred. 36-43  One study used a 0 
cm to 10 cm VAS, but converted those findings to yes or no (less than 1 cm was counted as no 
nausea).44   Only two instruments for measuring PDNV have been reported in any PDNV studies, 
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the Ambulatory Surgery Index of Nausea, Vomiting, and Retching (AS-INVR)22 and the 
Functional Living Inventory-Emesis (FLIE).26, 45 
The frequency of vomiting was not reported consistently in studies.  In some studies the 
number of times a patient vomited per day were reported while in other studies whether the 
patient experienced emesis during the day was reported as “yes” or “no.”  A confusing factor in 
reporting the number of episodes of emesis is whether the patient who is self-reporting 
understands the difference between an episode of vomiting (with results) or an episode of 
retching (dry heaves).  In two studies an emetic episode was defined as vomiting or retching.29, 33  
Rajeeva et al. 27 was the only investigator to rate the severity of vomiting by number of episodes 
over a 24-hour period other than Fetzer who used the AS-INVR.22    For a patient who is in the 
hospital or still present at the ambulatory surgery facility, an observer can rate the objective 
symptom of emesis. However, in the PDNV population, because the patient is at home and not 
observable, emesis must be self-reported, as is the experience of nausea. 
Ambulatory Surgery Index of Nausea, Vomiting, Retching (AS-INVR) 
 The Ambulatory Surgery-Index of Nausea and Vomiting (AS-INVR), an instrument 
based on Rhodes Index of Nausea and Vomiting (INV), was developed and modified for use in 
the ambulatory surgery population.46 The Rhodes INV was developed to separately measure the 
patient’s perception of nausea and vomiting.47   The instrument included the patient’s perception 
of duration of nausea, frequency of nausea and vomiting, distress from nausea, and amount of 
vomiting.  The final instrument had five items using a 5-point numerical score with verbal 
descriptors such as “I did not throw up during the last 12 hours.”48  Reliability for the instrument 
was determined using Cronbach’s alpha as .89 – .97 and the split-half correlation was .90. 
 During tests using the Rhodes INV, patients reported also experiencing retching or dry 
heaves, as well as distress from vomiting. 49 The Rhodes INV Form 2 added 3 items to the 
original Rhodes INV to measure those constructs.  Cronbach’s alpha for Form 2 was calculated as 
.98.  Concurrent validity was assessed during two administrations using Spearman’s correlation 
coefficient and were r = .87 and r = .83.49  Construct validity was supported by the ability of the 
instrument to distinguish between cancer patients and well persons .50  Zhou, et al.51 performed a 
confirmatory factor analysis of the Rhodes INV Form 2 in a sample (N = 161) of pregnant 
women.  The model that treated nausea and vomiting as one-factor, and the model that included 
two factors (symptom occurrence and symptom distress) did not fit the data.  The authors 
concluded that the three-factor structure measuring nausea, vomiting and retching should be used 
when measuring the nausea and vomiting of pregnancy.51   
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 In an effort to modify the Rhodes INV Form 2 to a more-user friendly format, Rhodes 
and McDaniel developed a new version entitled the Index of Nausea, Vomiting and Retching 
(INVR).52  The INVR has eight items that begin with an introductory statement using the same 
component as the INV-2 and allows the patient to complete the sentence by inserting one of five 
possible responses by checking the appropriate response box.  In a study to determine the 
reliability of the INVR and using a population of cancer, medical-surgical, and obstetric patients, 
the responses to the INVR were more frequently consistent than the INV-2.52  Ming, et al.53 used 
the INVR to measure incidence of PONV in an interventional study in the postoperative setting. 
Cronbach’s alpha was .85.  Fu, et al.54 examined the reliability and validity of the Chinese 
translation of the INVR and the INV-2.  Cronbach’s alphas for the Chinese translation of the 
INV-2 in two different samples were .95 and 0.93, and 0.95 and 0.94 for the INVR.  Both 
versions were found to have good reliability and validity and high agreement rates, although a 
majority of patients expressed preference for the INVR. 
 Fetzer et al.22, 46 evaluated a modified version of the INVR for use with an ambulatory 
surgery population.  The 8-item Rhodes INVR was modified by rewording the introductory 
statements as applicable to the ambulatory surgical patient and collecting the data via telephone 
call 24 hours after patient discharge.  Internal consistency reliability of the Ambulatory Surgery 
(AS)-INVR was determined using Cronbach’s alpha (0.897); the Guttman split-half procedure 
produced a correlation of .90.  The authors suggested that these data indicate the AS-INVR 
measures upper gastrointestinal distress as a single concept in ambulatory surgical patients.  Item 
eight was dropped from further analysis due to poor correlations of that item with the other seven 
items as well as the weak internal consistency of the retching subscale.  After dropping item 
eight, the Cronbach’s alpha increased to .91.46  Both Ming et al.53 and Fetzer et al.46 found a much 
lower incidence of retching among postoperative patients than in the pregnant and cancer 
populations.   
Functional Living Index Emesis (FLIE) 
 The only other preexisting scale used in the articles in Table 4-1 is the Functional Living 
Index Emesis (FLIE) developed to address the impact of CINV on daily living. 55  This 
instrument consists of 18 items and has nine items for nausea and nine for emesis.  Each item 
asks a question and then offers options of 1-7 using the anchors “not at all” or “none” and “a 
great deal” or “not at all”, e.g. “How much nausea have you had in the past three days?”  The 
instrument was used first to compare two groups of patients who had received chemotherapy, 
those who had emesis and those who did not for a three-day period.55 
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 There was a significant decrease in FLIE scores in patients who experienced emesis and a 
constant score for those who did not indicating that the instrument measured what it was intended 
to measure.   Pearson correlations between FLIE scores after treatment and patient-reported 
nausea and vomiting (-.65, -.68) show a negative effect on the patient’s daily living.  The nausea-
related subscale of the FLIE correlated (r = .83) with the nausea factor of the Functional Living 
Index Cancer (FLIC).55. Cronbach’s alpha was .90 for before and after responses to FLIE.  The 
authors conclude that the results demonstrated FLIE was a responsive instrument for assessing 
the effects of CINV on quality of life and daily function of patients after chemotherapy 
treatment.55 
 Martin and others56 modified the original FLIE for use with 5-day recall instead of  3-day 
recall of the original FLIE.  The patients completed the modified version on day one for training 
purposes and on day six after the first cycle of chemotherapy.  Cronbach’s alpha for nausea and 
vomiting domains was .79.  Acceptable construct validity was supported by item-domain 
correlations within domains (r = .74 to .97; p < .0001) stronger than across domains (r = .52 to 
.76; p < .0001).56  The modified version of the FLIE was a reliable and acceptable instrument to 
determine impact on daily living of patients after initiation of chemotherapy. 
 Only 45 studies were found during a PubMed search using the search term “functional 
living index emesis”.  Of those studies, only two were found for the PONV/PDNV population.  
The cancer population was the focus in the other 43 studies.  Zarate et al.45 used the FLIE to 
determine nausea and vomiting in a study on the use of transcutaneous acupoint electrical 
stimulation for preventing PONV after laparoscopic surgery.  The respondents were a mix of 
inpatients and outpatients who were evaluated after a 9-hour period of time.  No reliability or 
validity data are included in the published study.  It is interesting to note that even though existing 
reliability and validity statistics are for use after three days and five days, the authors used the 
instrument to measure PONV/PDNV after only nine hours, using a telephone call to contact 
outpatients who had been discharged.  Pan and others26 used a study investigator to administer the 
modified FLIE on the last day of the study (day 5) to participants.  The authors do note that the 
FLIE is a validated instrument for assessing impact of nausea or vomiting after chemotherapy.  
The modified FLIE used in this study differed from the original FLIE because items were rated 0 
to 10 instead of 1 to 7 as in the original instrument.  Also, no items were reverse scored as in the 
original FLIE.  No reliability or validity data were included in the study. 
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Morrow Assessment of Nausea and Emesis (MANE) 
 One instrument that has been used in studies of chemotherapy induced nausea and 
vomiting (CINV) is the Morrow Assessment of Nausea and Emesis (MANE).57.  This instrument 
has 17 items that assess occurrence, duration, and severity of pre-and post CINV.  The items are 
6-point verbal descriptive scales.  Reliability and validity of the MANE have been supported in 
the cancer-related chemotherapy population in use of this instrument.57.  This instrument has 
never been used for a study in the PDNV or PONV population, probably due to suspected 
differences in the cancer chemotherapy population and ambulatory surgery population related to 
the issue of anticipatory nausea.  Anticipatory nausea and vomiting are measured in the MANE, 
and those symptoms have not been established for the PONV/PDNV population. 
 
Discussion 
Definitions and Measurement  
Assessment and findings of PONV and PDNV have been inconsistent because endpoints 
are defined differently by study. 58  Consistency of the term PDNV in future studies should 
improve with the definitions published in ASPAN’s multidisciplinary clinical practice guideline 
for prevention and management of PONV and PDNV.8  At the present time, the terminology of 
nausea and vomiting is still used interchangeably in the literature PDNV, defined in some articles 
as late PONV and in others as after discharge from the hospital without specifying whether the 
patient was an outpatient or inpatient discharged after 24 or 48 hours from the hospital.  The term 
PDNV should be defined as nausea and vomiting after outpatient discharge from the healthcare 
facility.  Delayed PDNV defines nausea and vomiting that occurs after 24 hours post outpatient 
discharge.  For the outpatient, PONV would refer to nausea and vomiting experienced while in 
the PACU.  Any nausea and vomiting for the inpatient is defined as early, late, or delayed PONV.  
(Figures 1 and 2). 
One difficulty with measurement of PONV and PDNV is the confusion with terminology 
of nausea, vomiting, and retching.  Rhodes12 addressed the issue, defined all three terms, and 
went on to create an instrument that distinguishes between the three.  Khamales and others59 
define emesis for their study as “the number of vomits (excluding dry retches) in each 24 hours 
period.” Not all studies distinguish between vomiting and retching. For example,  Zarate et al 45 
defined an emetic episode as “a vomiting, or retching event, or a combination of these events, that 
occurred in a rapid sequence (<1 minute between events.)”  One study defined vomiting as 
“emesis or retching.”29 
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Fetzer et al.22, 46 determined that retching was not as significant a problem for the 
PONV/PDNV population as for the pregnant and cancer populations.  However, until further 
studies are completed that determine whether patients experiencing PDNV do not experience 
retching as a separate entity, nausea, vomiting, and retching should be measured separately.  
Researchers suggest that nausea and vomiting occur independently and should be assessed 
separately.13, 16, 60, 61   
Outcomes of Studies 
 Consistency when determining outcomes is an important measurement issue with PDNV.  
In some studies, emesis is measured as “no emesis” or “any number of emetic episodes”. In other 
studies, the number of episodes of emesis that occur each day is measured.  In some studies 
participants are simply asked if any emesis occurred during the day at all using a yes/no format.  
In a methodological discussion of antiemetic studies, Olver et al.13 discussed the importance of 
distinguishing between a complete response with no nausea or vomiting and a lesser response that 
the authors state is obtainable by use of a severity of nausea scale and recording the number of 
vomiting episodes during the study.  The authors go on to say that a “standardized system would 
be ideal and agreement on such a scale is of paramount importance.”13 
 The outcome of paramount interest should be the experience of PDNV for the patient.  
Nausea is a subjective experience and cannot be measured by an observer.  The patient must self-
report nausea.  Investigators should use the simplest scales that give the information needed.  
Vomiting is an observable behavior, but for the outpatient surgery patient who has been 
discharged, must also be measured by self-report.  It would be possible for a responsible adult to 
observe and report vomiting and/or retching, but none of the studies found described using 
observers. 
 Other outcomes that may be of interest in research about the patient experiencing PDNV 
are appetite, pain or comfort, quality of life, patient satisfaction with care, sedation issues (related 
to antiemetic use), anxiety, or an overall question to describe any changes in degree of severity.  
See Table 4-2 for suggested measurement of PDNV. 
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Difficulties with Collecting Data 
New research is needed to establish how effective self-reporting instruments are for 
patients who are asked to evaluate the phenomena while experiencing nausea and vomiting.  
Research should also determine other factors that may come into play and affect how the patient 
feels and is able to conduct activities of daily living, such as fatigue and anxiety.  Research 
should also determine the most effective method of rating PDNV, e.g. a 12-hour or daily basis. 
Some patients have difficulty distinguishing retching from vomiting or counting emetic 
episodes if they are continuous or prolonged.  This could affect the data obtained from a patient 
who had to self-report the information.  It is possible that the two instruments mentioned in this 
paper (FLIE, AS-INVR) would aid the patient in determining the best answers to the questions.  
Tonato, et al.17 believe that any information obtained by telephone or by questioning the patient 
on their next visit was unreliable.  Use of a daily diary card with scales imbedded in the card 
proved more satisfactory.  Studies of PDNV should incorporate a written instrument for the 
patient as well as telephone calls to maintain contact with the patient and encourage follow 
through. 
Both the FLIE and the AS-INVR are easy to use and reproducible.  They also allow the 
patient to record the information on a daily basis.  Follow-up telephone calls could be used to 
obtain the information or remind the patient to mail the card to the investigator in a pre-stamped, 
pre-addressed envelope.   
Reporting of Reliability and Validity of Instruments 
 Studies in the medical literature rarely discuss the issues of reliability and validity of the 
instrument used to determine nausea or emesis unless the study was designed for that specific 
purpose.  None of the studies reported in Table 4-1 discuss reliability or validity issues except 
Fetzer et al.22 when using the AS-INVR.  Pan, et al,26 when using the FLIE mentions the past 
reliability of the instrument, but gives no reliability data.  Use of established instruments to 
determine the frequency and distress associated with nausea and vomiting is warranted.  At this 
point in the PDNV literature, there are only three studies that have used established instruments, 
the FLIE or the AS-INVR.22, 26, 45  More studies should be performed using the two established 
instruments with normative values, timing needed to complete the instrument, and grade level 
established.  See Table 4-3. Those studies that are performed should report reliability and validity 
of instruments. 
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Conclusion 
 In conclusion, approximately one third of patients continue to experience nausea and 
vomiting after discharge from outpatient surgery settings.  In studies for that group of patients, 
there have been no clear and definitive instruments in use to measure the phenomena of nausea 
and vomiting.  The AS-INVR and the FLIE provide the possibility of standardization of outcome 
for studies with those patients.  Although they both possess strengths, more study is clearly 
needed to progress the measurement of nausea and vomiting in the post discharge ambulatory 
surgery patient. 
 
Copyright © Jan Odom Forren 2009
 Table 4.1 Measures Used to Assess PDNV 
Reference Publication 
Year 
Study Outcome Measurement Used for 
PDNV 
Candiotti, et al.62 2008 Evaluate efficacy and safety of three doses of 
palonsetron versus placebo for preventing 
PONV 
PONV/PDNV Emetic episodes and 
intensity of nausea 
measured at 2, 6, 24, 48, 
and 72 hours.  Intensity 
measured on 4 point scale 
(none to severe).   
Carroll, et al.2 1995 Patient experiences with nausea and vomiting 
after discharge from outpatient surgery 
PDNV Phone interview after 24 
hours with VRS 0 (no 
nausea or vomiting) to 10 
(very severe); mail in 
questionnaire after 5 days 
(incidence only). 
Claxton, et al.36 1997 Evaluate morphine and fentanyl for analgesia 
after outpatient surgery 
PDNV Phone interview at 24 
hours.  Asked if they 
experienced nausea or 
vomiting (yes, no). 
Coloma, White, 
Ogunnaike, et al.21 
2002 Evaluation of acustimulation compared to 
ondansetron for established PONV 
PONV/PDNV Phone call at 24 and 72 
hours. Incidence of N or V; 
VRS to score nausea 
 (0 = none to 10 = worst 
imaginable). 
Coloma, White, 
Markowitz, et al.37 
2002 Evaluate dexamethasone in combination with 
dolasetron on outcome after laparoscopic 
cholecystectomy 
PONV/PDNV Phone call at 24 hours to 
determine incidence of 
nausea or vomiting. 
Ernst, et al.38 1997 Incidence and impact of pain nausea and 
vomiting after outpatient surgery 
PDNV, pain, 
serious problems 
post discharge 
Questionnaire for 72 hours:  
Incidence of nausea and 
vomiting (yes/no) 
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 Table 4.1 (Continued) Measures Used to Assess PDNV 
Reference Publication 
Year 
Study Outcome Measurement Used for 
PDNV 
Fetzer, et al.22 2005 Self-care activities for PDNV PDNV required 
for inclusion in 
study 
Phone call at 24 hours. AS-
INVR for PDNV;  NRS 0 – 
10 for distress of PDNV 
Fish, et al.39 1999 Compare sevoflurane with use of TIVA in 
regard to rapidity of recovery to home 
readiness 
PONV/PDNV Telephone call at 24 hours.  
Asked about occurrence of 
N or V 
Gan, et al.23 2002 Administration of ondanetron ODT (orally 
dissolving tablet) for PDNV 
PDNV VRS 0 (no nausea) to 10 (as 
bad as it can be).  Incidence 
of vomiting—phone call at 
24 hours. 
Grimsehl, et al.33 2002 Comparison of cyclizine and ondansetron for 
prevention of PONV in outpatients 
PONV/PDNV Questionnaire for first 24 
hours. Nausea rated as none, 
mild, severe, and with use 
of 100-mm VAS.  Emetic 
event—nausea or retching. 
Hache, et al.40 2009 Aprepitant in a multimodal approach for 
prevention of PONV 
PONV/PDNV Information received on 
postop phone call for 24 
hours. Follow up phone 
interview in 1 -2 weeks that 
asked if there was any 
PDNV during 1st 48 hours. 
Recorded incidence only. 
Mattila, et al.31 2005 Postdischarge symptoms after ambulatory 
surgery 
PDN/PDV Mail-in questionnaire 
covering 7 days using 4 
point scale (0 = nonexistent 
to 3 = severe) 
Monagle, et al.24 1997 Compared ondansetron to moderate dosage of 
metoclopramide in minor gynecologic surgery 
PONV/PDNV Phone call at 24 hours. 
Verbal scale 0 – 10. 
Incidence of emesis 
recorded. 
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 Table 4.1 (Continued) Measures Used to Assess PDNV 
Reference Publication 
Year 
Study Outcome Measurement Used for 
PDNV 
Moore, et al.44 2008 Effect of anaesthetic agents on induction, 
recovery, and patient preferences in adult day 
case surgery 
PONV/PDNV Patients given 7 day mail-in 
diary to record N,V on 0 cm 
to 10 cm VAS.  Converted 
to Yes/No (<1cm = No). 
Paech, et al.25 2002 Effect of anaesthetic technique on outpatient PDNV Phone call at 24 hours and 4 
days.  Nausea = 0 to 10 
verbal scale; # of episodes 
emesis 
Pan, et al.26 2008 Antiemetic prophylaxis for postdischarge 
nausea and vomiting and impact on functional 
quality of living during recovery in patients 
with high emetic risks 
PDNV and QOL Daily diary for 5 days after 
surgery to record daily 
incidence and severity (0-
10) of emetic symptoms. 
Phone call at hours 8, 24, 
72, and 120 hours to go 
over diary. On last day, 
administered modified 
FLIE. 
Parlow, et al.32 1999 PDNV after ambulatory laparoscopy is not 
reduced by promethazine prophylaxis 
PDN, PDV 24 hour diary with 4 point 
scale for nausea (none, 
mild, moderate, severe); # 
episodes emesis. 
Information retrieved with 
phone call. 
Pfisterer, et al.9 2001 An international study of PONV in outpatient 
surgery 
PONV/PDNV Patient diary cards for DOS 
plus 4 days reporting nausea 
(none, mild, moderate, 
severe); distress by nausea 
(not at all to extreme); # 
emetic episodes 
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 Table 4.1 (Continued) Measures Used to Assess PDNV 
Reference Publication 
Year 
Study Outcome Measurement Used for 
PDNV 
Rajeeva, et al.27 1999 Compare ondansetron with ondansetron and 
dexamethasone in prevention of PONV 
PONV/PDNV Interviewed patient at 24 
hours. Nausea 0 (none) to 
10 (as bad as it can be); 
Vomiting episodes >2 = 
severe; 2 = moderate; <2 = 
mild; 0 =  none. 
Rothenberg, et 
al.41 
1998 Compare dexamethasone versus droperidol 
following outpatient laparoscopy with 
propofol general anesthesia 
PONV/PDNV Phone call at 24 hours.  
Presence of nausea or 
vomiting noted. 
Tang, et al. 34 1996 Comparison of ondansetron and droperidol 
for antiemetic prophylaxis in outpatinet 
gynecological procedures 
PDN, PDV Nausea VAS 0 mm (none) 
to 100 mm (maximum); # 
emetic episodes; phone call 
at 24 hours and 7 days.  
Thagaard, et al.42 2007 Analgesic and antiemetic effect of ketorolac 
compared to betamethasone and 
dexamethasone 
PONV/PDNV Questionnaire for patient to 
complete at 24 and 72 hours 
that asked about nausea and 
vomiting. 
Waterman, et al.35 1998 Assess the frequency and duration of PONV 
over 7 days post orbital hydroxyapatite 
implant surgery 
PONV/PDNV Nausea—ordinal scale (nil, 
mild,moderate, severe).  
Vomiting—presence or 
absence. Rated 4 times daily 
for 7 days by patient. 
White, et al.28 2002 Comparing efficacy of acustimulation to 
ondansetron when used alone or in 
combination 
PDNV VRS 0 (no nausea) – 10 
(worst imaginable); # 
episodes emesis; patient 
diary for 72 hours. Phone 
call at 24 and 72 hours. 
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Table 4.1 (Continued) Measures Used to Assess PDNV 
Reference Publication 
Year 
Study Outcome Measurement Used for 
PDNV 
White, et al.29 2006 Evaluate the hypothesis that oral granisetron 
would be cost-effective alternative to IV 
ondandsetron for preventing PONV and/or 
PDNV 
PONV/PDNV At 24 and 48 hours, patients 
asked about incidence of 
N/V. Nausea measured on 
11 point scale (0 = none; 10 
= maximum). Emesis = 
vomiting or retching. 
White, et al.43 2007 Comparison of two antiemetic strategies in 
high risk patients undergoing minor 
gynecologic surgery 
PONV/PDNV Phone call at 24 hours to 
determine presence or 
absence of PDNV 
Zarate, et al.30 2000 Compare costs and efficacy of ondansetron 
versus dolasetron 
PONV/PDNV Phone call at 24 hours; Post 
discharge side effects noted.  
Maximum nausea during 
previous 24 hours—VRS 
0(none) to 10 (worst 
possible). 
Zarate, et al.45 2001 Use of transcutaneous acupoint electrical 
stimulation for prevention of PONV 
PONV/PDNV Phone call after 9 hours to 
outpatients; FLIE measured 
nausea scores; # episodes 
vomiting or retching 
     
 
PDNV = Post discharge nausea and vomiting; PONV = Post operative nausea and vomiting; PDN = Post discharge nausea; PDV = Post discharge 
vomiting; N = nausea; V = Vomiting; VRS = verbal rating scale; AS-INVR = Ambulatory Surgery-Inventory of Nausea, Vomiting, and Retching; 
NRS = Numerical rating scale; VAS = visual analog scale; IV = intravenous; FLIE = Functional living index of emesis; Postop = postoperative, 
DOS = Day of Surgery. 
  
 
Table 4.2 Measurement of PDNV 
 
Instrument should contain: 
• Nausea, vomiting, and retching measured as a separate entities  
• PDNV as outcome 
• Separate measures of frequency, severity (intensity), and duration 
• Format should be daily diary card (mailed in, or data retrieved from telephone calls) 
 
Measurement: 
• Nausea 
o Easy to use scales (VAS, NRS, or VRS) that are simple and reproducible 
• Vomiting 
o Number of episodes 
o Duration 
o Volume (Information less useful) 
 
When to measure 
• Report every 12-24 hours  
• PDNV reported for 5 – 7 days after discharge 
 
Indirect measures of PDNV 
• Time to food intake 
• Appetite change over time 
• Comfort  
• Quality of life 
• Sedation as related to antiemetic side effects 
• Anxiety  
• Overall quality of life assessment 
• Overall question to capture change in degree of severity 
 
Data from: 13, 15-17, 51, 60, 61 
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 Table 4.3 Comparison of Two Self Report-Measures of PONV/PDNV 
Instrument Year Number of 
Items 
Response 
Options for 
Each Item 
 
Scoring and 
Range 
Time Required 
to Complete 
Grade Level Normative 
Values 
Functional Living 
Index Emesis 1992 (3 
Day) with validation 
in 2003 (5 Day) 
18 items ( 9 for 
nausea and 9 for 
vomiting) 
Scale range is 
from 1 (not at 
all affected) to 
7 (affected a 
great deal.) 
Responses for 
items are 
summed with a 
possible score 
range of 18 to 
126. 
Unknown Unknown Unknown 
Ambulatory Surgery 
Index of Nausea, 
Vomiting, and 
Retching 2004 
7 items (3 
related to 
nausea, 3 
related to 
vomiting, 1 
related to 
retching, 
symptoms 
distress 3 items, 
symptom 
occurrence 4 
items) 
Patient has 5 
choices for each 
item, such as 
no, 1-2, 3-4, 5-
6, 7 or more. 
5 choices per 
item are scored 
as 0-4 with a 
total score of 
possible of 0 – 
28. 
Unknown Unknown Unknown 
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Figure 4.1 PONV Timeline  
 
 
 
Used with permission.8 
 
 
 
Figure 4.2 PDNV Timeline 
 
 
 
Used with permission.8 
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 CHAPTER FIVE 
 
Over 34 million patients undergo ambulatory surgery annually in the U.S.1 with as many 
as 35-50% experiencing nausea and/or vomiting after discharge following ambulatory surgery.  
This phenomenon is called post discharge nausea and vomiting (PDNV),.2-6 With more than 60% 
of all surgeries performed in the ambulatory setting and millions of patients experiencing PDNV 
every year, it is imperative that we look more closely at incidence, management strategies, and 
outcomes for these patients.7  The impact of PDNV requires that treatment of this complication 
extend well beyond discharge. 
 Researchers have focused on patient risk for postoperative nausea and vomiting (PONV), 
nausea and/or vomiting that occurs within the first 24-hour period after inpatient surgery.2, 8, 9  
PONV has been well-described, risk factors determined, and is far better studied than PDNV.8, 9   
Little research is available in which the incidence and severity of PDNV is described. PDNV is 
an underreported condition that can affect quality of recovery, has the potential for morbidity and 
hospitalization in high-risk patients, and impacts patient satisfaction. 10-15  Patients who 
experience PDNV are likely to manage their symptoms using self-care strategies at home, 
sometimes by discontinuing medications they believe are contributing to the problem.16 
 Nausea and vomiting after surgery was noted by Kapur as the “big, little problem” over a 
decade ago.12   Recently, an editorial entitled “We’re tired of waiting” called for an end to nausea 
and vomiting after surgery noted the importance of solving  our “big, little problem” and 
emphasized treatment in the post discharge period.17  In another editorial this past year, authors 
called PDNV “an overlooked aspect of ambulatory anesthesia.”18  Although variable, earlier 
investigators described the incidence of PDNV to be as high as 55%. 4 5, 19   In current studies of 
this continuing problem,  an incidence of 30-60% has been reported. 3, 10, 11, 13, 15   
 Patients have expressed their aversion to nausea and vomiting after surgery.20, 21 When 
asked to rank postoperative and postanesthesia outcomes from the most undesirable to least 
undesirable, patients rated vomiting as the most undesirable outcome, ranking it as more 
undesirable than pain or shivering.20   Patients who had experienced nausea after surgery were 
willing to pay $73 (USD) out-of-pocket for a preventative drug, and those who experienced 
vomiting were willing to pay $100 (USD).22   It is likely that nausea and vomiting after surgery 
affects not only the cost of healthcare, but directly impacts patient satisfaction.23   
 The purposes of this study were to:  1) describe the incidence and severity of PDNV over 
a 7-day period in a sample of adult surgical patients undergoing outpatient surgeries under 
general anesthesia, 2) describe the pharmacologic and nonpharmacologic modalities of care used 
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 by patients with PDNV to manage it, 3) compare the incidence and severity of PDNV between 
those who do and do not use pharmacologic and nonpharmacologic modalities, 4) determine 
outcomes associated with PDNV, and 5) determine predictions for late (Days 3-7) PDNV.  This 
study was part of a multi-site study that had as a primary objective development of a simplified 
risk model for predicting patients most likely to suffer PDNV.3  This study differed from the 
primary study by following a subset of patients over a 7-day period to better describe the 
incidence and management of PDNV. 
 
Methods 
 Design and Sample 
The methods for this prospective, descriptive multi-site study have been described 
previously.3   Briefly, twelve U.S. ambulatory surgery sites received approval from local 
institutional review boards to conduct the study. Ten of the twelve sites collected data for 48 
hours post discharge and two of the twelve sites collected data for 7 days post discharge. Eligible 
patients were adults (> 18 years of age) who were undergoing an outpatient procedure under 
general anesthesia requiring a tracheal tube or laryngeal mask airway. Excluded from the study 
were those unable to communicate in English, individuals whose surgery ended in a planned or 
unplanned inpatient stay, current pregnancy, persistent or recurrent nausea and/or vomiting before 
anesthesia, and patients who required regional anesthesia only.  Eligible participants were 
recruited consecutively either in preadmission testing or in the preoperative area on the day of 
surgery by the primary investigator or trained research assistant.  Informed consent was obtained 
from all participants.   
Variables and Measurement 
Participants were asked to provide self-reported data including demographics, medical and 
surgery-related history, and to answer questions rating distress caused by pain, nausea, and 
vomiting; how these symptoms impaired their functional living and satisfaction, and the 
frequency of symptoms and actions taken to alleviate symptoms.  Postoperative data were 
assessed using standardized questions about severity of symptoms per time interval on an 11-
point numeric rating scale.  Specifics about measurement of each of these follow. 
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 Demographics and Clinical Characteristics 
An inpatient data report sheet was used to obtain patient characteristics including age, 
gender, height, weight, and ethnicity; medical history including history of smoking, motion 
sickness, and migraines; previous general anesthetics, and current diagnoses;  surgical procedure; 
anesthesia data including the type and length of surgery, airway device, anesthetic drugs (e.g. 
type and concentration of inhalational anesthetics), and type and dose of intraoperative opioids 
and other medications; and PACU/StepDown data including PACU and Step-Down arrival and 
departure, incidence and severity of nausea, presence of vomiting or retching, and drugs given to 
the patient. Basic demographics and clinical measures were obtained from patient interview 
during initial contact with the primary researcher or other trained personnel.  Other perioperative 
data were obtained from the clinical record.   
The Patient Diary 
Employment of a daily diary for the patient to record symptoms at home has been used 
successfully in assessment of patient nausea and vomiting.24 The investigators placed all the study 
questions regarding nausea and vomiting into one packet of information for the patients to take 
home and called it a Patient Diary. The cover page reminded the patient of the times they would 
receive phone calls; listed definitions of nausea, vomiting, and retching; and specified time-points 
to record symptoms within the diary.  During the Day of Surgery (DOS) through Day 2, the 
patients were asked to record symptoms at specific time intervals.  Patients were asked to rate 
nausea on day of surgery during drive home, from ride home to dinnertime and dinnertime to 
bedtime. On Days 1 and 2 patients rated nausea during the night, morning, afternoon and evening.  
From Days 3 – 7, nausea was rated for a 24-hour period each day. Patients were asked to record 
the number of times and worst severity of vomiting/retching during the same time periods they 
recorded nausea. Quality of life questions were included in the Patient Diary and rated once every 
24 hours.  The Patient Diary also had a space to record all new medications or remedies that the 
patient took for the past 24-hour period.  They were asked to record name of medication or 
remedy, time of the day, reason for taking and effectiveness of medication.   
 
Incidence and Severity of PDNV— Definitions for terms used in this study were the 
following:  1) nausea--a subjective, unobservable occurrence of the desire to vomit without 
expulsive muscular movements--an unpleasant sensation experienced in the back of the throat 
that may or may not end in vomiting; 2) vomiting-- the forceful ejection of the contents of the 
stomach, duodenum, or jejunum through the mouth; and 3) retching--an attempt to vomit with no 
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 stomach contents expelled, otherwise known as dry heaves.25, 26  These symptoms may occur 
alone or on their own.25, 26 Retching usually indicates an empty stomach, but is as unpleasant for 
the patient as vomiting.25 Because retching may or may not occur in these patients due to a much 
lower incidence of retching in the ambulatory surgery population than in the pregnant or cancer 
population, 27, 28 retching was noted, but combined with vomiting for this study.     
The operational definition of PDNV for the purpose of this study was   “nausea and/or 
vomiting that occurs after discharge from the health care facility after outpatient surgery.”2 
Nausea is a subjective experience that is defined by the patient and requires a self-report 
approach.25, 29  Severity of nausea was measured using an 11-point numerical rating scale where 0 
represented “no nausea” and 10 represented “worst nausea imaginable.”  Categorical rating scales 
(verbal rating scales, numerical rating scales, visual analog scales) have been found to yield 
consistent and reliable data when used to measure nausea.24, 30-34  Incidence and severity of nausea 
were recorded during the PACU stay at admission, 15, 30, 60, 120 and 240 minutes and 
discharge; during the ride home; and for 48 hours in 10 study sites and 7 days in two study sites.  
Incidence was measured as any number greater than 0 on the numerical rating scale, and severe 
nausea was defined as nausea of 7 or greater on the verbal rating scale.   
Vomiting was measured as the number of episodes that occurred at least one minute apart 
and severe vomiting as three or more emetic episodes.  Retching was included with vomiting in 
the analysis.  The PDNV data were collected from the clinical record and patient interview on 
Days one, two, and seven, and from the Patient Diary.   
Pharmacologic and Nonpharmacologic Modalities of Care  
 Pharmacologic modalities of care were measured by review of the Patient Diary where 
patients were asked to note the use of any medications during the previous 24-hour period for 
nausea or vomiting post discharge.  Over the counter medications and nutraceuticals (e.g. ginger) 
that were used by the patient for treatment of PDNV were included as pharmacologic modalities 
of care.  Nonpharmacologic care was measured by description of any nonpharmacologic modality 
used by the patient as prevention or treatment of PDNV post discharge.  The Patient Diary 
included a question at Day 2 that asked “Did you use any of the following means to prevent or 
treat nausea or vomiting since your surgery?” The checklist included:  acupressure bands, lying 
still, slow progression of diet to regular diet, drinking carbonated drinks, eating food, not taking 
pain medication on empty stomach, and a blank line for any other modality the patient wished to 
specify.35   These data were captured by review of the Patient Diary.   
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 Outcomes Associated with PDNV 
Outcomes were measured by use of investigator developed quality of life (QOL) 
questions.  Quality of life is an important dimension in the postanesthesia experience of the 
patient.36  Developing an instrument to measure quality of life is difficult because there is no 
“gold standard.”37  However, verbal analog scales and visual analog scales have been used for 
assessment of specific clinical outcomes such as emesis, pain and fatigue.37.  Any questions that 
pertain to quality of life should incorporate dimensions of physical functioning, mental health, 
cognitive functioning, symptoms, role and social functioning, general health perceptions, sleep, 
and energy, and should include aspects of life that are valued by the patient.37, 38 A single, global 
quality of life question has been recommended in clinical trials.39 Therefore, the investigator-
developed questions included a global quality of life question that stated “How much did nausea 
affect your quality of life yesterday?” and “How much did vomiting affect your quality of life 
yesterday?” The use of surrogate measures for nausea and vomiting should be considered, e.g. 
food intake, appetite change, and other measures of well-being.29  Therefore,  other quality of life 
questions that were included related separately to the effect of nausea and vomiting on the 
patient’s ability to eat and drink, ability to do necessary tasks, enjoyment of leisure, enjoyment of 
social activities, ability to do normal daily work, and ability to sleep.  The QOL questions for this 
study were measured by an 11-point numeric rating scale where 0 represented “not at all” and 10 
represented “most bothersome.”  Cronbach alpha coefficients for the QOL questions for each 24 
hour time period in this study were >.90.   
Patients were asked the following question to rate recovery from surgery on a scale of 0 
to 10 with 0 “far worse than expected”, 5 “as expected”, and 10 “far better than expected.” At one 
site, the researchers captured data regarding patient calls to health care providers during the first 
week after surgery by asking, “Did you call your health care provider during this past week” and 
“If yes, why?” 
Procedure 
At the time of consent, participants were informed that an investigator would call to ask 
questions about nausea, vomiting, and other symptoms that occurred after discharge on Days 1 
and 2, and again on Day 7, if applicable. Patients were instructed on use of the Patient Diary (see 
appendix A).  The Patient Diary also contained a space for patients to record medication use each 
day.  At ten sites, the data were collected via phone interview.  At two sites where patients 
reported symptoms for 7 days, data were collected by phone interview on Days 1 and 2, and 
patients were reminded with a phone call on Day 7 to place the Patient Diary in the mail to the 
investigator in a self-addressed, stamped envelope.  Upon return of the Patient Diary, patients 
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 received a $10 gift card in the mail from the primary investigator site.  Patient medical treatment 
remained fully at the discretion of the treating anesthesia provider and surgeon in order to reflect 
real-life conditions and current clinical practice in the US. 
Data Analysis 
 Descriptive statistics, including means and standard deviations or frequency distributions, 
were used to describe the sample, and summarize the data. Bivariate analyses, including two-
sample t-tests and chi-square tests of association, were used to determine factors associated with 
PNDV.  One-way analysis of variance (ANOVA) with Tukey HSD post hoc tests were used to 
determine significant differences in means of nausea between groups.  A one-way ANOVA was 
conducted to look at impact of antiemetic use and nonpharmacologic modalities of care on the 
mean of nausea ( 0 = none; 10 = worst).  Patients were divided into four groups according to use 
of pharmacologic and nonpharmacologic modalities (Group 1 = No use of antiemetics, no use of 
nonpharmacologic modalities of care; Group 2 = No use of antiemetics,  Yes use of 
nonpharmacologic modalities of care; Group 3 = Yes use of antiemetics, No use of 
nonpharmacologic modalities of care; Group 4 = Yes use of antiemetics, Yes use of 
nonpharmacologic modalities of care.)  A logistic regression was conducted to examine factors 
relevant for predicting PDNV in days 3 – 7.  Significance is set at the p < 0.05 value.   
A power analysis determined that with a sample size of 120 and a PDNV prevalence rate 
of approximately 30% approximately 36 participants would have this adverse event and the 
remaining 84 would not.  With these group sizes and an alpha level of .05, the power of a two-
sample t-test to detect a significant group difference was approximately 84% if the ratio of the 
difference in means to the standard deviation was as small as 0.6.  Cohen40 considers a difference 
of this magnitude to be slightly larger than a medium effect size. With a total of 120 subjects and 
a significance level of .05, the power of the chi-square test of association to detect an odds ratio 
as small as 4 was approximately 84%. One way to obtain an odds ratio of this magnitude would 
be if one group had a proportion of cases with a certain attribute of 20% while the other group 
had a 50% rate. With approximately 36 PDNV cases and 84 participants without this event, 
assuming a .05 level of significance, the power of the logistic regression to detect a significant 
odds ratio as small as 2.5 will be approximately 92%; if the odds ratio is as small as 2, the power 
under these conditions will be approximately 83%. Power estimates were obtained using nQuery 
Advisor.41  More subjects were available due to the requirements of the multi-site study, so the 
data analyses are at least as powerful as determined before data collection.42  Data analyses were 
performed with SPSS (version 17.0). 
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 Results 
 Two thousand four hundred ninety three patients were screened for the multi-site study.  
Data for the first 48 hours post-surgery were obtained from the 2170 patients who completed the 
study.  Within this group of 2170 was a subset of 260 patients from two centers who also 
completed data for a 7-day period.  Demographic and clinical characteristics for these two groups 
are included and compared in Table 5-1.  The subset of 260 patients was significantly different 
from the 1910 in the 48-hour sample in age, gender, ethnicity, income level, educational level, 
previous PONV, type of procedures performed, surgical approach, American Society of 
Anesthesiologists (ASA) physical status, and operating room (OR) time.  There was a significant 
difference in the presence of PDNV between groups, and significant difference in mean nausea 
scores between the groups.  
Incidence  
The overall incidence of nausea for the study was 36.8% and emesis was 12.0% with an 
overall incidence of PDNV of 37.1%. (Figure 5-1). During the ride home, 21.8% of patients had 
nausea with 4.6% of patients experiencing emesis.  During DOS, after arriving home, nausea 
increased to the highest of any single day (28.7%) and emesis increased to 8.5%. The next day 
after surgery (Day 1) the incidence of nausea and vomiting decreased to 18.2% and 3.9%, 
respectively.  The incidence of nausea and vomiting in the 48-hour group is presented in Figure 
5-2.  On Day 3, the subset of 260 patients reported the incidence of nausea and vomiting at 18.1% 
and 2.3%.  Nausea decreased to 6.3% on Day 7. Emesis was stable Days 5 – 7 at 1.2%. The 
incidence of nausea and vomiting over a 7-day period is presented in Figure 5-3.   
Demographic and clinical characteristics of patients who experienced PDNV and did not 
experience PDNV are listed in Table 5-2.  The presence of PDNV was significantly higher for 
females than males (p < 0.001).  There was a significant difference between means of age with 
younger patients more likely to experience PDNV than younger patients.  There was also a 
significant difference among ethnic groups when analyzing presence of PDNV with Latinos and 
Asians having a higher percentage of PDNV.  No significant differences were found among those 
with and without nausea in the categories of BMI, educational level, or income.     
 
The clinical characteristics of history of motion sickness, previous PONV, and migraine 
headaches were all significantly related to the presence of PDNV (p < 0.001; Figure 5-4).  The 
use of certain opioids (hydromorphone, p < .024; morphine, p < .027) during surgery was 
significantly related to presence of PDNV, although use of meperidine, remifentanil, and fentanyl 
during surgery were not significantly related to PDNV. However, the use of certain opioids in the 
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 PACU were significantly related to the presence of PDNV.  Use of oxycodone, morphine, 
meperidine, hydromorphone, and fentanyl in the PACU were related to presence of PDNV while 
use of codeine and hydrocodone were not related.  American Society of Anesthesiologists’ 
physical status classification system rating was significantly different for those patients who 
experience nausea and those who do not with the healthiest patients (ASA Class I and 2) more 
likely to experience PDNV than ASA Class 3.  There were not enough ASA Class 4 patients in 
that category (N = 8) to statistically compare although the few patients in that category seemed to 
follow the same pattern with only 25% experiencing PDNV.  Overall OR time was significantly 
different for those with or without PDNV (p <0. 01) with those patients who had a longer OR 
Time more likely to experience PDNV.  Interestingly, patients who received a regional block 
were more likely to have nausea than those who did not have a regional block (p < 0.001).  
Nitrous oxide had no effect on PDNV.   
Patients who experienced nausea and vomiting in the PACU were significantly more 
likely to experience PDNV (p < 0.001).  There was a significant difference in pain score means (0 
= no pain; 10 = worst pain) for pain during activity between patients who reported PDNV and 
those who did not (p = <0.008) until Day 4 when the difference was non-significant.  Mean scores 
for pain at rest show a significant difference (p<0.001) between those with and without nausea 
until Day 4 (p = 0.94), but are significant again on Day 5 only (p = 0.026). Those patients with 
higher pain scores during activity or at rest were more likely to experience PDNV.   The use of 
hydrocodone was significantly related to the presence of PDNV until Day 2.  The use of 
oxycodone after surgery was significantly related to the presence of PDNV until Day 3. 
Severity of Nausea 
 Nausea was rated with an 11-point scale where 0 was no nausea and 10 represented the 
worst possible nausea.  Severe nausea (> 7 on scale of 0 to 10) affected 10.2% of patients on day 
of surgery and continued to affect 2% of patients on Day 7. (Figure 5-5).  Of those who were 
nauseated, 31.2% experienced severe nausea during the drive home increasing to 35.5% of those 
with nausea during the day of surgery.  Of the 6.3 % with nausea on Day 7, almost a third 
(31.7%) continued to have severe nausea. 
Females reported a significantly higher overall mean of nausea (as measured on a 0 – 10 
numerical rating scale) than males (p < 0.001). When analyzed by day, there was a significant 
difference in means of nausea scores between males and females until Day 3. (See Figure 5-6).  
Mean nausea intensity was compared between age groups (<42, 43-57, and > 58).  There was a 
statistically significant difference (p < 0.001) between all age groups with the youngest age group 
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 (< 42) experiencing the highest mean. (Figure 5-7).  Using overall mean nausea scores, there no 
statistically significant differences for ethnicity [F (4, 2147) = 1.465, p = .21].   
Type of surgical procedure was significantly related to mean scores of nausea (p < .001). 
(Figure 5-8).   Prostate surgery was associated with the lowest nausea mean score (.2821) and 
cholecystectomy with the highest nausea mean score (1.4386). There were significant differences 
between general surgery and knee arthroscopy (p = .013), breast surgery and knee arthroscopy (p 
= .04), cholecystecomy and prostate surgery (p < .001), gynecological and prostate surgery (p = 
.037) and knee arthroscopy and prostate surgery (p < .001).  The impact of gender and surgical 
procedure on mean nausea scores was explored.  The interaction effect between gender and 
surgical procedure was significant [F(10, 2126) = 1.943, p = .036].  The type of surgical approach 
was also related to mean nausea scores with the endoscopic and conventional approach having a 
lower mean nausea and less likely to have nausea than the arthroscopic and laparoscopic 
approaches (p < .007). (Figure 5-9) 
Patients at the lowest risk for anesthesia complications (ASA 1) had a mean nausea score 
of 1.12 and those with a highest risk (ASA 4) of 0.29. However there were only 8 patients 
classified as ASA 4, and mean nausea scores were not significantly different than any other 
group. (Figure 5-10). The ASA 1 (p < .001) and ASA 2 (p < .02) patients had significantly higher 
nausea means than ASA 3.   
The use of analgesics codeine and hydrocodone in PACU for pain were not significantly 
associated with mean nausea scores (p >.58).  The use of morphine (p < 0.001), meperidine (p < 
0.001), hydromorphone (p < 0.001),  fentanyl (p < 0.001), and oxycodone (p <  .001) for pain in 
the PACU were significantly associated with overall mean post discharge nausea scores. When 
analyzed by post discharge day, the use of opioids in PACU became nonsignificant for PDNV for 
all opioids by Day 3.  
Prediction of Late PDNV 
Using the data from this study and completing the primary objective for the multi-site 
study, Independent risk factors for early PDNV (within 48 hours) were determined:  female 
gender, age less than 50 years, history of PONV, opioids administered in the PACU, and nausea 
in the PACU.3  To determine which factors predict the presence or absence of PDNV for days 3-
7, we performed a logistic regression analysis with possible factors ethnicity, age, gender, BMI, 
Previous PONV, previous motion sickness, ASA status, smoking status, OR Time, surgical 
procedure, surgical approach, use of antiemetics (three variables, one each for use in surgery, 
PACU, or post-discharge), use of opioids (again three variables, one each for use in surgery, 
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 PACU, or post-discharge), and pain scores (divided into none for pain=0, mild for pain=1,2,3, 
moderate for pain=4,5,6, or severe for pain=7,8,9,10). 
Variable selection was done by backward elimination using approximate likelihood ratio 
tests (logistic regression is a special case of a generalized linear model, the likelihood ratio tests 
are a substitute for the F-tests used in ordinary linear regression), at the 0.05 level for the 
exclusion of variables. Most variables were eliminated resulting in a final model that included a 
previous history of PONV, OR Time, and pain score. The significance of these variables is 
described in Table 5-3.  
The coefficients of the regression are contained in Table 5-4, with 95% confidence 
intervals for the odds ratios (note the estimates in a logistic regression provide estimated log odds 
and must be exponentiated for odds ratios, the confidence intervals for the log odds are symmetric 
around the estimated logodds). 
Note for pain level, all odds ratios are computed relative to “no pain”. Thus, the estimated 
odds ratios of 10.40 for Moderate Pain is the odds ratio concerning the likelihood of PDNV with 
moderate pain compared to the likelihood of nausea with no pain. The long upper tails of the odds 
ratios are due to the fairly minimal number of individuals who had no pain but also had nausea, as 
seen in table 5.5. 
As can be seen in Table 5.5, the observed proportion of individual experiencing PDNV 
dramatically increases as the pain level increases. Furthermore, of the 70 individuals with “no 
pain”, only 3 reported nausea. When computing odds ratios relative to “no pain”, this small 
number of individuals with PDNV produces much variation in the resulting estimates. While we 
may be quite confident that individuals with pain are sizably more likely to experience PDNV, 
the exact magnitude of these effects is hard to pin down.  
 
Management Strategies 
 The most commonly used antiemetics in the OR during surgery were: ondansetron 
(77.4% of patients); steroids (48.5% of patients); droperidol (12.8% of patients); and dopamine 
antagonists (12.8% of patients.)  After discharge home, 4.2% of patients recorded use of an 
antiemetic.  The antiemetics used by patients were ondansetron (15 patients), a 5HT-3 antagonist; 
dexamethasone (6 patients), a steroid; diphenhydramine (3 patients), an antihistamine; and 
promethazine (67 patients), a butyrophenone (Figure 5-11).  Only one patient recorded use of 
metoclopramide, a benzamide.    
 A wide variety of nonpharmacologic methods were reported by patients in order to 
relieve nausea.  Only 3 patients reported use of acupressure wrist bands (0.1%), while 341 
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 (15.7%) gradually moved from liquids to food, 471 (21.7%) took medication with food, 451 
(20.8%) ate food to relieve or prevent nausea, 399 (18.4%) drank carbonated drinks, and 592 
(27.3%) lay down to relieve the nausea.  Other non-pharmacologic strategies for the relief of 
nausea that were reported by patients included resting/being still (154), stopping their medication 
(9), air conditioning or fresh air (16), wet washcloth or cold compress (10), deep breathing, 
relaxing (11), and letting it “go away by itself (23).” 
 Patients were divided into four groups according to use of pharmacologic and 
nonpharmacologic modalities.  Of those patients who had severe nausea on the Day of Surgery 
(DOS), 34.1% were in Group 1 using neither antiemetics or nonpharmacologic means of nausea 
control.  Over half of those with severe nausea on DOS (52.7%) used nonpharmacologic methods 
of control only, 1.4% used antiemetics only, and 3.2% used antiemetics and nonpharmacologic 
modalities. (See Table 5-3). By Day 3 the majority of patients with severe nausea were using the 
combination of antiemetics and nonpharmacologic methods of nausea relief.  There was a 
significant difference in mean nausea scores among the 4 groups divided according to use of 
pharmacologic and nonpharmacolotic modalities (Figure 5-12).  Post hoc comparisons using the 
Tukey HSD test indicated that the mean nausea score for Group 1 (M = .4170, SD + 1.16) was 
significantly less than Group 2 (M = 1.6780, SD + 1.93), Group 3 (M = 2.0159, SD + 2.05), and 
Group 4 (M = 3.3952, SD + 2.49).  Less nausea was associated with patients in Group 1 than in  
Groups 2, 3, or 4.  More nausea was associated with Group 4 than Groups 1, 2, or 3.  There were 
no differences in mean nausea scores between Groups 2 and 3. 
Outcomes  
Quality of Life  
 Patients were asked to separately rate the effect of both nausea and vomiting on overall 
QOL.  The mean score (0 = not at all and 10= most bothersome) for effect of nausea on overall 
quality of life for patients was significantly higher (p < 0.002) for those who did experience PDN 
than for those who did not.  The significance was present on all days (Day of Surgery – Day 6). 
See Figure 5-13.  When patients were asked to rate the effect of vomiting on QOL, the mean 
score on overall quality of life was significantly higher for those with PDV (meaning more 
bothersome) than those without PDV (p < 0.001).  By Day 3, there was no longer a significant 
difference (p = 0.164).  See Figure 5-14. 
 Patients were asked the degree to which nausea affected ability to eat and drink; do 
necessary activities and tasks; enjoy leisure and recreational activities; enjoy social activities; do 
normal work; and sleep.  The QOL was significantly different based on nausea score in all areas 
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 compared to those without PDN for every day post discharge (p < 0.006). By Day 6, only normal 
work (p = .06) and sleep (p = .112) were non-significant. 
Post discharge vomiting significantly affected (p < 0.001) ability to eat and drink; do 
necessary activities and tasks; enjoy leisure and recreational activities; enjoy social activities; do 
normal work; and sleep until Day 3, when the effect of vomiting on each of these indicators of 
QOL was non-significant. 
To further determine outcomes in patients with PDNV, patient expectation of PDNV, 
healthcare provider calls during the first week, and patient rating of prevention and treatment of 
nausea was documented.   
Patient Expectation of PDNV 
 There was a significant difference in rates of nausea and vomiting based on patient 
expectation of PDNV.  Patients were asked to rate the likelihood that they would experience 
nausea or vomiting (0 = not likely; 10 = likely; Figure 16) Patients who experienced nausea rated 
themselves before surgery as more likely to experience nausea (M = 2.57) than those patients 
who did not experience nausea (M = 1.42).  Patients who experienced vomiting, as well, rated the 
likelihood they would experience vomiting as higher (M = 2.06) than those who did not 
experience it (M = 1.30). 
Healthcare Provider Calls 
 Out of the seven day subset of patient (N = 260), 180 patients answered the question “Did 
you call your health care provider during this past week, and if yes, why?”  Forty-six patients out 
of the 180 patients (25%) had called the physician or physician’s office during the past week. 
However, only 2 patients (1.1%) called to report symptoms of nausea and vomiting.  No patients 
were rehospitalized due to nausea and/or vomiting.  In contrast 15 patients called regarding pain 
issues such as continuing pain or problems with the pain medication. 
Patient Rating of Prevention and Treatment of Nausea 
 Patients were asked to compare how their recovery from surgery met their expectations 
before surgery. When asked to rate prevention and treatment of nausea between 0 and 10 with 0 
(far worse than expected), 5 (as expected) and 10 (far better than expected), patient responded 
with an overall mean of 7.81.  Patients without nausea rated treatment as significantly higher than 
those who did experience nausea (p < 0.001; Figure 17).  Of patients who reported nausea, 19.5% 
rated treatment below expectations compared to 1.2% of patients without nausea who rated 
treatment as below expectations.  Of patients who reported nausea, 80.5% rated treatment as 
expected or better than expected while 98.8% of those who did not report nausea rated treatment 
as expected or above expectations. 
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Discussion 
 The data in this study substantiate the continuing problem of nausea and vomiting after 
outpatient surgery, a population of patients that has been unrecognized and undertreated. 15, 16 The 
overall PDN incidence of 36.8%, PDV incidence of 12%, and overall PDNV rate of 37.1% falls 
within the published range of 30-55%.4-6, 15, 19  Several demographic and clinical characteristics 
were significantly related to the PDNV in this study including female gender, use of 
postoperative opioids, a history of PONV or motion sickness.  Some characteristics that are 
associated with PONV were not associated with this population of patients, e.g. nonsmoking 
status.  We found that severity of PDNV peaks on the day of surgery and gradually decreases 
over the next 7 days.  Sicker patients (higher ASA classification), those who experienced PONV 
in the PACU, patients with higher pain scores, and younger patients were more likely to 
experience PDNV.  Only a small number of patients manage their symptoms with the use of 
antiemetics or nonpharmacologic modalties of care such as acupressure.  Most patients use minor 
self-care treatments, e.g. cool cloths, lying down, drinking carbonated fluids, and do not contact a 
healthcare provider.  Both PDN and PDV have a negative effect on the patient’s perception of 
global QOL.   
In this study we attempted to provide a real-world incidence of PDNV in a sample of 
patients who received general anesthesia for outpatient surgery by not excluding by procedure, 
dictating anesthesia regime, or stratifying by risk.  The only high-risk inclusion criterion was use 
of inhalation anesthesia. This study focused on the ambulatory surgery population over a 7-day 
period describing incidence, severity, management strategies and quality of life.  Without 
focusing specifically on patients at demographic or procedural high-risk, the overall incidence of 
PDNV was 37.1%.  Other studies have established an overall PDNV incidence of 35.7% over a 5 
day period 4, PDN of 57% in a control group versus 20% in a study group and PDV of 20% 
versus 3% for 5 days post discharge15, a PDV incidence of 5 – 9% based on risk factor 
stratification (2 – 4 factors) at 24 – 72 hours10, 17% PDNV in patients who received inhalation 
anesthesia and 11% in those with total intravenous anesthesia (TIVA)43, 32.6% PDN and 14.7% 
PDV,5 and in a systematic review and analysis, an  overall PDN of 17% with a  range of 0 to 
55%. 19  Incidences of PDNV across studies are difficult to compare because of the varying 
patient samples, e.g. high risk patients, specific procedures performed, or using female gender 
only.  Many of the studies that have reported PDNV in the past have reported PDNV as a 
secondary outcome or only assessed PDNV for the first 24 hours instead of the 7 days post 
discharge in our study.15 
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 The incidences of PDN and PDV during the ride home have seldom been reported in the 
few studies available on PDNV 44, although Ernst and Thwaites reported 20% with nausea and 
4% with vomiting during the ride home.45   In our study, 21.8% of patients experienced PDN 
during the ride home and 4.6% experienced PDV.  The incidence of PDN and PDV peaks after 
arrival home on the day of surgery to 28.6% PDN and 12%.  After DOS the incidence of PDN 
and PDV decrease gradually until Day 7 when overall incidence is 6.3% of nausea and 1.2% 
emesis.  Results from this study are similar to those reported in an abstract by Philip, et al.46 who 
reported an incidence of PDN of 46% in high-risk patients during the first 24 hours after surgery 
decreasing to 8% on Day 7, and an incidence of PDV of 12% during the first 24 hours decreasing 
to 1% on Day 7.   It is significant that even a week later some patients were still experiencing the 
negative symptoms of nausea and vomiting, a symptom that has been described by patients as 
worse than pain.20 21 
  Apfel et, al. determined that female gender, nonsmoking status, history of PONV or 
motion sickness, and use of perioperative opioids were strong predictors for PONV.8 Using the 
Apfel simplified risk assessment tool, the risk for PONV increased from 10% for no risk factors 
to 79% if all 4 factors were present.  Patients in this study who experienced PDNV were also 
more likely to be female, had a history of PONV, motion sickness or migraine headaches, 
undergone laparoscopic surgery, and spent more time in the OR during the procedure. Other 
differences that were significant were younger age, healthier patient status (ASA 1 status) and 
cholecystectomy.  It is possible that cholecystectomy was significant because of the laparoscopic 
surgical approach which has been identified as related to PONV.47   
Interestingly, nonsmoking status, strongly related to PONV,8, 47 was not related to PDNV 
experienced in this study.   As other studies have found, BMI, educational status, and income are 
not related to PDNV.47, 48  Nitrous oxide or use of inhalation agents was not related to PDNV as 
has been found significantly related to PONV.47, 49-52 This is more than likely due to the short 
acting effects of the volatile anesthetics. 50 One interesting finding in this study that has not been 
identified in other studies is that use of local anesthetic at the surgery site was significantly 
related to PDNV, and does merit further study. It is possible that more surgeons are using local 
anesthetics for pain control during surgery, so it may be related to care of the patient.  It may be 
used for the more major surgeries in which we expect more pain, and therefore when it 
metabolizes in the first 24 hours, the patient experiences a spike in pain.  In one study, patients 
who experienced PONV in the PACU were unlikely to experience PDNV4, while Wright found 
that patients who experienced PONV in PACU were more likely to have PDNV.53  In this study, 
we found that patients who experienced PONV in the PACU were significantly more likely to 
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 experience PDNV.  Use of intravenous opioids in the PACU was significantly related to PDNV 
until the third day post-surgery, and use of oral opioids was related to the presence of nausea on 
most days after discharge.  This finding is similar to other studies, in which researcher have found 
postoperative opioids in the PACU linked to PONV.8, 47  Use of short-acting opioids in the PACU 
should not be related to delayed PDNV.  However, the use of those IV opioids in the PACU may 
be significant until Day 3 because patients who need IV opioids may continue to need an oral 
opioid after discharge home. However, use of hydrocodone was not associated with PDNV after 
Day 2 and oxycodone after Day 3.  Patients with higher pain scores, however, were associated 
with higher pain scores.  It is possible that patients who have stopped taking pain medication have 
higher pain scores and then a resulting increase in PDNV.54  
Risk factors have not been identified for PDNV until now.  Apfel, et al. using the data 
from this multi-site study recently determined predictors for a simplified assessment tool for early 
PDNV (48 hours after surgery).3 The five statistically significant independent risk factors for 
PDNV for the first 48 hours are female gender, age less than 50 years, history of PONV, opioids 
administered in the PACU, and nausea in the PACU.3  In this study, we determined factors that 
impact the presence of PDNV during Days 3 – 7 using logistic regression analysis.  The final 
model included history of PONV, OR time and pain score.  It is possible that the presence of 
nausea later post discharge has different causes than the PDNV that has resolved over the first 48 
hours.  Opioids given in the PACU or presence of PONV in the PACU are no longer significant 
factors.  It is also possible that age was not in our final model for late PDNV because it correlated 
with pain, e.g. the younger the patient, the higher the pain score for those with late PDNV.   The 
odds of having PDNV with severe pain are estimated to be 4.49 times as high as the odds of 
PDNV with no pain.  It is interesting that OR time continues to be a factor for late PDNV.  For 
every one hour of OR time the odds of PDNV are 1.86 times higher.  We thought it possible that 
the more major surgeries were related to the OR time, and the patient may have a longer recovery 
based on type of surgery.  However, even with OR times removed from the model and surgery 
type and approach added, neither surgery type nor surgical approach were significant.  Thus, OR 
time is not acting simply as a surrogate for surgical procedure.  The history of PONV continues as 
a factor for late PDNV.   The odds of nausea are 2.9 times higher when one has a history of 
PONV.   
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 Management Strategies  
In this study, patients with PDNV were likely to use minor self-care strategies to manage 
symptoms.  In the subset of patients who answered the question about calling the healthcare 
provider, only 2 persons with PDNV contacted a healthcare provider (HCP) for those symptoms.  
This is in line with results other researchers have found in patients with PDNV.  Patients tend to 
manage symptoms themselves4, seldom contact a HCP4, 55, and stop taking pain management 
medication16, 56.   
Of significance in this study is that only 4.2% of patients recorded use of an antiemetic 
even though 37.1% recorded evidence of PDNV. Patients with the lowest mean nausea scores did 
not use antiemetics.  Patients who do not have nausea or who have only mild cases of nausea may 
be less likely to take a pharmacologic modality or use any nonpharmacologic method of nausea 
control.  The mean nausea level (0 – 10) for patients who used nonpharmacologic modalities only 
(Group 2) and patients who used antiemetics only (Group 3) were not significantly different from 
each other.  Patients who had the highest mean for nausea were more likely to use both 
antiemetics and nonpharmacologic methods of controlling PDNV.  In this study, patients who are 
experiencing severe nausea were more likely to take antiemetics for their symptoms.  We were 
able to determine that a small percentage of patients who have PDNV actually take antiemetics 
for control of symptoms.  Many studies that have reported incidences of PDNV are interventional 
studies with anesthetic routine pre-prescribed.  It is significant that in a real-time environment 
only 9.7% of patients who had PDNV actually took an antiemetic. 
We do not know the percentage of patients who actually went home with a prescription 
for an antiemetic. This information should be obtained in any future studies.  Also of note is the 
fact that only 3 patients recorded use of acupressure or acustimulation bands which have been 
found to decrease incidence of PDNV in studies.57, 58  Future guidelines for care of the patient 
with PDNV should suggest appropriate antiemetics for patients at risk for PDNV, and any 
algorithm for care of the patient with PDNV should include nonpharmacologic methods of nausea 
control such as acupressure.   These patients relied on self-care techniques as shown in other 
studies, sometimes to the detriment of care, such as stopping pain medication.16   
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 Outcomes 
 We found that nausea was significantly related to overall QOL on every day post 
discharge and that vomiting was significantly related to overall QOL until Day 3.  Other studies 
have shown a negative relationship of PDNV and QOL.   Pan found that 33% of the study group 
and 60% of the control group were negatively affected by emetic symptoms.15  Carroll found that 
patients who experienced PDNV were negatively affected in performing normal daily activities.4  
Few studies have related QOL questions specifically to nausea or vomiting.  When quality of 
recovery is studied, typically QOL is related to a number of outcome measures.  For example, the 
Quality of Recovery Score has nine questions with only one related to nausea and vomiting.36  
The FLIE focuses on nausea and vomiting, but does not incorporate other QOL indicators that 
would aid in determining the effect of PDNV on patient QOL.15 
 Nausea affected patients’ ability to eat and drink; do necessary activities and tasks; 
enjoyment of leisure and recreational activities; and enjoy of social activities on all 7 days.  
Ability to do normal work and ability to sleep were affected until Day 6.  Vomiting affected all 
QOL questions until Day 3 which correlates with the decrease in incidence of vomiting.  It is 
clear that some patients are affected by nausea up to one week after surgery.   
 PDNV does affect patient satisfaction with treatment.  Interestingly, though, even the 
patient with PDNV rated their treatment as 6 on a scale of 0 – 10 (0 as far worse than expected, 5 
as expected, and 10 far better than expected).  Patients without PDNV had a higher satisfaction 
with a rating of 8.8.  However, even a rating of 6 is better than expected on the scale used by the 
patient.  This could mean that some patients believe that PDNV is to be expected after surgery, or 
that the PDNV experienced by the patient was less than expected.   
 Research Implications  
Future studies should focus on patient education needs related to PDNV and use of risk 
assessment tools for PDNV. Future studies should include determination of a detailed patient 
education program and its effectiveness.  More research should be conducted to determine the 
relationship of pain and PDNV including the association of post discharge opioids.  Barriers to 
patient decision to take pain medication and antiemetic medication should be determined.   It is 
imperative that randomized controlled trials that determine appropriate long-term antiemetics and 
non-pharmacologic methods to control nausea and vomiting are conducted.  Other factors of 
interest that need to be studied are patient anxiety and how it relates to PDNV, patient 
comprehension of discharge instructions, and ability to discern appropriate strategies for self-
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 care. Research should be conducted to determine instruments with validity and reliability to 
accurately capture the effect of nausea or vomiting on QOL.   
Practice Implications 
Patients should be screened for risk of PONV and treated according to published 
guidelines based on risk factors.  With further identification of PDNV risk factors, ambulatory 
surgery patients should be screened for risk of PDNV.  Prophylactic interventions for PDNV, 
such as transdermal scopolamine; longer acting 5HT3 receptor antagonists, such as palonsetron; 
promethazine suppository; ondansetron dissolving tablet; or NK1 receptor antagonist agent, such 
as aprepitant should be available and incorporated into any guideline for care.  Nonpharmacologic 
interventions should be available and taught to the patient, such as acupressure.  A rescue 
antiemetic should be prescribed upon discharge as part of the medication regimen for the post 
discharge patient.  Effective pain medication of the patient who is discharged is imperative, as 
well as assuring that the patient understands the importance of taking the medication.  Patient 
education is imperative.  This study did not obtain information that related to the quality of 
discharge instruction, but adding information on treatment of PDNV to patients before discharge 
is suggested.  The anesthesia department should become a larger partner with the surgeon when 
determining effective post discharge care of pain and nausea and other anesthesia related 
symptoms.  An appropriate follow-up program should be in place in all healthcare facilities. 
 
Limitations 
 Limitations to this study include the differences between the 48-hour sample and the 7-
day sample.  The 48- hour sample was comprised of 2140 patients from 12 sites across the United 
States. On Day 3, the sample decreased to 260 patients from two sites.  The 7-day sample was 
significantly more likely to experience PDNV.  This may be related to the higher percentages of 
females to males; history of PONV; cholecystectomies performed; and laparoscopic incisional 
approach which are all risk factors for PDNV.  It is also possible that patients were treated 
differently in the 2 centers preoperatively and intraoperatively that may have contributed to the 
differences in samples.  However, both sites had differing populations; one a university setting, 
and the other a private hospital.  And the smaller sample (N = 260) was powered to detect 
significant group differences between those with PDNV and those without.   
 The sample was a convenience sample, although purposeful with consecutive patients 
who met inclusion criteria recruited for the study.  The study could be replicated using random 
assignment of patients who met inclusion criteria.  However, the sample was large and from 
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multiple centers across the U.S. and should give a real-life picture of the incidence and severity of 
PDNV, management strategies, and QOL outcomes for a week-long period of time. 
 Questions used to obtain patient QOL have undergone face validity, but no further 
validity or reliability testing. The statements were taken from the literature by experts and are 
similar to statements in other instruments, e.g. modified Osoba module11, 59, FLIE,15, 60 but have 
not specifically been tested in the postoperative population. 
 
Summary 
 The incidence of PDNV continues to be unacceptably high in a population of patients 
who until recently have flown beneath the anesthesia, surgical, and perioperative radar.  There are 
some patients who suffer with PDNV up to a week after surgery.  The majority of these patients 
are not taking any antiemetic or using productive nonpharmacologic methods of symptom 
control.  Quality of life is affected by these symptoms for several days after surgery.  A directed 
patient education program may be helpful in instructing patients in medication compliance, how 
to manage PDNV symptoms as well as other anesthesia outcomes, and informing patients on an 
appropriate follow-up with the healthcare provider. 
Copyright © Jan Odom Forren 2009
 Table 5.1 Demographic and Clinical Characteristics  
 
 DOS – 48 hours 
N = 1910 
DOS – 7 days 
N = 260 
P value Total 
N = 2170 
Demographics     
Age 
     Mean + SD 
     Median 
     Range 
 
49.19 + 15.46 
49.0 
17 - 90 
 
51.99 + 14.71 
53.5 
19 - 87 
 
0.006 
 
49.52 + 15 
50 
17 - 90 
BMI 
     Mean + SD 
     Median 
     Range 
 
28.24 + 6.9 
26.65 
14.5 – 63.7 
28.99 + 6.6 
27.62 
17.6 – 57.7 
.10  
28.33 + 6.9 
 
14.5 – 63.7 
 N (%) N (%)   
Gender  
Female 
Male 
 
1220 (63.9) 
 690 (36.1) 
 
184 (70.8) 
 76 (29.2) 
 
0.029 
 
1404 (64.7) 
 766 (65.3) 
Ethnicity 
     African-American 
     Asian 
     Caucasian 
     Latino 
     Other 
 
185 (9.7) 
69 (3.6) 
1371 (71.8) 
108 (5.7) 
177 (9.3) 
 
24 (9.2) 
- 
224 (86.2) 
  3 (1.2) 
  9 (3.5) 
 
<0.0001 
 
209 (9.6) 
69 (3.2) 
1595 (73.5) 
111 (5.1) 
186 (8.6) 
Educational level 
     High school 
     College 
     Graduate degree 
     None of these 
     Did not answer 
 
282 (14.8) 
764 (40) 
204 (10.7) 
37 (1.9) 
622 (32.6) 
 
96 (36.9) 
139 (53.5) 
13 (5.0) 
5 (1.9) 
7 (2.7) 
 
<0.001 
 
378 (17.4) 
903 (41.6) 
217 (10) 
42 (1.9) 
529 (20) 
Income level 
     <$25,000 
     $25, 000 - $50,000 
     $50,000 - $75,000 
     $75,000 - $100,000 
     >$100,000 
     Did not answer 
 
196 (10.3) 
242 (12.7) 
202 (10.6) 
200 (10.5) 
292 (15.3) 
777 (40.7) 
 
32 (12.3) 
58 (22.3) 
53 (20.4) 
48 (18.5) 
47 (18.1) 
22 (8.5) 
 
<0.0001 
 
228 (10.5) 
300 (13.8) 
255 (11.8) 
248 (11.4) 
339 (15.6) 
799 (36.8) 
Clinical Characteristics     
Smoker 
     No 
     Yes 
 
1619 (84.8) 
291 (15.2) 
 
221 (85) 
 39 (15) 
 
.994 
 
1840 (84.8) 
 330 (30.2) 
Previous PONV 
     No 
     Yes 
 
1317 (69) 
 526 (27.5) 
 
150 (57.7) 
110 (42.3) 
 
<0.0001 
 
1467 (76.6) 
  636 (69.8) 
Previous motion sickness 
     No 
     Yes 
 
1433 (75) 
 477 (25) 
 
187 (71.9) 
 73 (28.1) 
 
.316 
 
1620 (74.7) 
 550 (53.1) 
History migraine 
headaches 
     No 
     Yes 
 
 
1462 (76.5) 
447 (23.4) 
 
 
199 (76.5) 
 61 (23.5) 
 
.987 
 
 
1661 (76.5) 
 508 (46.9 
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Table 5.1 (Continued) Demographic and Clinical Characteristics 
 
 DOS – 48 hours 
N = 1910 
DOS – 7 days 
N = 260 
P value Total 
N = 2170 
Clinical Characteristics     
Procedures 
     General 
     Breast 
     Cholecystectomy 
     Cystoscopy 
     D&C 
     ENT 
     Gynecologic 
     Hernia 
     Knee arthroscopy 
     Orthopedic 
     Prostate 
     Upper extremity 
 
402 (21) 
195 (10.2) 
 61 (3.2) 
121 (6.3) 
159 (8.3) 
169 (8.8) 
216 (11.3) 
 69 (3.6) 
190 (9.9) 
125 (6.5) 
75 (3.9) 
127 (6.6) 
 
39 (15) 
28 (10.8) 
35 (13.5) 
10 (3.8) 
24 (9.2) 
17 (6.5) 
22 (8.5) 
21 (8.1) 
40 (15.4) 
7 (2.7) 
3 (1.2) 
14 (5.4) 
 
<0.0001 
 
441(20.3) 
223(10.3) 
96(4.4) 
131 (6.0) 
183 (8.4) 
186 (8.6) 
238(11.0) 
90 (4.1) 
230 (10.6) 
132 (6.1) 
78 (3.6) 
141 (6.5) 
Surgical Approach 
     Conventional 
     Arthroscopic 
     Endoscopic 
     Laparoscopic 
 
1031 (54) 
253 (13.2) 
409 (21.4) 
216 (11.3) 
 
96 (36.9) 
51 (19.6) 
42 (16.2) 
71 (27.3) 
 
<0.0001 
 
1127 (51.9) 
304 (14.0) 
451 (20.8) 
287 (13.2) 
ASA Status 
     ASA 1 
     ASA 2 
     ASA 3 
     ASA 4 
 
388 (20.3) 
1145 (59.9) 
368 (19.3) 
  8 (0.4) 
 
44 (16.9) 
179 (68.8) 
37 (14.2) 
- 
 
0.037 
 
432 (19.9) 
1324 (61) 
405 (18.7) 
  8 (0.4) 
OR Time in Hours 
     Mean + SD 
     Median 
     Range 
 
1.71 + .868 
1.53 
0.22 – 11.20 
 
1.40 + .723 
1.18 
0.48 – 5.15 
 
<0.0001 
 
1.67 
1.48 
0.22 – 11.20 
Presence of PDNV 
     No 
     Yes 
 
1235 (65.5) 
649 (34.5) 
 
107 (43.1) 
141 (56.9) 
 
<0.001 
 
1335 (62.8) 
790 (37.2) 
Mean Nausea Scores 
     Mean + SD 
     Median 
     Range 
 
.8506 + 1.60 
0 
0 - 10 
 
1.491 + 2.10 
.50 
0 – 8.67 
 
<.001 
 
.9274 + 1.68 
0 
0 - 10 
DOS = Day of Surgery; PONV = Postoperative nausea and vomiting; D & C = Dilatation and 
Curettage; ENT = Ear, Nose, and Throat; ASA = American Society of Anesthesiologists; OR = 
Operating Room; PACU = Post Anesthesia Care Unit 
 
 
 Table 5.2 Demographic and Clinical Characteristics of Patients with PDNV and without PDNV 
 PDNV No PNDV 
 
P value 
Demographics    
Age 
     Mean + SD 
     Median 
     Range 
 
44.93 + 14.60 
44.0 
17 - 88 
 
 
52.29 + 15.23 
53.0 
18 - 90 
 
<0.001 
BMI 
     Mean + SD 
     Median 
     Range 
 
28.57 + 7.05 
26.96 
14.53 – 58.72 
 
28.21 + 6.89 
26.65 
15.35 – 63.70 
.247 
 N (%) N (%)  
Gender  
     Female 
     Male 
 
598 (43.4) 
192 (25.5) 
 
780 (56.6) 
562 (74.5) 
 
<0.001 
Ethnicity 
     African-American 
     Asian 
     Caucasian 
     Latino 
     Other 
 
76 (37.8) 
32 (47.1) 
580 (36.9) 
49 (45.0) 
53 (29.1) 
 
125 (62.2) 
36 (52.9) 
992 (63.1) 
60 (55.0) 
129 (70.9) 
 
<0.029 
Educational level 
     High school 
     College 
     Graduate degree 
     None of these 
     Did not answer 
 
137 (37.0) 
331 (37.4) 
 78 (35.9) 
16 (38.1) 
228 (37.0) 
 
233 (63.0) 
554 (62.6) 
139 (64.1) 
26 (61.9) 
389 (63.0) 
  
.990 
Income level 
     <$25,000 
     $25, 000 - $50,000 
     $50,000 - $75,000 
     $75,000 - $100,000 
     >$100,000 
     Did not answer 
 
 90 (40.4) 
113 (38.6) 
87 (34.7) 
95 (39.1) 
115 (34.4) 
290 (36.8) 
 
133 (59.6) 
180 (61.4) 
164 (65.3) 
148 (60.9) 
219 (65.6) 
497 (63.2) 
 
.642 
Clinical Characteristics    
Smoker 
     No 
     Yes 
 
662 (36.6) 
128 (39.4) 
 
1145 (63.4) 
197 (60.6) 
 
.345 
Previous PONV 
     No 
     Yes 
 
469 (32.6) 
297 (47.3) 
 
969 (67.4) 
331 52.7) 
 
<0.001 
Previous motion sickness 
     No 
     Yes 
 
544 (34.3)  
246 (45.2) 
 
1044 (65.7) 
298 (54.8) 
 
<0.001 
History migraine 
headaches 
     No 
     Yes 
 
 
561 (34.4) 
229 (45.9) 
 
 
1071 (65.6) 
270 (54.1) 
 
 
<0.001 
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Table 5.2. (Continued) Demographic and Clinical Characteristics of Patients with PDNV and 
without PDNV 
 
Clinical Characteristics    
 PDNV No PNDV P value 
Procedures 
     General 
     Breast 
     Cholecystectomy 
     Cystoscopy 
     D&C 
     ENT 
     Gynecologic 
     Hernia 
     Knee arthroscopy 
     Orthopedic 
     Prostate 
     Upper extremity 
 
140 (32.2) 
 79 (35.9) 
 62 (66.0) 
 36 (27.5) 
 66 (37.3) 
 61 (33.5) 
103 (43.6) 
 28 (32.2) 
104 (46.0) 
 46 (35.9) 
 11 (14.1) 
 54 (39.4) 
 
 
295 (67.8) 
141 (67.9) 
 32 (34.0) 
 95 (76.5) 
111 (62.7) 
121 (66.5) 
133 (56.4) 
 59 (67.8) 
122 (54.0) 
 82 (60.6) 
 67 (85.9) 
 83 (80.6) 
 
<0.001 
Surgical Approach 
     Conventional 
     Arthroscopic 
     Endoscopic 
     Laparoscopic 
 
385 (34.8) 
131 (43.7) 
126 (28.4) 
148 (52.5) 
 
720 (65.2) 
169 (56.3) 
318 (71.6) 
134 (47.5) 
 
<0.001 
ASA Status 
     ASA 1 
     ASA 2 
     ASA 3 
     ASA 4 
 
184 (43.3) 
493 (37.9) 
111 (35.8) 
  2 (25) 
 
241 (47.2) 
807 (62.1) 
287 (72.1) 
6 (75) 
 
<0.001 
OR Time in Hours 
     Mean + SD 
     Median 
     Range 
 
1.74 + .913 
1.48 
.42 – 11.20 
 
1.63 + .811 
1.46 
.22 – 7.15 
 
<0.01 
Regional Block 
     No 
     Yes 
 
603 (34.7) 
187 (47.7) 
 
1137 (65.3) 
205 (52.3) 
 
<0.001 
Nitrous oxide  
     No 
     Yes 
 
701 (36.5) 
 89 (42.6) 
 
1222 (63.5) 
 89 (42.6) 
 
.08 
DOS = Day of Surgery; PDNV = Post discharge nausea and vomiting; PONV = Postoperative 
nausea and vomiting; D & C = Dilatation and Curettage; ENT = Ear, Nose, and Throat; ASA = 
American Society of Anesthesiologist; OR = Operating Room; PACU = Post Anesthesia Care 
Unit 
 
  
 
 
Table 5.3 Significance Levels for Final Logistic Regression Model 
 
Variable df Deviance Likelihood Ratio p-value 
Intercept  214.715   
Previous PONV 1 224.517 9.802 0.0017 
OR Time 1 222.615 7.900 0.0049 
Pain Factor 3 241.005 26.290 <0.0001 
 
 
Table 5.4 Estimated Regression Coefficients 
 
Variable Estimated 
Log Odds 
Standard 
Error of Log 
Odds 
Estimated 
Odds Ratio 
Lower CI 
limit for 
Odds Ratio 
Upper CI 
limit for 
Odds Ratio 
Previous 
PONV 
1.0662 0.3475 2.90 1.47 5.74 
OR Time 0.6209 0.2275 1.86 1.19 2.91 
Mild Pain 1.5968 0.6614 4.94 1.35 18.05 
Moderate 
Pain 
2.3417 0.6635 10.40 2.83 38.17 
Severe Pain 2.9183 0.7230 18.51 4.49 76.35 
 
 
Table 5.5 Pain Level and Presence/Absence Nausea in Days 3-7 
 
 No late Nausea Some late Nausea 
No Pain 67 (95.7%) 3 (4.3%) 
Mild Pain 71 (80.7%) 17 (20.3%) 
Moderate Pain 42 (56.0%) 33 (44.0%) 
Severe Pain 15 (53.6%) 13 (46.4%) 
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Table 5.6 Percentages of Patients with Severe Nausea who Used Pharmacologic and Non-
Pharmacologic Methods of Nausea Control  
Days Post 
Surgery Severe 
Nausea (% of 
Total Severe 
Nausea) 
Group 1 
No AE 
No NP 
Group 2 
No AE 
Yes NP 
Group 3 
Yes AE 
No NP 
Group 4 
Yes AE 
Yes NP 
Day of Surgery 
(12.8%) 
30% 55% 1.8% 13.2% 
Day 1 (4.6%) 27% 53% 2% 18% 
Day 2 (2.8%) 26.2% 50.8% 4.9% 18% 
Day 3 (4.5%) 25% 25% 0 50% 
Day 4 (2.3%) 0 33.3% 0 66.7% 
Day 5 (1.9%) 0 40% 0 60% 
Day 6 (2.7%) 0 42.9% 0 57.1% 
Day 7 (2%) 20% 0 20% 60% 
 
AE = Antiemetics; NP = Nonpharmacologic modalities 
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 CHAPTER SIX 
 
Conclusions and Discussion 
The purposes of this dissertation were to (1) review the current knowledge in the area of 
post discharge nausea and vomiting; (2) present results of an integrative review of the research 
literature to determine best evidence for prevention of PDNV in adults or rescue of patients who 
suffer from post discharge nausea and vomiting (PDNV); (3) present a critical review and 
analysis of measurement of nausea and vomiting after discharge from outpatient surgery, and (4) 
present findings of a prospective research study.  The purposes of the empirical research study 
conducted as part of this dissertation were to:  1) describe the incidence and severity of PDNV 
over a 7-day period in a sample of adult surgical patients undergoing outpatient surgeries under 
general anesthesia, 2) describe the pharmacologic and nonpharmacologic modalities of care used 
by patients with PDNV to manage it, 3) compare the incidence and severity of PDNV between 
those who do and do not use pharmacologic and nonpharmacologic modalities, 4) determine 
outcomes associated with PDNV, and 5) determine predictions for late (Days 3-7) PDNV.  
In this dissertation, four papers are presented, two of which have been published to date.  
In the first paper, current knowledge of PDNV was systematically reviewed.2  We found that 
PDNV had not been assessed and evaluated as thoroughly as postoperative nausea and vomiting 
(PONV).  It was evident from the literature review, that covered a decade of studies, that patients 
have continued to have problems with nausea and vomiting upon discharge. We do not know how 
those symptoms impact the patient’s recovery, how extensive the delay in recovery is due to the 
symptoms, or the costs attributable to these symptoms.3 Suggestions for research based on this 
systematic review included study of (1) antiemetic efficacy in the post discharge setting, (2) the 
effectiveness of a detailed education program to manage symptoms for these patients, and (3) 
economic impact of the symptoms. 
In the second paper, interventions for PDNV in the outpatient surgery population were 
specifically targeted.4 In the paper an integrative review was presented in which the evidence for 
prevention of PDNV in adults or for the rescue of patients who suffer from PDNV was reviewed.  
The evidence included information on the association of anesthetic techniques (e.g. total 
intravenous anesthesia was associated with decreased PDNV for the first 24 hours, but not 14 
days later), antiemetics (e.g. use of transdermal scopolamine as an effective antiemetic for the 
outpatient), and pain medication (e.g. patients who received morphine in PACU were more likely 
to have PDNV at 24 hours than those who received fentanyl) with PDNV incidence.  The paper 
also included several studies in which nonpharmacologic methods of controlling nausea and 
vomiting were included, (e.g. acupuncture/acustimulation and ginger).  We found that there was a 
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 paucity of nursing research focused on PDNV.  Since physicians have focused on research that 
requires a treatment regime intraoperatively, we concluded that nurse researchers could conduct 
studies on the effectiveness of patient or caregiver education, preoperative anxiety, interactions of 
pain and pain medication, and non-pharmacologic methods of relief.  We also suggested that 
nurse researchers collaborate with medical researchers to determine the best antiemetics for use in 
the postdischarge setting or the most appropriate medication for pain relief in the postdischarge 
setting that will alleviate pain, but cause less PDNV. 
 The third paper was a critical review and analysis of the literature on measurement of 
patient nausea and vomiting after discharge from outpatient surgery and in which we discussed 
relevant needs in the area of measurement.  In that paper, we determined there was a lack of 
standardized definitions of PONV and PDNV, of psychometrically sound instruments to measure 
PONV and PDNV, and a reliance on investigator developed instruments used in only one study.  
Assessment of nausea and vomiting has been inconsistent throughout studies.  For example, there 
is not only inconsistency with the definition of PONV and PDNV per study, but also differing 
definitions of the basic terms, nausea, vomiting and retching, with some researchers measuring 
each entity separately and others considering all as emetic episodes.  That inconsistency has 
contributed to the difficulty comparing study findings.  We found that there are no clear and 
standardized instruments in use to measure the phenomena of PDNV.  There were two 
instruments found with adequate psychometric properties, the ambulatory surgery-inventory of 
nausea vomiting and retching (AS-INVR) and the functional living inventory-emesis (FLIE), 
whose use will provide the possibility of standardizing assessment of PDNV symptoms in 
research studies.  Most of the psychometric testing for these instruments was in the chemotherapy 
population.  Although these two instruments both possess strengths, more study is needed to 
progress the measurement of nausea and vomiting in the post discharge ambulatory surgery 
patient. 
The fourth paper was the results of a research study in which we described the incidence 
and severity of PDNV in adult outpatients after ambulatory surgery.  In the study we also 
describe the pharmacologic and nonpharmacologic modalities of care used by patients with 
PDNV to manage it, compare the incidence and severity of PDNV between those who do and do 
not use pharmacologic and nonpharmacologic modalities, and determine outcomes associated 
with PDNV.   
We found that over one third of ambulatory surgery patients experience PDNV.  With 
over 34 million patients undergoing ambulatory surgery annually in the U.S. alone, that translates 
to millions of patients who go home after surgery and suffer these post discharge symptoms of 
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 nausea and vomiting.  We found that PDNV peaks on the day of surgery and continues to 
decrease over the week; however, some patients are still experiencing PDNV one week after 
discharge home.  Predictors for early PDNV (48 hours) were determined recently by investigators 
using data from this study as: female gender, age less than 50 years, history of PONV, opioids 
administered in the PACU, and nausea in the PACU.  We determined that predictors for late 
PDNV (history of PONV, OR time and pain score) were somewhat different than early 
predictors.  
Even though 37.1% of our patient experienced PDNV, only 4.2% of those patients used 
antiemetics for management of symptoms.  Most patients self-managed at home with lying down, 
carbonated drink intake, and taking medication with food.  Some patients stopped taking their 
pain medication, and only 3 patients in the study used acupressure bands.  Those who did use 
antiemetics had a higher mean nausea score than those who did not.  Only two patients out of 180 
who responded to the question called their healthcare provider for PDNV symptoms.   
We found that PDNV negatively affected the mean quality of life (QOL) scores.  PDNV 
affected the patients’ ability to eat and drink, to sleep, to socialize and to perform activities of 
daily living.  We also found that patients who expected to have nausea or vomiting were more 
likely to experience nausea and vomiting.  Patients with PDNV rated their satisfaction with 
treatment as lower than patients who did not have PDNV. 
Implications for the Future 
Nausea and vomiting after surgery has been a long-term problem that began with 
hospitalized patients after surgery and moved out into the home with the advent of ambulatory 
surgery.   There is a death of literature that describes this phenomenon.2, 4  In this study we 
addressed the issue of PDNV with the first long-term multi-site study to focus on a description of 
this phenomena since Carroll, et al.5 What we discovered was that over one third of ambulatory 
surgery patients suffer from PDNV after discharge.  That tells us there has been no progress in 
relieving those symptoms since the first report in 1995 in which 35.7% of participants 
experienced PDNV.5   
 
Research Recommendations  
Systematic inquiry to discover appropriate venues of prevention and treatment for 
patients who suffer from PDNV is needed.  Patients with PDNV are typically unseen and 
unheard.  These patients tend not to call a healthcare provider during the week after surgery, but 
try to manage symptoms with self-care, or they may report the symptoms to the surgeon, and the 
information never gets back to the anesthesia team.6  Imperative to further research conducted in 
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 this population of patients is clear definition and measurement of research terms.  Inconsistency 
with assessment and measurement of nausea, vomiting, and retching throughout studies has made 
it difficult to compare study results in the area of PDNV.  PDNV should clearly be defined as 
nausea and vomiting after discharge from the healthcare facility.  Studies of PDNV should follow 
patients for at least 48 hours after discharge. In this dissertation, we discovered that 6.3% of 
patients had symptoms of nausea up to a week after surgery, so long-term studies are also needed 
to further describe this smaller segment of PDNV population.   
Reliable and valid instruments are not consistently used in studies with patients who have 
PDNV, although use of the visual analogue scale (VAS), verbal descriptor scale (VDS), and 
numerical rating score (NRS) is common, and use of these instruments has been described as 
valid and reliable by other researchers.7-10  More studies should be performed using the two 
established instruments, Ambulatory Surgery-Inventory of Nausea, Vomiting, and Retching (AS-
INVR) and Functional Living Index-Emesis (FLIE), to establish normative values, timing needed 
to complete the instrument, and grade level.  The AS-INVR and the FLIE provide the possibility 
of standardization of outcome for studies with those patients.11-14 In all studies on PDNV, 
reliability and validity of instruments should be reported. Researchers should also determine 
whether it is more effective for the patient to rate PDNV on a daily basis, at 12- hour intervals, or 
shorter intervals after arrival home. 
Further research needs to be conducted into the newer specific drugs that are available for 
care in the PDNV population.  The short-acting antiemetics that are given typically in the PACU 
before patient discharge do not protect against PDNV once the patient is home.  Some work has 
begun in this area with recent studies on palonosetron, a 5HT-3 receptor antagonist much like 
ondansetron, but longer-acting.15,16  Other drugs that possibly will protect against PDNV include 
transdermal scopolamine,17 promethazine suppositories,18 ondansetron dissolving tablets (ODT)19, 
20, and aprepitant, a new NK-1 receptor antagonist.21, 22  Researchers should focus on 
nonpharmacologic means to manage symptoms of PDNV including, but not limited to 
acupressure, acupuncture, 23acustimulation,24, 25 imagery, music therapy, distraction, relaxation, 
aromatherapy, and use of ginger.26 There is little research to document effectiveness in the PDNV 
population, but some of the nonpharmacologic methods have shown potential. These 
nonpharmacologic means of control could work in conjunction with antiemetics to resolve 
symptoms of PDNV. 
Through research, we should develop an algorithm to guide management of PDNV.6  At 
the present time, only one practice guideline attempts to guide management of PDNV.  An 
algorithm to guide care for PDNV would use the predictors determined by Apfel, et al. to assess 
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 patients for risk. Then the patient could be assigned treatment based on risk. That same algorithm 
could make recommendations for anesthesia care based on patient risk as available algorithms for 
PONV do presently, e.g. total intravenous anesthesia (TIVA) instead of volatile anesthetics.27, 28 
That same algorithm could then drive rescue treatment in the PACU.  Assessing patient risk 
before surgery is extremely important because three of the medications are effective in this 
population of patients require administration before surgery for adequate prophylaxis (i.e., 
aprepitant, palonsetron, transdermal scopolamine).   Then the algorithm can guide rescue 
treatment in the PACU and then later at home. 
There are other areas of research that could be advanced.  Only one group of investigators 
tested a patient education intervention designed to compare the efficacy of existing generic 
education instructions with specially designed procedure-specific instructions.29 Patients in both 
groups felt they received adequate discharge instructions, so there was no significant difference 
between groups.  However, other researchers have pointed out the need to improve preoperative 
patient teaching, including topics of drug and nondrug interventions.30  In PDNV studies, patients 
have attempted to self-manage symptoms, so research that looked at self-efficacy issues would be 
appropriate.  Genetic and other molecular biological patient characteristics that predispose a 
patient to PDNV need to undergo research.31 
Many of the research suggestions mentioned above could be conducted by nurses in a 
nursing research program.  Some of the research suggestions could be conducted with nurses as 
part of a research team including pharmacy, anesthesia and surgery for the total care of the 
patient.   
Research of PDNV symptoms could be part of a larger program that focuses on all 
discharge symptoms experienced by the patient after ambulatory surgery.  These symptoms 
include, but are not limited to pain,32-34, the emetogenic role of opioids in PDNV,35 somnolence or 
level of sedation, bleeding, dizziness, fatigue, headache, backache, sore throat, hoarseness, 
elevated temperature and voiding difficulty.  Also of importance is how the patient symptoms 
affect the quality of recovery including ability to drink liquids, eat, make meals, do 
recreation/leisure activities, interact with family and friends, affect daily functions, and affect 
ability to return to work.36-40  This research has focused on the adult population. Research should 
also continue in the pediatric population because PDNV affects children as well as adults.   
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Clinical Recommendations 
Specifically for nursing, the preanesthesia nurse in the ambulatory setting is a part of the 
anesthesia team and can assess the patient for risk, as well as collaborate with the team for 
management of PONV and PDNV. If the patient has come in for preadmission testing before the 
day of surgery, this is a perfect opportunity for the nurse to assess the patient early for the risk of 
PDNV and to also provide specific patient education for management of symptoms at home 
should they occur.   In the PACU, the postanesthesia nurse, also a part of the team, assesses the 
patient for PONV, and assesses the severity of nausea when it does occur.  That nurse is also a 
vital member of the anesthesia care team and collaborates in making treatment recommendations 
for the patient.  The nurse in the postanesthesia phase II unit prepares the patient for discharge 
home which includes patient education for the patient and caregiver.  This is another point of care 
where the nurse can provide education and support for management of symptoms should they 
occur at home.  The weak link is after discharge home when the patient may suffer without 
contacting a health care provider, or with care managed by the surgeon who may or may not be 
aware of newer medications and techniques for managing symptoms.  The anesthesia care team 
should be more involved in planning patient care for negative anesthesia symptoms at home.  An 
algorithm could guide care for this period of patient recovery and would be an asset for surgeon, 
anesthesia provider, or nurse who was in contact with the patient. 
 
Summary 
PDNV is not a symptom that typically causes mortality, but is a negative symptom that 
can impact a patient’s feeling of well-being, as well satisfaction with care and the healthcare 
facility.41 The economic effect of any postdischarge symptom is unclear at the present time, but is 
related to incidence, impact of the symptom, and delays in return to normal function by the 
patient.3  The incidence of PDNV has not changed in the last decade, and it is time that we moved 
forward with interventions that can affect this group of patients with either prevention or effective 
treatment.  This study is a foundation that tells us where we are and where we should go in the 
future for care of this negative, uncomfortable, and many times, serious entity. 
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 APPENDIX A: Patient Diary Instruction: 
 
PATIENT DIARY INSTRUCTION                                      Participant Code: _________________ 
Thank you for participating in our survey. We hope that by following up with you to better understand difficulties you might have encountered 
after anesthesia and surgery so that we will be able to treat our patients better in the future.  
We will call you on your 1st day after surgery between    and  .  
We will call again on your 2nd day after surgery between    and  . 
We will call again on your 7th day after surgery between    and  . 
For Days 1-2, please fill out your diary at each of the following times (morning, lunchtime, dinnertime and bedtime) so that we can go through 
questions with you more effectively when we call you.  
For Days 3 – 7, please fill out the information when you first wake up in the morning.  After the last page is filled out, please send back to the 
researcher in the self-addressed stamped envelope. 
For the purposes of this survey, you may find the following definitions of symptoms useful. 
Nausea is a sensation of queasiness in your stomach or throat that may lead to vomiting.  
Vomiting is bringing up stomach contents due to involuntary muscle contractions.  112 Retching is similar to vomiting with the exception that no stomach contents come up, it is also known as “dry heaves”. 
We will also be asking you to enter your symptoms according to different time intervals. In some instances, the time points might not literally fit.  
For example, when we talk about bedtime we mean when you decided to try to go to sleep for the night, even if you have actually been in bed all 
day because of your surgery.  Here is a rough definition of the time-points and intervals:  
Morning to Lunchtime: From wake-up until just before your lunchtime, e.g. around noon. 
Lunchtime to Dinnertime: From start of your lunchtime until just before your dinnertime, e.g. around 6 pm. 
Dinnertime to Bedtime: From start of your dinnertime until your bedtime, e.g. around 10 pm. 
Bedtime to Morning: From your bedtime until you wake-up the next morning.  
Thank you in advance for completing this survey! Your information will help us take better care of patients in the future. 
You will receive your $10 gift card in the mail approximately 2-4 weeks after we have received your completed diary. 
 
Jan Odom Forren, PhD candidate, MS, RN, CPAN, FAAN; College of Nursing, University of Kentucky, Lexington, KY  40506; email: jan.forren@uky.edu; phone 502.552.8299 
  
 
 DAY OF SURGERY 
Symptoms after Surgery 
Your self-assessments below are most accurate and useful to us if you complete them near the end of each time interval.  For example, you should 
fill out how you felt during your ride home as soon as you arrive home. If you were asleep at the end of the time interval please complete the 
assessment as soon as you can.  
Please use the 0-10 scale with 0 being “none at all” and 
10 being the “worst possible” to rate your symptoms. 
As the day goes on please fill out each question at the 
end of each time interval. If you have no symptoms please enter a “0.”  
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
 
 Please answer each question below at the 
end of each time interval to the right ? 
During 
Ride 
Home 
Ride Home 
to 
Dinnertime 
Dinnertime 
to 
Bedtime 
1. What was your severity of pain at rest?    
2. What was your severity of pain during activities?    
3. What was your worst severity of nausea?    
4. If you had nausea, for how long did you have it?[min]    
5. How many times did you have vomiting/retching?     
6. What was your worst severity of vomiting/retching?     
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     Answer these questions at the end of each day.                                                                                                             
 Day of Surgery 
7. How tired were you during the day (0-10)  
8. How much headache did you have (0-10)  
9. What made your pain worse during the day?   
10. What relieved your pain during the day?   
11. What made your nausea worse during the day?   
12. What relieved your nausea during the day?   
13. What made your vomiting worse during the day?   
14. What relieved your vomiting during the day?   
 
PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 114 1.  In the last 24 hrs, I threw up 
_____times. 
7 or more 5-6  3-4  1-2  I did not throw up 
2. In the last 24 hours, from retching or 
dry heaves I have felt _____distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from vomiting or 
throwing up, I have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I have felt 
nauseated or sick at my stomach____ 
Not at all 1 hour or less 2-3 hours 4-6 hours More than 6 hours 
5. In the last 24 hours, from 
nausea/sickness at my stomach, I have 
felt ____ distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each time I threw 
up I produced a_______amount. 
Very large (3 
cups or more)
Large (2-3 
cups) 
Moderate (½ 
- 2 cups) 
Small (Up to 
½ cup) 
I did not throw up 
7. In the last 24 hours, I have felt 
nauseated or sick at my stomach ____ 
times 
7 or more 5-6  3-4 1-2 No  
 
 
 1ST DAY AFTER SURGERY 
Symptoms after Surgery 
Your self-assessments below are most accurate and useful to us if you complete them near the end of each time interval.  If you were asleep at the 
end of the time interval please complete the assessment as soon as you can.  
 
Please use the 0-10 scale with 0 being “none at all” and 
10 being the “worst possible” to rate your symptoms. 
As the day goes on please fill out each question at the 
end of each time interval. If you have no symptoms  
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
please enter a “0.”  
 
 
Please answer each question below at the 
end of each time interval to the right ? 
Bedtime 
to 
Morning 
Morning 
to 
Lunchtime 
Lunchtime 
to 
Dinnertime 
Dinnertime
to 
Bedtime 
15. What was your severity of pain at rest?     
16. What was your severity of pain during activities?     
17. What was your worst severity of nausea?     
18. If you had nausea, for how long did you have it?[min]     
19. How many times did you have vomiting/retching?      
20. What was your worst severity of vomiting/retching?      
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     Answer these questions at the end of each day. 
 1st Day after Surgery 
21. How tired were you during the day (0-10)  
22. How much headache did you have (0-10)  
23. What made your pain worse during the day?   
24. What relieved your pain during the day?   
25. What made your nausea worse during the day?   
26. What relieved your nausea during the day?   
27. What made your vomiting worse during the day?   
28. What relieved your vomiting during the day?   
 
Please answer questions below when you wake up in the morning on the 1st day after surgery. 
  116 29. In the space below, please list all new medications or remedies that you took from when you returned home yesterday to when you woke 
up today. New medications or remedies are those that you did not take regularly before your surgery. 
  
Name of new medication 
or remedy 
 Time  
of the day 
 Strength of doses 
taken (mg) 
 Reason for taking 
 
 
How effective was it? 
0 = not at all, 
10 = completely effective 
         
         
         
         
         
 
 
 
 Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the 
0-10 scale with  
0 being “not at all” and 10 being “most bothersome”. 
0   1   2    3   4    5    6    7   8    9    10 
not at all  most bothersome 
 
  Nausea  Vomiting  Pain   
30. How much did         Affect your quality of life yesterday? 
31. How much did         Affect your usual ability to eat and drink yesterday? 
32. How much did         Affect your usual activities and tasks yesterday? 
33. How much did         Affect your usual enjoyment of leisure and recreational activities yesterday  (for example: reading, listening to music)? 
34. How much did         Affect your usual enjoyment of social activities yesterday? 
35. How much did         Affect your usual ability to do your normal daily work yesterday? 
36. How much did         Affect your usual ability to sleep yesterday? 117  
  
 
 PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
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 2ND DAY AFTER SURGERY  
Symptoms after Surgery 
Your self-assessments below are most accurate and useful to us if you complete them near the end of each time interval.  If you were asleep at the 
end of the time interval please complete the assessment as soon as you can.  
Please use the 0-10 scale with 0 being “none at all” and 
10 being the “worst possible” to rate your symptoms. 
As the day goes on please fill out each question at the 
end of each time interval. If you have no symptoms please enter a “0.”  
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
 
 
Please answer each question below at the 
end of each time interval to the right ? 
Bedtime 
to 
Morning 
Morning 
to 
Lunchtime 
Lunchtime 
To 
Dinnertime
37. What was your severity of pain at rest?    
38. What was your severity of pain during activities?    
39. What was your worst severity of nausea?    
40. If you had nausea, for how long did you have it?[min]    
41. How many times did you have vomiting/retching?     
42. What was your worst severity of vomiting/retching?     
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     Answer these questions at the end of each day. 
 2nd Day after Surgery 
43. How tired were you during the day (0-10)  
44. How much headache did you have (0-10)  
45. What made your pain worse during the day?   
46. What relieved your pain during the day?   
47. What made your nausea worse during the day?   
48. What relieved your nausea during the day?   
49. What made your vomiting worse during the day?   
50. What relieved your vomiting during the day?   
 
Please answer the questions below when you wake up in the morning on the 2nd day after surgery. 
  120 51. In the space below, please list all new medications or remedies that you took yesterday.  
New medications or remedies are those you did not take regularly before surgery. 
Name of new medication 
or remedy 
 Time  
of the day 
Strength of doses 
taken (mg) 
 Reason for taking 
 
How effective was it? 
0 = not at all, 
10 = completely effective
         
         
         
         
         
 
 
0   1   2    3   4    5    6    7   8    9    10 
 
 Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the  
0 being “not at all” and 10 being “most bothersome”. 
 0-10 scale with 
not at all  most bothersome 
 
 Nausea  Vomiting  Pain   
52. How much did        Affect your quality of life yesterday? 
53. How much did        Affect your usual ability to eat and drink yesterday? 
54. How much did        Affect your usual ability to do necessary activities and tasks yesterday? 
55. How much did        Affect your usual enjoyment of leisure and recreational activities yesterday  
(for example: reading, listening to music)? 
56. How much did        Affect your usual enjoyment of social activities yesterday? 
57. How much did        Affect your usual ability to do your normal daily work yesterday? 
58. How much did        Affect your usual ability to sleep yesterday? 
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 PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
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59. Did you use any of the following means to prevent or treat nausea or vomiting since your surgery? 
? Yes – No ? Wearing acupressure wrist bands (elastic bands that pt pressure on the wrist) 
? Yes – No ? Moving slowly from clear liquids to solid food 
? Yes – No ? Taking medicines with food 
? Yes – No ? Eating food 
? Yes – No ? Drinking carbonated drinks or other fluids 
? Yes – No ? Laying down 
Other (please specify)  
 
 60. If you are a smoker, when did you resume smoking: Date: _____  
and did this cause you some nausea or vomiting?  ? Yes – No ? – N/A ? 
 
For the following questions, please compare how your recovery from surgery has lived up to the expectations you had before surgery. 
Please use the following scale. Please note that if your recovery went as expected, you would rate it as “5” per the scale below. 
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Compared to what you expected before surgery 
61. …how would you rate your anesthesia?  
62. …how would you rate your pain control?  
63. …how would you rate your prevention and treatment of nausea?  
64. …how would you rate your prevention and treatment of vomiting?  
65. …how would you rate your overall medical treatment?  
0   1   2    3   4    5    6    7   8    9    10 
     far worse 
than expected
   as 
     expected 
far better  
than expected 
 
66. If there were a drug that could have prevented the pain you had but you would have to  
pay for it out of your own pocket to get it, how much would you be willing to pay for it? $ __________ 
67. If there were a drug that could have prevented the nausea you had but you would have to  
pay for it out of your own pocket to get it, how much would you be willing to pay for it? $ __________ 
68. If there were a drug that could have prevented the vomiting you had but you would have to  
pay for it out of your own pocket to get it, how much would you be willing to pay for it? $ __________ 
69. What is your highest level of education? ? High School – ? College – ? Doctoral Degree – ? none of these 
70. What is your average annual household income?  
? under $25,000 – ? $25–$50,000 – ? $50–$75,000 – ? $75–$100,000 – ? over $100,000 
71. Do you have any suggestions about how we can improve patient recovery in the future?   
 
 3RD DAY AFTER SURGERY 
Symptoms after Surgery 
 
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out 
each question at the end of each time interval. If you have no symptoms please enter a “0.”  
 
 0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible   
 
Please answer each question below at the 
end of each time interval to the right ? 3rd Day after Surgery 
72. What was your severity of pain at rest?  
73. What was your severity of pain during activities?  
74. What was your worst severity of nausea?  
75. If you had nausea, for how long did you have it?[min]  
76. How many times did you have vomiting/retching?   
77. What was your worst severity of vomiting/retching?   
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    Answer these questions at the end of each day. 
 rd Day after Surgery 
78. How tired were you during the day (0-10)  
79. How much headache did you have (0-10)  
80. What made your pain worse during the day?   
81. What relieved your pain during the day?   
82. What made your nausea worse during the day?   
83. What relieved your nausea during the day?   
84. What made your vomiting worse during the day?   
85. What relieved your vomiting during the day?   
 
Please answer the questions below when you wake up in the morning on the 3rd day after surgery. 
  
86. In the space below, please list all new medications or remedies that you took yesterday.  
New medications or remedies are those you did not take regularly before surgery. 
Name of new medication 
or remedy 
 Time  
of the day 
Strength of doses 
taken (mg) 
 Reason for taking 
 
How effective was it? 
0 = not at all, 
10 = completely effective
         
         
         
         
         
 
 
0   1   2    3   4    5    6    7   8    9    10 
 
 Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the  
0 being “not at all” and 10 being “most bothersome”. 
 0-10 scale with 
not at all  most bothersome 
 
 
 Nausea  Vomiting  Pain   
87. How much did        Affect your quality of life yesterday? 
88. How much did        Affect your usual ability to eat and drink yesterday? 
89. How much did        Affect your usual ability to do necessary activities and tasks yesterday? 
90. How much did        Affect your usual enjoyment of leisure and recreational activities yesterday  
(for example: reading, listening to music)? 
91. How much did        Affect your usual enjoyment of social activities yesterday? 
92. How much did        Affect your usual ability to do your normal daily work yesterday? 
93. How much did        Affect your usual ability to sleep yesterday? 126  
  
 
  
PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
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 4TH DAY AFTER SURGERY 
Symptoms after Surgery 
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out 
each question at the end of each time interval. If you have no symptoms please enter a “0.”  
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Please answer each question below at the 
end of each time interval to the right ? 4th Day after Surgery 
94. What was your severity of pain at rest?  
95. What was your severity of pain during activities?  
96. What was your worst severity of nausea?  
97. If you had nausea, for how long did you have it?[min]  
98. How many times did you have vomiting/retching?   
99. What was your worst severity of vomiting/retching?   
    Answer these questions at the end of each day. 
 4th Day after Surgery 
100. How tired were you during the day (0-10)  
101. How much headache did you have (0-10)  
102. What made your pain worse during the day?   
103. What relieved your pain during the day?   
104. What made your nausea worse during the day?   
105. What relieved your nausea during the day?   
106. What made your vomiting worse during the day?  
107. What relieved your vomiting during the day?   
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
 
 Please answer the questions below when you wake up in the morning on the 4th day after surgery. 
  
108. In the space below, please list all new medications or remedies that you took yesterday.  
New medications or remedies are those you did not take regularly before surgery. 
Name of new medication 
or remedy 
 Time  
of the day 
Strength of doses 
taken (mg) 
 Reason for taking 
 
How effective was it? 
0 = not at all, 
10 = completely effective
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Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the 
0-10 scale with  
0 being “not at all” and 10 being “most bothersome”. 
 Nausea Vomiting  Pain   
109. How much did        Affect your quality of life yesterday? 
110. How much did        Affect your usual ability to eat and drink yesterday? 
111. How much did        Affect your usual ability to do necessary activities and tasks yesterday? 
112. How much did        Affect your usual enjoyment of leisure and recreational activities yesterday  
(for example: reading, listening to music)? 
113. How much did        Affect your usual enjoyment of social activities yesterday? 
114. How much did        Affect your usual ability to do your normal daily work yesterday? 
115. How much did        Affect your usual ability to sleep yesterday? 
0   1   2    3   4    5    6    7   8    9    10 
not at all  most bothersome 
 
  
PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
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 5TH DAY AFTER SURGERY 
Symptoms after Surgery 
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out 
each question at the end of each time interval. If you have no symptoms please enter a “0.”  
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Please answer each question below at the 
end of each time interval to the right ? 5th Day after Surgery 
116. What was your severity of pain at rest?  
117. What was your severity of pain during activities?  
118. What was your worst severity of nausea?  
119. If you had nausea, for how long did you have it?[min]  
120. How many times did you have vomiting/retching?   
121. What was your worst severity of vomiting/retching?   
 
    Answer these questions at the end of each day. 
 5th Day after Surgery 
122. How tired were you during the day (0-10)  
123. How much headache did you have (0-10)  
124. What made your pain worse during the day?   
125. What relieved your pain during the day?   
126. What made your nausea worse during the day?   
127. What relieved your nausea during the day?   
128. What made your vomiting worse during the day?   
129. What relieved your vomiting during the day?   
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
 
  
Please answer the questions below when you wake up in the morning on the 5th day after surgery. 
  
130. In the space below, please list all new medications or remedies that you took yesterday.  
New medications or remedies are those you did not take regularly before surgery. 
Name of new medication 
or remedy 
 Time  
of the day 
Strength of doses 
taken (mg) 
 Reason for taking 
 
How effective was it? 
0 = not at all, 
10 = completely effective
         
         
         
         
 
Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the 
0-10 scale with  
0 being “not at all” and 10 being “most bothersome”. 
132 
 
 
 Nausea  Vomiting Pain  
131. How much did      Affect your quality of life yesterday? 
132. How much did      Affect your usual ability to eat and drink yesterday? 
133. How much did      Affect your usual ability to do necessary activities and tasks yesterday? 
134. How much did      Affect your usual enjoyment of leisure and recreational activities yesterday  
(for example: reading, listening to music)? 
135. How much did      Affect your usual enjoyment of social activities yesterday? 
136. How much did      Affect your usual ability to do your normal daily work yesterday? 
137. How much did      Affect your usual ability to sleep yesterday? 
0   1   2    3   4    5    6    7   8    9    10 
not at all  most bothersome 
 
 PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
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 6TH DAY AFTER SURGERY 
Symptoms after Surgery 
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out 
each question at the end of each time interval. If you have no symptoms please enter a “0.”  
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Please answer each question below at the 
end of each time interval to the right ? 6th Day after Surgery 
138. What was your severity of pain at rest?  
139. What was your severity of pain during activities?  
140. What was your worst severity of nausea?  
141. If you had nausea, for how long did you have it?[min]  
142. How many times did you have vomiting/retching?   
143. What was your worst severity of vomiting/retching?  
    Answer these questions at the end of each day. 
 6th Day after Surgery 
144. How tired were you during the day (0-10)  
145. How much headache did you have (0-10)  
146. What made your pain worse during the day?   
147. What relieved your pain during the day?   
148. What made your nausea worse during the day?   
149. What relieved your nausea during the day?   
150. What made your vomiting worse during the day?   
151. What relieved your vomiting during the day?   
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
 
 Please answer the questions below when you wake up in the morning on the 6th day after surgery.  
152. In the space below, please list all new medications or remedies that you took yesterday.  
New medications or remedies are those you did not take regularly before surgery. 
Name of new medication 
or remedy 
 Time  
of the day 
Strength of doses 
taken (mg) 
 Reason for taking 
 
How effective was it? 
0 = not at all, 
10 = completely effective
         
         
         
         
         
 
 135 Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the 
0-10 scale with  
0 being “not at all” and 10 being “most bothersome”. 
0   1   2    3   4    5    6    7   8    9    10 
not at all  most bothersome 
 Nausea  Vomiting Pain   
153. How much did       Affect your quality of life yesterday? 
154. How much did       Affect your usual ability to eat and drink yesterday? 
155. How much did       Affect your usual ability to do necessary activities and tasks yesterday? 
156. How much did       Affect your usual enjoyment of leisure and recreational activities yesterday  
(for example: reading, listening to music)? 
157. How much did       Affect your usual enjoyment of social activities yesterday? 
158. How much did       Affect your usual ability to do your normal daily work yesterday? 
159. How much did       Affect your usual ability to sleep yesterday? 
 
 
 PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
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 7TH DAY AFTER SURGERY 
Symptoms after Surgery 
Please use the 0-10 scale with 0 being “none at all” and 10 being the “worst possible” to rate your symptoms. As the day goes on please fill out 
each question at the end of each time interval. If you have no symptoms please enter a “0.”  
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Please answer each question below at the 
end of each time interval to the right ? 7th Day after Surgery 
160. What was your severity of pain at rest?  
161. What was your severity of pain during activities?  
162. What was your worst severity of nausea?  
163. If you had nausea, for how long did you have it?[min]  
164. How many times did you have vomiting/retching?   
165. What was your worst severity of vomiting/retching?   
    Answer these questions at the end of each day. 
 7th Day after Surgery 
166. How tired were you during the day (0-10)  
167. How much headache did you have (0-10)  
168. What made your pain worse during the day?   
169. What relieved your pain during the day?   
170. What made your nausea worse during the day?   
171. What relieved your nausea during the day?   
172. What made your vomiting worse during the day?   
173. What relieved your vomiting during the day?   
0   1   2    3   4    5    6    7   8    9    10 
none at all  worst possible 
 
 Please answer the questions below at dinnertime on the 7th day after surgery. 
  
174. Below, please list all new medications or remedies that you took today since waking up.  
New medications or remedies are those you did not take regularly before surgery. 
Name of new medication 
or remedy 
 Time  
of the day 
Strength of doses 
taken (mg) 
 Reason for taking 
 
How effective was it? 
0 = not at all, 
10 = completely effective
         
         
         
         
         
 138 Below indicate how much nausea, vomiting and pain 
bothered you during your recovery and please use the 
0-10 scale with  
0 being “not at all” and 10 being “most bothersome”. 
0   1   2    3   4    5    6    7   8    9    10 
not at all  most bothersome 
 
 Nausea  Vomiting Pain   
175. How much did      Affect your quality of life today? 
176. How much did      Affect your usual ability to eat and drink today? 
177. How much did      Affect your usual ability to do necessary activities and tasks today? 
178. How much did      Affect your usual enjoyment of leisure and recreational activities today  
(for example: reading, listening to music)? 
179. How much did      Affect your usual enjoyment of social activities today? 
180. How much did      Affect your usual ability to do your normal daily work today? 
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PLEASE CIRCLE THE ANSWER TO CORRECTLY FILL IN THE BLANKS: 
 
1.  In the last 24 hrs, I threw 
up __times. 
7 or more 5-6  3-4  1-2  I did not 
throw up 
2. In the last 24 hours, from 
retching or dry heaves I 
have felt ___distress 
No Mild Moderate Great Severe 
3. In the last 24 hours, from 
vomiting or throwing up, I 
have felt____distress 
Severe Great Moderate Mild  No 
4. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach____ 
Not at all 1 hour or 
less 
2-3 hours 4-6 hours More than 
6 hours 
5. In the last 24 hours, from 
nausea/sickness at my 
stomach, I have felt ____ 
distress 
No Mild Moderate Great Severe  
6. In the last 24 hours, each 
time I threw up I produced 
a_______amount. 
Very large 
(3 cups or 
more) 
Large (2-3 
cups) 
Moderate 
(½ - 2 
cups) 
Small 
(Up to ½ 
cup) 
I did not 
throw up 
7. In the last 24 hours, I 
have felt nauseated or sick 
at my stomach ____ times 
7 or more 5-6  3-4 1-2 No  
 
Thank you for filling out and reporting these questions to us. Once our data are complete we will send you a gift card in the mail in 
approximately 2-4 weeks.  Please let us know what kind of gift card you would prefer: 
Blockbuster · Borders/Waldenbooks ·Chevy’s · Cybelle’s Pizza · Jamba Juice · Pasta Pomodoro · Starbucks 
 APPENDIX B Permission 
 
 
 
 
 
 
 
 
 
 
 
To Whom It May Concern: 
 
This note is official permission on behalf of the American Society of PeriAnesthesia Nurses 
(ASPAN) to allow Jan Odom-Forren, RN, CPAN, FAAN, PhD Candidate use Figure 1 and 
Figure 2 from ASPAN’s Evidence-Based Clinical Practice Guideline for the Prevention and/or 
Management of PONV/PDNV, J Perianesth Nurs 2006; 21:233-234 as part of her doctoral 
dissertation at the University of Kentucky. 
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